8th Annual

EUROPEAN LIFE SCIENCE
CEO FORUM

for PARTNERING & INVESTING

3rd – 4th March 2015
Hilton Zurich Airport Hotel

Conference Guide

www.sachsforum.com
Welcome

Sachs Associates are delighted to welcome you to the:

8th Annual
European Life Science CEO Forum for Partnering & Investing

3rd - 4th March 2015
Hilton Zurich Airport Hotel

Sachs Associates are delighted to welcome you to the 8th Annual European Life Science CEO Forum for Partnering & Investing. Following its success from previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharma.

This exclusive and transactional event compliments our Annual Biotech in Europe Investor Forum, held later in the year, but with added focus on Partnering & the pharmaceutical industry, feature presentations from Big Pharma representatives demonstrating their current and future partnering strategies through thought-provoking case studies.

This year’s programme features a series of panels and presentations from leading investment, pharmaceutical and biotech companies, highlighting the current issues surrounding the evolving Finance and M&A market, Partnering activity, Vaccines, Oncology and Biomedical Investment, and includes special keynote speeches, providing an expert outlook on Europe’s Biotech industry. In addition, the event holds exclusive Partnering Workshop Presentations and more than 60 exclusive company presentations from an exciting and diverse range of publicly listed and private life science companies, looking to raise finance and/or find partners.

General Information

• The registration desk is open from 8am on both days although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

• Wireless Internet connection is available throughout the venue for the duration of the event. Please ask for an access code at the registration desk.

• The one-to-one meetings are being held in the La Place A and B. Please bring with you a copy of your diary. Should you have any queries about your schedule, the laptop situated by the meeting tables is available for your assistance.

Request for Presentations

Please use the agenda to mark off presentations that you are interested in and email your request to silvia@sachsforum.com after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference.
**Events Diary**

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Silvia Kar on Silvia@sachsforum.com

**Sachs Immuno-Oncology: BD&L and Investment Forum**
29th May 2015 • Hyatt Chicago Magnificent Mile • USA

**15th Annual**
**Biotech in Europe Forum**
For Global Partnering & Investment
29th – 30th September 2015 • Congress Center Basel • Switzerland

The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s bio industry, this event will once again be covered by our regular media partners. We expect over 600 delegates and 100 presenting companies.

The 15th Annual is again being held in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one-to-one meetings as well as significant exhibition space. The Programme will feature plenary panels/workshops covering BD & Licensing in the main therapeutic areas. There will be significant networking opportunities at the Forum and receptions.

Event details available at: [www.sachsforum.com/basel15](http://www.sachsforum.com/basel15)

**3rd Annual**
**Medtech & Diagnostics Innovations Summit**
16th November 2015 • Düsseldorf • Germany

The Summit is designed to bring together a specialist audience from leading and growth companies focused on M+A, alliances and Investment. The program will feature keynotes from industry leaders and plenary panels on industry acquisitions; public markets, venture investment and growth, company finance, and diagnostics. The subjects of regulation and reimbursement will also be covered.

The program will also feature public and private company presentations focused on innovation and alliances/investment opportunities. The MedTech and Device companies track will cover; Oncology, Cardiovascular, Imaging, Surgical Devices & Implants, with a separate track for Diagnostics.

View last year’s event at: [www.sachsforum.com/mdis14](http://www.sachsforum.com/mdis14)
Speakers

Adrian Mills, CBO, Novimmune SA
Adrian Mills joined Novimmune in July 2014 after an extensive career with GSK. Most recently he was their EU Commercial Director in the Rare & Critical Diseases Business Unit where he was responsible for launching new orphan medicines for neuromuscular disorders, metabolic diseases and immuno-deficiencies, as well as leading the European rare diseases sales and marketing teams promoting a portfolio of orphan and critical care medicines.
Adrian's professional background includes launching new medicines and negotiating market access and pricing hurdles in Europe, Japan, Latin America and North America.
With over 20 years experience in life sciences, Adrian has led commercial functions in both R&D, strategy development and commercial operations.
Prior to GSK, he worked in consulting (Booz & Co) and investment banking (Schroders) advising life sciences companies.
Adrian holds an M.A. (Hons) in Engineering from Queens’ College, Cambridge, and an MBA from the London Business School.

Ajan Reginald, Chief Executive Officer, Cell Therapy Ltd
Co-Founder and Chief Executive of Cell Therapy Ltd - the innovative regenerative medicine company that he founded with Nobel Laureate, Professor Martin Evans.
Cell Therapy invents and develops Regenerative Medicines for Life™ - breakthrough cellular medicines that treat life threatening / life changing diseases. In 2014, Cell Therapy completed Phase II clinical trials in End-stage heart failure with Phase III trials starting in 2015. The company's pipeline also includes consists of 2 more disease specific products in Phase II trials for Orthopaedic and Dermatology indications.
Ajan is an inventor of CTL's core technology and tissue specific regenerative medicine products and leads the company's commercial and operational activities.
Ajan was Roche's Global Head of Emerging Technologies overseeing the identification, acquisition and development of the next generation of breakthrough Biopharma technologies and products. He joined Roche as Business Development Director in Roche Pharma, where he led M&A teams and major licensing transactions including the $1.3B licensing transaction with Alnylam.
Prior to Roche, Ajan was a consultant with the Boston Consulting Group and received a MBA from Kellogg Business School, Northwestern University where he was awarded the Biotechnology scholarship. In 2002, he was awarded the UK Fulbright Scholarship.

Alexander Breidenbach, Director, Global Business Development, F. Hoffmann La Roche AG
Alexander has over 15 years experience in the pharma industry in research & development in multiple disease areas and in business development, now specializing in neuroscience. In his current role Alexander is Business Development Director for Roche Partnering.
Alexander is project leader for licensing and M&A projects, such as the recently announced acquisition of Trophos around oleosine for the treatment of spinal muscular atrophy.
Prior to this Alexander was project leader in Strategic Partnering being responsible for “White Space” opportunities and was leading the in-license project of oral octreotide from Chiasma. Prior to that Alexander was Due Diligence Director supporting all disease areas.
Andre Hoekema, SVP Corporate Development, Galapagos

Dr. Hoekema joined Galapagos in March 2005 from Invitrogen Corporation, where he was Managing Director of Corporate Development Europe. He brings 20 years of biotech experience from positions at Molecular Probes Europe (Managing Director), Crucell (Director of Business Development), DSM Life Sciences and MOGEN (Research and Project Management) and Genentech, Inc (R&D). Dr. Hoekema has a PhD degree from Leiden University and is the inventor of over 20 series of patent applications, resulting in 15 patents issued in the US.

Anja König, Managing Director, Novartis Venture Fund

Dr. Anja König is a Managing Director in Basel, Switzerland. She is active in the UK, Switzerland and the rest of Europe. Prior to joining Novartis Venture Fund she was an Associate Partner at McKinsey and Company in New York, a global consultancy, where she worked with healthcare companies in the US, Europe and Emerging Markets. Anja holds a PhD in physics from Cornell University. Anja serves on the boards of Bicycle Therapeutics, F2G, Forendo Pharma and Heptares Therapeutics.

Anker Lundemose, CEO, Mission Therapeutics Ltd.

He has extensive experience from business and corporate development as well as R&D in several key therapeutic areas including oncology, diabetes and anti-infectives. He has a comprehensive international experience and network, and has been responsible for successful mergers and acquisitions within biotech, venture investments and licensing. His background includes biotech startups, large biotech and big pharma, as well as an initial career in academia.

He was Chief Executive Officer and President of Bionor Pharma ASA from 2013 to 2015, Chief Executive Officer of Prosidion Limited in the UK from 2003 to 2005, Executive Vice President OSI Pharmaceuticals Inc. in the US and President of Prosidion Ltd from 2005 to 2009. He was Executive Vice President Corporate & Business Development, OSI Pharmaceuticals Inc., from 2009 until Astellas Pharmaceutical Inc’s acquisition of OSI in 2010. He has previously held positions as Managing Director at OSI Pharmaceuticals venture arm in Zug, Switzerland, and as Business Development Director at Novo Nordisk, Denmark. Anker has MD, PhD and DMSc qualifications in medical microbiology.

Anne Altmeyer, VP, Business Development, Head Negotiation, Oncology, Novartis Pharmaceuticals

Anne Altmeyer is Vice President, Head Global Negotiations in Business Development & Licensing (BD&L) in the Oncology Business Unit at Novartis. In this capacity, her responsibilities are to in-license or acquire Oncology assets that can further strengthen the Novartis Oncology portfolio. She also oversees the group responsible for Companion Diagnostics transactions and manages several ongoing alliances.

Anne has over 15 years of experience in the Pharmaceutical Industry working in positions of increasing responsibilities in Research, Development, and BD&L. Anne joined the Oncology Project Management group of Novartis in 2004 as a Project Leader. There, she led numerous multidisciplinary Project Teams through the generation and implementation of strategies for various compounds in development and on the market. Before joining Novartis, Anne worked as a Project Manager in various Therapeutic Areas at Merck & Co.

Anne received her Ph.D. in Molecular Immunology from Strasbourg University, France. She then performed a postdoctoral fellowship at New York University School of Medicine, USA, and subsequently became a Research Associate at Cornell University Medical College, New York, USA. In addition to her scientific training, Anne also received a MBA and a MPH from the University of Medicine and Dentistry of New Jersey/Rutgers, USA.
Speakers

Arthur Franken, Partner, Gilde Healthcare

Arthur Franken joined Gilde in 2001. He led the investments in Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by C. R. Bard), Levicept, Maximed, MTM Laboratories (acquired by Roche) and ProQR Therapeutics (IPO on NASDAQ). He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext), Agenda, uniQure (IPO on NASDAQ), BG Medicine (IPO on NASDAQ) and Pieris.

He represents Gilde on the boards of Levicept, Maximed and Symphogen. He served as a board member for FlowCardia, MTM Laboratories and ProQR Therapeutics until the trade sales or IPO.

Prior to joining Gilde he was active in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a masters degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national.

Beat Merz, Managing Director, Rockport Venture Partners

Dr. Merz joined Rockport in 2013 as Managing Director of Rockport Venture Securities and Head of European Equity. Dr. Merz brings 15 years of experience in venture and growth stage equity financing and operations to Rockport, including management and leadership of over $150 million in equity financings. Prior to joining Rockport, Dr. Merz was a Partner with Ares Life Sciences. Previously, he was responsible for venture and private equity investment management as Investment Advisor of HBM Partners. Prior to joining HBM Partners, he was Managing Director of NMT New Medical Technologies, where he provided capital, professional management consulting and start-up support for young medical device companies. During his career he has directed investments in the US, Europe and Israel-domiciled companies and has served as co-founder or has held board seats for many of them. He currently serves or has served on the Boards of Directors of Micrus Endovascular (acquired by JNJ), Thommen Medical (acquired by private investors), Asthmatx (acquired by BSX), Precimed (acquired by Greatbatch), Devax (acquired by BioSensors), BioControl Medical, South Eastern Technologies and several other medical device companies. Dr. Merz holds a Ph.D. in biomechanics from ETH Zurich/Switzerland and an MBA from the University of Strathclyde, Glasgow/UK.

Bernard Huber, CEO and Founder, Oryx Translational Medicine

Dr. Huber is a molecular biologist and patent attorney who has been involved in setting up several biotech companies. He gained more than 20 years of experience in intellectual property right protection, technology transfer and business management in the biotech sector, since 1996 at his own patent and law firm. Among others, he successfully represented the German Cancer Research Center (DKFZ), Heidelberg in patent/license matters regarding cervical cancer vaccines Gardasil® and Cervarix®.

Bernhard Sixt, President and CEO, ImmuniD

Dr. Sixt has over 25 years of pharmaceutical industry experience in the development and commercialization of laboratory services, in vivo and in vitro diagnostics, and pharmaceuticals for industry leaders such as Amersham (now part of GE Healthcare), and Nycomed (now part of Takeda). He is a co-founder of Agenda and has served as the company’s CEO from 2003 until 2011. Dr. Sixt holds a Master of Science degree in Biochemistry and Chemistry from Ludwig Maximilians University, and a PhD from the Technical University, both in Munich, Germany.
Speakers

Bethan Hughes, Senior Business Analyst, Wellcome Trust
Interim Head of the Translation Fund, a £24 million annual funding scheme administered by the Wellcome Trust’s Innovations division. Applicants from small and medium-sized companies, large pharmaceutical and med-tech companies, universities and not-for-profit organisations from any geographical region are welcome to apply. The aim of Translation Awards is to develop innovative and ground breaking new technologies in the biomedical area. Projects must have already demonstrated proof of principle, supported by experimental data. Applications should bridge the funding gap in commercialisation of new technologies in the biomedical area and must plan to take the product, technology or intervention to a stage at which it is sufficiently developed to be attractive to another party. Please see the following URL for more information.

Boris L. Zaïtra, Head of Corporate M&A, F. Hoffmann-La Roche Ltd.
Boris L. Zaïtra is the Global Head of Group M&A at Hoffmann-La Roche and is based in Basel, Switzerland: in this role he leads Roche’s strategic mergers and acquisitions across the Roche Group businesses. He joined Roche in April 2012 from the Airbus Group where he worked for six years as Head of the M&A department. Prior to joining EADS in 2005, he was a Partner with the mid-market private equity firm Duke Street Capital and was involved in deals in the UK and France. Previously, he was an M&A Associate with JP Morgan in London, focusing primarily on the Oil & Gas industry. Boris graduated from Ecole Polytechnique in France in 1995 and the Harvard Advanced Management Programme in 2009.

Carles Domènech, CEO, Ability Pharmaceuticals
Carles obtained a BS/MSc degree in biology (first class honors) from the Autonomous University of Barcelona and also a PhD degree in cellular biology from the same University, working at the Council of Science Research (CSIC). He has additional business training at ESADE business school and other business programs.
Carles started developing his career in cancer research at CSIC in Barcelona (1985-89) and at Memorial Sloan-Kettering Cancer Center in New York (1990-1992).
Carles has 15 years international experience in business development and licensing in the pharmaceutical industry. He held senior positions at the Barcelona pharmaceutical companies Almirall, SA (1992-2003, Manager and Head, Business Development and Licensing) and Lacer, SA (2005-2007, Director, Business Development and Licensing).
Carles has also 4 years’ experience in biotech venture capital and business angels associations and has also been collaborating with government innovation agencies. Between 2004 and 2005 he was Director, Biotech Investments at the seed venture capital firm Barcelona Emprèn, SCRSA. During 2008-2009 he collaborated with agencies of the Government of Catalonia as Director, Technology Transfer and Valorization and as Managing Director, Investment and Enterprise Growth. He had under his responsibility the seed venture capital company Invertec; SA and the entrepreneurship finance programs Genesis Capital and Concept Capital. Since July 2009 he also advises Keiretsu Forum Barcelona in biotech investments. In 2009 Carles cofounded Ability Pharmaceuticals, SL to become its Chief Executive Officer in September 2009.

Carina Schmidt, Chief Executive Officer, Athera Biotechnologies AB
Ms Schmidt has nearly 30 years industrial experience, mainly in business development and management, international marketing and product management within the life science area. During 15 years she has worked with Pharmacia Biotech/Amersham Biosciences (now GE HealthCare). Later she founded Grasp Bioscience AB, where positions included management consultant, board director, interim CEO and business advisor to several biotech start-ups. She joined Athera as the CEO in 2007. Former board director of Genovis AB (public), a company that develops and sells unique enzymes that facilitate development and quality control of biological drugs. Currently she is a delegate of the investment committee in ALMI Invest region Nor, a state funded seed investor. Carina Schmidt holds a MSc Chem Eng from the Royal Institute of technology, Stockholm, Sweden.
Speakers

Chandra Leo, Partner, HBM Partners AB

Dr. Leo has more than 15 years of experience in venture capital, clinical practice and biomedical research. He is a member of the private equity team at HBM, a healthcare-focused investment group managing >USD 1 billion in assets. Dr. Leo is currently a board member at CardiacAssist, Delenex, Gynesonics, i-Optics and Symbiomix. He previously served as a board member or board observer at Anthera Pharmaceuticals (IPO NASDAQ), ChemoCentryx (IPO NASDAQ), ESBAtech (acquired by Alcon/Novartis) and Panomics (acquired by Affymetrix). Moreover, he managed a strategic investment collaboration between HBM Partners and a US-based biopharmaceutical company. Dr. Leo completed his medical studies in Berlin and London and holds a doctoral degree from the Freie Universität Berlin (Charité) and an MBA degree with distinction from INSEAD. His prior roles include working as a principal at Wellington Partners, as a physician at the University Hospital Leipzig and as a postdoctoral scientist at Stanford University.

Charles Bailey, Head of Search & Evaluation, Neurosciences, Global Business Development & Licensing, Novartis Pharma AG

Chris Britten, Head, Business Development, Sanofi Pasteur MSD

Chris is currently Head of Business Development at Sanofi Pasteur-MSD with responsibility for all business and corporate development activities. He is also a Non-executive Director at Phico Therapeutics Ltd. Sanofi Pasteur-MSD is a Joint Venture between Sanofi Pasteur and Merck & Co. and is focused on the development and commercialisation of vaccines in Europe. Chris is also the Managing Director of Vantage Life Sciences, offering strategic and transaction advisory services to the life science sector, and a Non-Executive Director at Phico Therapeutics Ltd.

Chris joined Sanofi Pasteur-MSD in 2013 following positions at Astellas (Europe) in Business and Commercial Development and several years at Deloitte Corporate Finance where he headed up the Life Science Advisory practice assisting clients across the life science sector in a wide range of transactional activities (M&A, divestments, partnering, valuation, fund-raising). Prior to Deloitte, Chris was at GlaxoSmithKline where he held roles of increasing responsibility in Business Development, Corporate Ventures and R&D.

Chris holds a PhD in Biochemistry and an MBA in Finance.

Chris Maggos, Consultant, BioConfidant Sàrl

Chris has over 20 years of experience in the life sciences industry covering business development, investor relations, communication, investing and molecular neurobiology. Recently, he founded BioConfidant Sàrl a strategic consulting firm that helps senior executives achieve their financing and partnering goals. He also is co-founder of the Alpine Institute for Drug Discovery, a not-for-profit social enterprise whose mission is to help commercialize academic discoveries. Previously, at Addex Therapeutics, Chris was a member of the executive management board and held the positions of head of investor relations & communication (2007-2010) and director of business development (2010-2013). Before that he worked as: a journalist for the leading biotechnology trade publication BioCentury (2001-2007); an investor at Casdin Life Science Partners (later Cooper Hill), a NYC-based biotechnology hedge-fund (1997-2000); and a molecular neurobiologist studying drug dependence at The Rockefeller University (1993-1997), where he co-authored twelve peer-reviewed publications. Chris holds a BA in English Literature from Yale University, where he also completed pre-medical studies.
Speakers

Corrine Savill, Head Business Development & Licensing, Novartis Pharma AG

Corrine has over 15 years of broad experience in both the pharmaceutical and biotech arena. In her current position, she has responsibility for all Business development and partnering deals within Novartis.

After a Ph.D. in Immunology and a number of academic and pharmaceutical research positions, Corrine joined Imutran Ltd a UK based Biotech as Director of Research. In 1996 Imutran was acquired by Novartis and Corrine made the COO. She moved to Basel in 2001 as the CEO of the Novartis Bio Venture Fund, managing a CHF 100 million investment fund. In 2005 Corrine moved to head up Global Search and Evaluation with Novartis Business development where she was responsible for the identification and evaluation of potential license-in or M&A opportunities, growing the Novartis development pipeline and supporting the business goals of Novartis. In 2010 Corrine became Novartis’s Global Head of Pricing and Market Access responsible for the pricing and market access strategies for the portfolio of Novartis Pharma’s development and in Market products world-wide.

In June 2013 Corrine was appointed Head Business Development and Licensing Novartis Pharma AG.

David Phillips, Partner, S.R. One, Limited.

David joined SR One in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and subsequently joined the team focusing on European investments. David brings a range of experience to SR One, including senior management roles in sales and marketing, commercial strategy and business development at Glaxo Wellcome, Cephalon, Medical Venture Management, The Automation Partnership and Galapagos. David has significant deal making experience in the pharmaceutical and biotech sectors and has run a number of successful businesses deriving healthy exits for investors.

David has a BSc (Hons) in Pharmacology from the University of London and is a member of the Charted Institute of Marketing. David is based in London.

Dinesh Patel, President & Chief Executive Officer, Protagonist Inc.

Dinesh Patel has 30 years of experience spanning big pharma, biotech, and the biopharmaceutical industry. He joined Protagonist therapeutics as its President & CEO in 2009. He was previously the CEO of Arête Therapeutics, and CEO/Co-founder of Mlkinana Therapeutics, an oncology company acquired by Entremed in 2005. Dr. Patel was a co-founder of the anti-infective Company Versicor/Vicuron which was acquired by Pfizer in 2005 for $1.9 billion. Prior to Vicuron, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax (1993-96) which was acquired by GSK for $533 M. He started his career as a medicinal chemist at Bristol-Myers Squibb in 1985.

He received his Ph.D. in chemistry from Rutgers University, New Jersey and conducted post-doctoral research at the University of Wisconsin, Madison, and has >100 patents and publications to his credit.

Donnie McGrath, Vice President Business Development, Bristol-Myers Squibb

Donnie McGrath is Vice President, Business Development at BMS. He has been working in academic medicine and the biopharmaceutical industry for 20 years. He leads a global team responsible for identifying, evaluating and transacting for all business development opportunities of interest to BMS. He works with senior R&D and commercial leadership to design and execute the business development strategy for BMS.
Speakers

Eduardo Margallo, CEO, MedLumics S.L.
Eduardo Margallo obtained his M.Eng. degree in Telecommunications from the Polytechnic University of Madrid, a M.Sc. Degree in Physics from UNED and a M.Eng. degree in Electrical Engineering (Dipl.-Ing. Elektrotechnik) from the University of Stuttgart (Germany). He completed his doctorate at Delft University of Technology (The Netherlands) in the area of biophotonic instrumentation. He has accumulated 8 years of experience in the design and manufacturing of biophotonic instrumentation and integrated optics, with in-depth knowledge of the physics of light propagation in tissue, sensor microfabrication techniques and silicon photonic devices. During this time he participated in the definition and implementation of clinically driven research projects in collaboration with several universities and hospitals in the Netherlands and Italy. Eduardo co-founded MedLumics in 2009 and is currently its CEO, having guided the company through its seed and start-up phases. In particular, he led fund-raising activities resulting in a 3.5M€ A-Round closed in November 2011.

Esteban Pombo Villar, COO, Oxford BioTherapeutics
Esteban is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20 years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz Neuroscience Research in Basel in 1988. At Sandoz he worked on drug discovery projects as well as leading collaborative projects investigating the potential of emerging technologies. Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry.

Fabian Buller, Director, New Ventures, Covagen AG / Johnson & Johnson Innovation
Fabian Buller is a Director New Ventures of Johnson & Johnson Innovation and Director of Business Development of Covagen AG, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. After Fabian joined Covagen in 2011, he established a major strategic collaboration and licensing agreement with Mitsubishi Tanabe Pharma in 2012 and concluded the sale of the company to Johnson & Johnson in August 2014 in his business development role. Prior to this, Fabian led the immuno-oncology research at Covagen as Director of Discovery Research with a focus on multi-specific protein therapeutics. Fabian studied at Münster University, UCSB and the Max-Planck Institute for Molecular Physiology in Dortmund and he holds a diploma in Chemistry from Münster University. In 2010, he earned his PhD under Prof. Dario Neri at the Department of Chemistry and Applied Biosciences at ETH Zurich. His dissertation focused on DNA-encoded chemical libraries was awarded with the ETH Zurich silver medal.

Fabien Sebille, Head of Alliances, Debiopharm International S.A.

Fintan Walton, CEO, PharmaVentures Ltd
In 1992 Dr Fintan Walton co-founded CONNECT Pharma, a predecessor company to PharmaVentures focused on assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. In 1997 this company became PharmaVentures. Since its inception, PharmaVentures has worked with blue chip clients on a global basis, delivering more than 600 assignments for companies in 38 countries. Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic and OTC companies. Its clients have included major banks, investment/merchant banks, and private equity and venture capital groups. In 1996 he also founded PharmaDeals, the leading database and publishing business related to dealmaking. Thousands of customers from around the world have either bought or subscribed to these PharmaDeals publications. PharmaDeals was sold to IMS Health in Aug 2012. Educated at Trinity College (Dublin, Ireland), Fintan subsequently gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Speakers

Florian Kemmerich, Chief Executive Officer, Histide AG
Business leader and entrepreneur investing in and/or managing life science companies in different countries. Broad expertise in vision, strategy, startup, turnaround, repositioning, build out and fundraising within global corporations as well as for small to mid-size enterprises. More than two decades of expertise in biotech, pharma, drug device, implants and medical device with a deep understanding of the healthcare industry associated with a strong knowledge of market dynamics and cultures around the globe.

François Thomas, Managing Partner, Inserm Transfert Initiative
Dr. François Thomas is managing partner of Inserm Transfert Initiative (ITI). He is a medical oncologist and a former assistant professor at the Gustave Roussy Institute. He also holds an MBA from MIT (Boston). François Thomas was successively vice president (VP) for clinical development of Ipsen, managing partner of Bioserve Ltd. VP in charge of pharmacogenomic programs and licensing at Genset, partner in the venture capital firm Atlas Venture, in charge of healthcare banking activities at Bryan Garnier, and president of Cytheris. His professional activity over the last 15 years has been dedicated to the creation and development of biotech companies in Europe.

Frank Kalkbrenner, Head, Boehringer Ingelheim Venture Fund
Dr. Frank Kalkbrenner is Managing Director of the Boehringer Ingelheim Corporate Venture Fund. Over the last four years, he has been involved in several investments of the fund. He serves as board member of STAT Diagnostica in Barcelona, Eyefvensys in Paris, Hookipa in Vienna and Acousia Therapeutics in Tübingen. In addition, he is member of the supervisory and the advisory board of Inserm Transfer Initiative a French Seed Investment Fund based in Paris.
Dr. Kalkbrenner studied medicine and holds a degree in Pharmacology and Toxicology. He spent more than 10 years in academic research in the Max-Planck-Institute for Molecular Genetics in Berlin and in the Institute of Pharmacology of the Freie Universität, Berlin. His academic research focused on gene regulation and signal transduction mediated by ion channels and G proteins.
In 1997 he began his industrial career by joining Schering AG as senior scientist in Experimental Dermatology. Dr. Kalkbrenner joined Boehringer Ingelheim in 1999 and held several positions in the department of Pulmonary Research. In 2005 he took over the responsibility for the Licensing Department. In this function, he was responsible for the licensing activities of the German Boehringer Ingelheim organization as well as for competitive assessment and scientific information systems. In addition, he built up the NBE Research unit at the German Research site in Biberach.
Dr. Kalkbrenner joined the BI Venture fund shortly after its start in 2010.

Frans Wuite, President & Chief Executive Officer, Oncos Therapeutics
Frans Wuite has over 25 years of experience in commercialization, business and drug development in pharmaceutical industry. He is currently President and Chief Executive Officer of Oncos Therapeutics Ltd and serves on the Board of Directors of Herantis Pharma and Faron Pharmaceuticals Ltd. Previously, he was co-founder and Chief Operating Officer of Araiim and Warren Pharmaceuticals Inc. Prior to that he was member of Amgen’s European management team and director of marketing at Amgen Europe. Before joining Amgen Mr. Wuite was President of Pharmacia-Leiras BV. His career in the pharmaceutical industry started at Organon International BV, where he served in various international management and marketing roles. Mr. Wuite is a Medical Doctor and Master of Business Administration.
**Speakers**

**Gary Clements, Head of Research Alliances, Shire Pharmaceuticals**
Gary Clements is Head of Research Collaborations and Divestments and a member of Shire’s BD Leadership team. He has a broad range of BD transaction experience built up over greater than 10 years at Shire.

---

**Graham Birrell, Regional Head, Business Development, OCT - Clinical Trials**
Graham Birrell has over 20 years experience in the pharmaceutical industry. He has been with OCT since 2014 as Regional Head of Business Development with responsibility for Europe and the USA.

Graham originally graduated from the University of Edinburgh Medical School with a BSc and PhD in Neuropharmacology. He subsequently worked in discovery research with GSK in the UK and Parke-Davis in the US before heading up analgesia R&D at Servier in France. Graham completed an MBA and moved into clinical development where he was successful in a number of senior business development and clinical project management roles within the CRO sector. Graham has managed clinical studies from Phase I-IV and lead global development programs across a wide range of therapeutic areas. Prior to joining OCT Graham was based in SE Asia where he was responsible for clinical project management across the region for a major global CRO.

Graham brings a wealth of experience in pulling together highly productive operational and business collaborations and partnerships between sponsors and clinical service providers both in established and new markets across the globe.

---

**Graziano Seghezzi, Partner, Sofinnova Partners AS**
Graziano Seghezzi is a Partner. He joined the firm in 2006, and primarily invests in biopharmaceutical companies. Prior to joining Sofinnova, Graziano was a principal at Index Ventures in Geneva, Switzerland, where he invested in biotechnology and biopharmaceuticals companies. Before this, he worked for Sofinnova Partners, identifying new investment opportunities in Italian pharmaceutical and medical device companies. Graziano began his career as a biomedical researcher at New York University’s School of Medicine, where he gained five years of hands-on experience studying the molecular mechanism of angiogenesis in oncology and cardiovascular diseases. Graziano has invested in Creabilis Therapeutics (Italy), a specialty dermatology company; Crescendo Biologies (UK), a fragment antibody company; GlycoVaxyn (Switzerland), a bacterial vaccines company; Hookipa Biotech (Austria), a viral vaccines company; Mission Therapeutics (UK), an oncology company; and Omthera (US), in cardiovascular disorders. Graziano is a board member of each company. Graziano has a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from the RSM, Erasmus University (Netherlands).

---

**Guillaume Vignon, Director Business Development Oncology - Global Business Development and Licensing, EMD Serono**
Guillaume Vignon is Director of Business Development Oncology at Merck/EMD Serono, responsible for leading business development initiatives, designing deal structures, and negotiating terms of strategic partnerships in the field of Oncology. Guillaume hold several positions within Global Business Development and Licensing with increasing responsibilities in all aspects of deal making. During his career at Merck/EMD Serono, Guillaume closed successfully several complex transactions and forged key partnerships in the fields of Oncology, Companion Diagnostic, and Antibody Discovery, strengthening Merck/EMD Serono’s portfolio of innovative products and enhancing R&D capabilities in the field of Biologics.

Recently, Guillaume was the business development lead of the collaboration between Merck and BeiGene, which has received the 2013 BayHelix Elsevier Alliance of the Year Award recognizing a ground breaking pharmaceutical collaboration agreement involving a Chinese entity.

Guillaume holds an MBA from Hult International Business School, Cambridge, USA, and a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6/ Pasteur Institute, Paris, France.
8th ANNUAL
European Life Science CEO Forum & Exhibition

Speakers

Håkon Sæterøy, CEO, Pre Diagnostics AS

With more than 25 years of experience in management, corporate finance and business development, Sæterøy is shareholder and board member of several life science companies in Norway. He is a board member of Nansen Neuroscience Network (chairman from 2010 – 2012) and was a board member of Oslo Cancer Cluster (2007 - 2014). Sæterøy was Executive Chairman of DiaGenic ASA from 2002 – 2010. He has a Master of Science in Business from NHH in Bergen, Norway.

Hamza Suria, President & Chief Executive, AnaptysBio, Inc.

Mr. Suria was appointed CEO in 2011 and has since led AnaptysBio’s transformation from its early platform technology focus to the development of a robust antibody product pipeline across key therapeutic areas. Prior to AnaptysBio, Mr. Suria was at Maxygen, where he was responsible for partnering and alliance management of next-generation protein therapeutics in oncology supportive care, hematology and autoimmunity, including partnerships with Roche, Sanofi-Aventis, Bayer and Astellas. Mr. Suria holds a B.Sc. in biochemistry from Kalamazoo College, an M.S. in immunology from the University of Western Ontario and an Executive MBA from the Richard Ivey School of Business. Marco Londei, M.D.

Hans T. Schambye, CEO, Galecto Biotech AG

Hans Schambye is a seasoned biotech entrepreneur with extensive experience in drug discovery and development. Previously, Hans served as the Chief Executive Officer of ReceptIcon from 2006 to 2009 and as the CEO of Gastrotech Pharma A/S from 2004 to 2006. Before joining Gastrotech, he was Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company. Hans has co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen in 2000. Prior to this he had a successful research career at Stanford University and Copenhagen University within the field of receptor biology. Hans holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University.

Heinz Schwer, CEO, Lanthio Pharma

Heinz Schwer is a highly experienced CEO and a successful biotech entrepreneur. Before he stepped in as CEO he was Senior Director at MorphoSys, responsible for the company’s corporate venture activities. At MorphoSys he started as Strategic Advisor where he was involved in several technology based deals and the company’s M&A activities. He joined this company in 2010 after he has sold Sloning Biotechnology to MorphoSys. Heinz Schwer co-founded Sloning in 2000 and managed the company as CEO from 2005 until 2010. In the years before, he held the positions as Chief Operating Officer and Head of R&D. Heinz Schwer spent several years as postdoc at the Harvard Institute of Medicine and the Dana-Farber-Cancer Institute in Boston. In this time, he has received numerous awards, including a fellowship for his research in the field of leukemia disease and the biogenesis of blood platelets. He obtained his Ph.D. in clinical chemistry from the University of Regensburg and holds an MBA from Henley Management College in UK. He is also a founding member and Vice President of the International Association of Synthetic Biology.
Speakers

Jakob Lindberg, CEO, Oncopeptides AB
Mr Jakob Lindberg, physician by training, was appointed as CEO in 2011. In addition to being CEO of Oncopeptides AB he is also Venture Partner at Investor AB.

Previous positions include; co-founder of Cellectricon AB where he also served as CEO, Engagement Manager for McKinsey&Co., and analyst for Merrill Lynch & Co.

Mr Lindberg holds a Med Lic in Molecular Immunology, an MSc in pre-clinical medicine from the Karolinska Institutet and a BA in Finance and Administration from Stockholm University.

Jane Atkins, Global Licensing & Business Development, Director, Search & Evaluation, Takeda Pharmaceuticals International GmbH
Jane is a member of Global Licensing and Business Development at Takeda heading efforts for sourcing and transacting European-based technologies and early stage pipeline programs. Jane joined Takeda 14 months ago and is based in Zürich. Prior to Takeda, Jane held various Business Development positions with Merck Serono, Mundipharma International and Hospira. Jane obtained her Ph.D. in Biochemistry from the University of Leicester and held research positions at the MRC Laboratory of Molecular Biology and Cambridge Institute for Medical Research in Cambridge, UK.

Jason Coloma, Global Head Venture & Innovation at Roche Partnering, F.Hoffmann La Roche AG
Jason Coloma is the Head of Venture and Innovation in Roche Partnering responsible for (1) external innovation with academia and venture capitalists (2) new modalities or technology platforms that can potentially be applied across therapeutic areas (3) opportunities in adjacent sectors that may translate into innovative solutions for patient care, including healthcare IT.

Jason was previously Head of the Diagnostics Program Office responsible for supporting the Diagnostics Chief Operating Officer in various strategic initiatives and partnering activities. Jason led a number of partnering activities including commercial and academic agreements, mergers and acquisitions as well as strategic investments. He also oversaw Divisional Portfolio Management as well as Market and Competitive Intelligence.

Prior to his time at Roche, Jason worked in the biopharmaceutical industry both as a strategy consultant and working in operational roles. As a strategy consultant, he primarily worked with biotechnology start-up companies venture capital and private equity firms working on a range of issues including partnering deal support, evaluating the business opportunity of innovative discoveries and implementing external innovation models. Jason also held research and business positions at Amgen, the University of California, San Francisco as well as biotechnology startups.

Jason completed his graduate studies in Immunology at the University of California, Berkeley as well as his MBA from the Tuck School of Business at Dartmouth.

Jasper Bos, Director, MS Ventures
Jasper is Director with MS Ventures, the corporate venture arm of the prescription medicines division of Merck KGaA, Darmstadt, Germany. Prior to joining MS Ventures, Jasper was instrumental in the founding of IFHA, a private equity fund investing in the healthcare and insurance sectors in emerging economies. Before IFHA, Jasper worked as health economics and strategy manager at the Netherlands Vaccine Institute.

Currently, he is a Member of the Board of Directors of Asceneuron, EpiTherapeutics, Galecto Biotech, Neviah Genomics, Prenox therapeutics, Calypso Biotech, ObsEva, and an Observer to the Board of Vaximm. He holds a PhD in Pharmacy from the University of Groningen, the Netherlands.
Jeanne Bolger, Vice President Venture Investments, Johnson & Johnson Innovation

Jeanne joined Johnson & Johnson Development Corporation (JJDC) as Vice President, Venture Investments, in February 2013. She is based in London, UK at the Johnson & Johnson Innovation Centre. Jeanne’s responsibilities are focused on investing in and managing portfolio investments in the pharmaceuticals and biotechnology areas in Europe. Jeanne has over 25 years of pharmaceutical industry experience in management roles across R+D, Commercial and Business Development. She spent 11 years in Licensing and Acquisition, most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined the Johnson & Johnson Family of Companies in 2005 from the Business Development group at GSK.

In 2009, Jeanne became VP Alliance Management and Board Director at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan on immunotherapies targeting beta amyloid for Alzheimer’s disease.

Jeanne received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). She has served as the sole pharmaceutical industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.

Jesse Schulman, Chief Executive Officer, Canbex Therapeutics

Jesse Schulman took over as CEO of UCL spin-out Canbex Therapeutics in 2012, after working with the firm as a financing and business development consultant from 2009. In 2013 he helped the firm close a Series A fundraising round led by Merck Serono Ventures, also supported by UCL Business and the Wellcome Trust, which enabled a successful Phase I safety trial in healthy volunteers of the firm’s lead compound, VSN16R, aimed at the treatment of spasticity in people with multiple sclerosis. Jesse Schulman was trained as a Neuroscientist at UC San Diego and the Salk Institute, and has worked extensively in corporate finance for the biotech sector, assisting firms with fundraising, licensing and M&A transactions.

Jesús Martin-Garcia, Founder and General Partner, Eclosion

Jesus Martin-Garcia is a highly successful entrepreneur who has created, invested in and developed several technology-focused start-ups such as VTX, Silverwire and LeShop, Switzerland’s largest e-commerce company that he co-founded in 1997. Jesus began his career at McKinsey & Co where he managed teams in the pharma and consumer goods industries. Jesus holds a BSc in Business Administration and a MSc in Law from UNIGE and a MBA from Harvard Business School.

Jim Phillips, Chief Executive Officer, Midatech Group

Dr Phillips has a strong background in company leadership and business development, and is a physician by training. He founded Talisker Pharma in 2004, which was the first and cornerstone acquisition of EUSA Pharma in 2006. As President of Europe and Senior Vice President, Corporate Development of EUSA Pharma Inc., Dr Phillips led the strategy resulting in the acquisition of OPI and its ultimate acquisition by Jazz Pharmaceuticals in 2012. Dr Phillips is currently a Non-executive Director of Herantis Pharma plc (listed in Helsinki), Insense Ltd (a private spin-out from Unilever), and, until joining Midatech, was Chairman of Prosonix Limited, guiding its successful transformation into a respiratory focused business.

Dr Phillips initially held senior positions at Johnson & Johnson and Novartis Pharmaceuticals. At Novartis, he was in Clinical & Business Development and was a Board Director of the $1.3bn Arthritis, Bone, Gastrointestinal, Haematology and Infectious Diseases business unit and a member of the company’s Clinical Leadership Team.
Speakers

John Kelly, CEO, Imanova Ltd
John has twenty years industry experience and was Chief Operating Officer at ASX and now NASDAQ listed Unilife Corporation from 2005-2008. John holds degrees in both Engineering and Manufacturing Systems as well as an Executive MBA at the University of Sydney where he was awarded the business school’s inaugural ‘Excellence in Leadership’ scholarship.

Katya Smirnyagina, Partner, Capricorn Venture Partners NV
Dr Ekaterina Smirnyagina is a Partner at Capricorn Venture Partners (Belgium) since 2012. Prior to this, she worked for ten years at Alta Partners, a healthcare focused venture capital fund in San Francisco, CA. She has a PhD in Cellular & Molecular Biology (University of Wisconsin-Madison, USA), BS in Biochemistry (Lomonosov Moscow State University, Russia). Katya completed her scientific training at the Stanford University School of Medicine, then worked in management consulting and biotech business development. She represents Capricorn on the board of iSTAR Medical SA and Nexstim Oy, and serves as independent board member of Adocia SA (NYSE Euronext: ADOC.PA).

Kevin Cox, CEO, Imanova Ltd
Kevin is CEO of Imanova, a unique joint venture between the MRC and Kings, Imperial and UCL. Imanova has world-leading expertise in imaging sciences.
Kevin’s has lead high-growth businesses, and worked with the NHS and academia. He is experienced in biopharmaceutical development, laboratory diagnostics, and technology translation.
Kevin’s public sector roles include: Chair, UKTI’s Bio/Pharma Advisory Committee, Chair, BioNow, UK Life Sciences Marketing Strategy Board, TSB advisory board for stratified medicine, NED of the BNA and the BIA.

Kia Motesharei, Head, Immunology Licensing, EMD Serono
Kia Motesharei is currently Head of Global Licensing & Business Development, Immunology at EMD Serono (Merck Serono outside the US and Canada). He is responsible for Search & Evaluation and all transactions within the Immunology Franchise at Merck KGaA. Prior to EMD Serono, Kia was Vice President of Business Development & Alliance Management at Dyax, a biopharmaceutical company specializing in rare disease. Previously, Kia managed the US operation of Genfit - a French biotech company – in Cambridge and led its global business development as the company’s Chief Business Officer. Kia has a successful track record of transactions which include strategic alliances, product and technology licensing, distribution, divestitures, and M&A agreements with major pharmaceutical and biotechnology companies in the US, Europe, Japan, China, LATAM, and Middle East. In addition, he has been involved in a number of financing activities.
Kia received his B.A. in Chemistry from The Colorado College and his Ph.D. in Organic Chemistry from University of California, Los Angeles. He completed his postdoctoral training at The Scripps Research Institute as an NIH Fellow.
Speakers

Kondrad Glund, *Chief Executive Officer, Probiodrug AG*

Prior to setting up Probiodrug in 1997, Dr Glund founded IFB Halle GmbH. After Probiodrug sold its DP-4 diabetes assets to (OSI) Pharmaceuticals in June 2004, he joined (OSI) Prosidion, the metabolic subsidiary of (OSI) Pharmaceuticals, based in Oxford, UK, as Chief Operating Officer and Vice President of Business and Corporate Development. During this time at (OSI) Prosidion he helped integrate the diabetes program and has been responsible for several licensing deals with pharma companies. He returned to Probiodrug in 2006 as CEO.

Dr Glund holds a PhD in Biochemistry from the Martin-Luther-University of Halle. After completing his studies in biochemistry, he spent about 15 years as academic lecturer and conducted research in biochemistry as project and team leader at the University of Halle. Dr Glund is author or co-author of over sixty publications and is co-inventor on more than 10 patents.

---

Lothar Steidler, *Vice President Technology, ActoGeniX NV*

Dr Lothar Steidler is the main inventor of the TopAct™ technology.

Lothar started his research career at the University of Ghent (Belgium) during the early 1990s and became principal investigator at the VIB in 2001. In 2003 he relocated to the prestigious Alimentary Pharmabiotic Centre at University College Cork (Ireland), headed by Professor Fergus Shanahan.

In September 2006, Lothar returned to Belgium to take up the position of Director of Technology Development at ActoGeniX. Lothar’s research has shown that Lactococcus lactis, and food-grade microorganisms and commensal bacteria in general, can be genetically engineered to secrete biologically-active therapeutic molecules and can be applied as therapeutic products to treat diseases.

In recognition of this scientific breakthrough, Lothar received the 2001 William Grant and Sons Young European Prize for Invention and Discovery. In 2003, he was also awarded a Science Foundation Ireland investigatorship. His work has been published in various high-level scientific journals such as Science, Nature Biotechnology and Gastroenterology.

Lothar holds a PhD in Biotechnology from the University of Ghent and is currently a guest professor at Ghent University, teaching host-bacteria interactions.

---

Luca Bolliger, *VP and Group Licensing Director, RECORDATI S.A.*

Luca Bolliger studied biochemistry at the ETH in Zürich and completed his undergraduate studies with a Master in Immunology. He graduated at the Biocenter in Basel in biochemistry, and then became Member of the Basel institute for Immunology. He then joined the pharmaceutical industry as a Global discovery portfolio manager in the Pharma Strategy Unit at Hoffmann-La Roche Ltd. He then pursued his career in the financial industry as a Fundamental analyst at BT&T asset management, and as a freelance consultant. He established Biopol Ticino where he also participated in the creation of the Swiss marketing platforms Swiss Biotech and Swiss Medtech before becoming Director Business Development at Actelion. Luca Bolliger joined Recordati from Novimmune where he was director Business Development.
Speakers

Marco Superina, Head M&A Switzerland, Head of Healthcare M&A Europe, Credit Suisse AG


Marco Superina is a Managing Director and the Head of Healthcare Switzerland as well as the Head of M&A Switzerland based in Zurich. Marco Superina joined Credit Suisse directly after receiving his Dr. oec. publ. in banking and finance from the University of Zurich.

Marco Superina has extensive investment banking experience. His M&A experience covers a broad range of industries and he has been involved in notable transactions including Switzerland’s first public takeover battle (Centrepulse, ultimately acquired by Zimmer), the first public LBO of a Swiss listed company (Rank Group Holding’s acquisition of SIG Holding) and defence assignments for Ciba (against activist investors), Leica Geosystems (against Hexagon) or Converium (against Scor).

Selected transaction experience includes:

- M&A: • Sale of Synthes to Johnson & Johnson for $21.3bn • Sale of Ciba to BASF (CHF6.1bn) • Acquisition of Valeant’s dermatology assets by Galderma ($1.4bn) • Sale of Preglem to Gedeon Richter for CHF445m • Sale of Nutrition & Santé by Novartis for EUR220m • Novartis acquisition of Alcon ($51bn) • Advisor to the Special Committee of Serono on the sale of Merck KG ($12.9bn) • Sale of Zimmer to Gedeon Richter for CHF2.3bn • Advising Actelion against Elliott Associates • Synthes-Stratec acquisition of Mathys (CHF 1.5bn) • Synthes acquisition of intellectual property rights (CHF 1bn) • Acquisition of Groupe OGF by Vestar Capital Partners Europe (EUR 300m) • Galderma acquisition of Spirig Pharma (undisclosed) • IPO of Ypsomed SelfCare Solutions.

Margarita Chavez, Director, Ventures & Early Stage Collaborations, AbbVie Biotech Ventures, Inc.

Margarita Chavez has over 15 Years of dealmaking experience. Margarita started her career as corporate and securities lawyer in Silicon Valley advising startups, venture funds and investment banks in financings, M&As and IPOs, first with the firm of Rosenblum, Parish & Isaacs (acquired by Pillsbury Winthrop) and then at Brobeck Phleger & Harrison. Margarita joined Abbott as Corporate Counsel in 2004 and became Senior Counsel in 2005, advising Abbott and its diabetes division on transactions, including licensing and acquisitions. In 2007, Margarita joined Abbott’s Global Pharmaceutical Licensing & Acquisitions team, where she worked on the TAP dissolution (Lupron acquisition), in-licensing of Elagolix among other strategic transactions. Margarita then joined Abbott Biotech Ventures (became AbbVie Biotech Ventures in 2013), where she has been leading investments and managing portfolio companies in the US and Europe since 2010, including AM Pharma (NL), AuraSense (US) and Aline (US). In late 2013, AbbVie Biotech Ventures became AbbVie Ventures & Early Stage Collaborations. Since that time, Margarita closed a number of transactions, including options, licenses and acquisitions. Margarita received her Juris Doctor from Santa Clara University School of Law in 1997, and her Bachelor’s Degree from Santa Clara University in 1994.
8th ANNUAL
European Life Science CEO Forum & Exhibition

Speakers

Markus Goebel, Partner, Novartis Venture Funds

Markus Goebel started his career in the Health Care Industry in 1990. An MD by training and certified, amongst others, in hematology/oncology he worked for Farmitalia Germany and later held several global positions in R&D, Marketing and Strategy at Roche headquarters to include a worldwide alliance with Amgen. He joined Novartis in 2000 and first worked as Global Head Nervous System BD&L Pharma and later as Global Head Pharma Corporate M&A. In 2004 he joined the Novartis Venture Fund as a Managing Director in the US, moving back to Europe in 2009. Previously he received an MD and a PhD from the Ludwig Maximilian’s University in Munich and an MBA from Henley Management College. Markus serves on the boards of several Novartis Venture Fund portfolio companies, having exited, amongst others from Sirtris, FoldRx, EraGen, Intellikine and LigoCyte.

Michael Scherz, Chief Executive Officer, Metys Pharmaceuticals

Senior drug development and discovery expert, with synthetic & medicinal chemistry Ph.D. and 23 years of pharmaceutical industry experience. Founder & CEO of Metys Pharmaceuticals.

Michèle Ollier, Partner, Index Ventures

Michèle joined the Index Life Sciences Team as a Partner in 2006. Michele’s invested and sits on the board of a number of Index Life Science portfolio companies including Epsilon 3 Bio, FunXional Therapeutics, LinguaFlex, Minerva Neurosciences and OncoEthix. She was also a Director at Aegerion. Prior to joining Index, Michele was Investment Director at EDRIP (Edmond de Rothschild Investment Partner) in Paris for three years. Before she spent more than 15 years in several development and marketing positions at Sanofi International, BMS, RPR/Aventis international and Serono International, her experience spans over different therapeutic areas as CNS, cardiovascular, oncology and reproductive health.

Mick Cooper, Head of Research, Healthcare, Edison Investment Research

Dr Mick Cooper is the Head of Research, Healthcare at Edison Investment Research, having joined the healthcare team in January 2010. Previously, he worked for three years at Astaire Securities as the pharmaceuticals & biotechnology equity analyst, covering a wide range of healthcare companies. He holds a doctorate from Cambridge University and completed an MBA at INSEAD business school in France after working as a parliamentary researcher.

Mike Khan, CMO, Silence Therapeutics

Mike is a consultant physician and the Director of the Lipid and Coronary Prevention Clinics for Warwickshire, having previously been the Head of Molecular Medicine at the University of Warwick. He is an expert advisor to the UK Clinical Guidelines Development Group and The National Institute for Clinical Excellence (NICE), and has served on numerous advisory boards for pharmaceutical companies.

Mike is a highly cited researcher and experienced clinician with a long track record in metabolic medicine and cancer biology research as well as in the running of clinical trials. He has written several books on diabetes, cholesterol problems and cancer biology and teaches postgraduates and undergraduates in medicine and biological sciences. He has contributed to furthering the understanding of cancer cell biology and diabetes and along with colleagues is currently working on identifying novel tissue-based biomarkers for colorectal cancer and the development of novel diagnostic tools. Mike is a fellow of the Royal College of Physicians of London and a member of the Association of Physicians, HEART UK and Diabetes UK.
Nanna Lüneborg, *Investment Director, Novo Seeds, Novo A/S*

Nanna is Investment Director of Novo Seeds, the early stage investment arm of Novo A/S. Novo Seeds is a leading early stage investor, actively creating new biotech companies primarily in Scandinavia through seed and venture investments. Nanna joined Novo A/S in 2012. Previously, she was part of the life science investment team at Apposite Capital, a successful London-based healthcare venture fund, investing in drug development, medical devices and healthcare services. Earlier in her career, she was at Cancer Research UK. Nanna completed her BA at St Hughs College, University of Oxford, her PhD in Neuroscience at University College London, and an MBA at University of Cambridge. She currently serves on the board of Directors of Affinicon, Glionova, IO Biotech, Minervax and Pcovery, and she is an observer on the board of Galecto Biotech.

Neil Butler, *Chief Executive Officer, Spectromics*

Founding CEO of Spectromics  
Chairman of Atlas Genetics  
Supervisory Board Director of Genomic Vision  
Director of Radisens Diagnostics  

Pascal Touchon, *Vice President - Scientific Cooperation & Business Development, Les Laboratoires Servier*

Pascal Touchon has over 26 years’ experience in the pharmaceutical industry in Research, Marketing and Sales, General Management and Business Development. He has extensive international experience in managing commercial operations and as CEO in France, Central & Eastern Europe, Northern Europe, Asia, Australia, Canada, and South Africa. As head of Business Development for Servier over the last 3 years, he led the closing of more than 18 partnerships with biotech companies and academic institutes, managed various existing alliances and conducted two company acquisitions. Servier is a private research based pharmaceutical company with sales of 3.9 billion euros worldwide and activities in cardiovascular diseases, type II diabetes, neurology, psychiatry, rheumatology and oncology. Pascal holds a Doctorate in Veterinary Medicine, a DESS in Management and an MBA from INSEAD.


Patrick J. Doyle has served as our Chief Business Officer since May 2014, and as a consultant from January 2014 to May 2014. From March 2013 to January 2014, he served as Vice President of Strategic Partnerships for PPD Inc., a global contract research organization. From October 2009 to March 2013, Mr. Doyle was the President of Kareus Therapeutics, SA, a biopharmaceutical company in Switzerland. From June 2006 to September 2009, he served as Chief Executive Officer of Syntain, a biopharmaceutical company. Prior to joining Syntain, Mr. Doyle served as Chief Corporate Development Officer of Metabolix Inc., a biopharmaceutical company, and Global Head of Pre-Clinical Partnering of Hoffmann La-Roche, a global healthcare company. Mr. Doyle received a B.Sc. (Hons.) in Pharmacology from University of Sunderland, where he also completed Ph.D. coursework and received a post-doctoral specialization in the role of the brain in metabolic diseases from the University of Geneva, Switzerland. Pascal holds a Doctorate in Veterinary Medicine, a DESS in Management and an MBA from INSEAD.

Olivier Litzka, *Partner, Life Sciences, Edmond de Rothschild Investment Partners*
Speakers

Peter Culpepper, CFO & COO, Provectus Biopharmaceuticals Inc.
More than 20 years of finance experience and working with high-growth start-up companies
Led the national operating unit of a $1 billion publicly traded telecom company

Philippe Lopes-Fernandes, Senior Vice-President, Head of Global Licensing & Business Development, EMD Serono, Inc.
Philippe Lopes-Fernandes is the Senior Vice-President, Head of Global Licensing & Business Development for Merck Serono / EMD Serono. His team provides end-to-end transactions support to ensure execution of high-quality global deals for all Merck Serono business units and all stages of development, from early technology to clinical stage and marketed products.
Philippe is a results driven, innovative and committed executive with more than 20 years of experience in the pharmaceutical industry (in Prescription, Generic and OTC fields). He brings strong expertise in licensing and M&A, project management, marketing and sales, having directly negotiated key deals for Merck KGaA, including the in-licensing of Erbitux, the acquisition of Serono, the sale of Merck’s generic business to Mylan, and most recently the alliance with Pfizer on PDL1. He has lived and worked in France, Portugal, Germany, Switzerland and the U.S.
Philippe holds a graduate degree in Business Administration from Institut Superieur de Gestion in Paris, France.

Rainer Metzger, Vice President, Global Head Business Development Pharma, Qiagen GmbH
2013 to present – VP, Global Head BD Pharma, QIAGEN GmbH
2011 to 2013 – VP, Pharma Partnerships, LEICA BIOSYSTEMS, Nussloch, D
2007 to 2011 – VP, Head Biomarker Ops, ROCHE PHARMA, Basel, CH
2002 to 2006 – VP, Head BD Oncology, ROCHE DIAGNOSTICS, Basel, CH
2002 to 2002 – CEO, MEGAMEDICS, Hamburg, D
1995 to 2002 – Founder & CEO, CELLCONTROL AG, Munich, D
1992 to 1995 – Product Manager, MOLECULAR DEVICES, D, US

Educational Background
- PhD, Molecular Biology & Pharmacology, University of Heidelberg / Karolinska Institute, Stockholm
- Diploma (Masters), Biology, University of Heidelberg
Speakers

Rao Movva, Executive Director, Novartis Institutes for BioMedical Research, Inc.

Rao was born in India and pursued his studies leading to M.Sc degree from Nagpur university in India. He completed my Graduate studies with a Ph.D degree in Molecular Biology at SUNY at StonyBrook, New York in 1980. Subsequently, he joined Biogen S.A., then, a novel start-up biotech company in Geneva, Switzerland as a research scientist in 1980 and worked there until 1987 in various capacities as Project leader, Program executive and Senior research scientist focusing on cloning of novel genes and the expression of recombinant protein.

He moved to Sandoz AG in Basel, Switzerland in 1987 and have been with the organization since in several research environments and in various capacities.

As a group leader in the Biotechnology (1987-92), he had developed methods for successful production of various recombinant proteins, including lymphokines IL-3, IL-6 and LIF from E.coli.

From 1992-1996, as the head of Signal transduction Biology group, he contributed to elucidate the of Mechanism of action of immunesuppressive drugs, including, notably the identification of TOR protein as the target of Rapamycin, the active component of Novartis transplant (Certican) and cancer (Affinitor) drug.

As the Head of Molecular biology and Gene therapy unit in the (1996-2004), he led very early efforts to evaluate the gene therapy technologies and developed screening strategies for small molecules to identify tool and lead compounds for drug development.

In the past 10 years, he focused his efforts in chemical biology to connect the chemicals with their biological targets to accelerate drug discovery.

In addition he is involved in setting up multiple collaborations between Novartis and the various leading academic institutions of the world by acting as a scout to identify and initiate new drug discovery projects including the Human microbiome efforts in Novartis Institute for Biomedical research (NIBR).

Overall, Rao has more than 30 years of biotech and large pharma research and drug discovery experience and has authored several peer reviewed publications.

Ravi Sodha, Senior Director Business Development, Actelion Pharmaceuticals, Ltd.

Ravi studied in the UK obtaining B.Sc. in Pharmacology, Ph.D. and MBA. He spent several years in Research (London University, Zurich University Hospitals, Ciba Geigy Basel), Clinical Development (SmithKline Beecham) and Sales & Marketing (Novartis). In 1999 Ravi moved to Business Development & Licensing at Novartis, where he spent 8 years in various functions and therapeutic areas. His last responsibility at Novartis was Alliance Management for a Business Franchise and Asia-based job rotation for Business Development activities in the emerging markets, including India, China, Korea and Taiwan.

Ravi joined Actelion Pharma Switzerland in 2008 as Senior Director, Business Development, where his responsibilities include structuring and negotiating licensing deals across several therapeutic areas. Ravi has three women in his life, and enjoys cooking, soccer (from the comforts of his arm chair), and spiritual reading.
Regina Hodits, General Partner, Wellington Partners

Regina joined Wellington Partners in spring 2010. She is a General Partner and represents the Wellington Partners funds on the Board of Middle Peak Medical, Ayoxxa, Sapiens and Atopics, and is an external director at GlaxoSmithKline’s Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences.

Until January 2010, Regina led the life sciences efforts of Atlas Venture in Europe, a leading transatlantic venture capital firm. As a Partner at Atlas Venture, she led numerous financing rounds and was the founding investor in Bicycle Therapeutics, Fibreex, F-star and Jenavalve. Regina served on several Boards, including the Board of U3 Pharma, which was acquired by Daiichi Sankyo Co. Ltd in 2008 and Novamed, which was acquired by SciClone in 2010.

From 2000 to 2004, while working for Apax Partners, she was responsible for healthcare investments in Germany and was closely involved in investments such as Genmab, Silence Therapeutics and WiLex. She started to build her extensive network in the global healthcare industry during her tenure at McKinsey from 1997 to 2000.

In the 90s, Regina gained profound insights into the fast-growing biotech sector as university lecturer and post-doctoral researcher at the University of Vienna and the MRC Cambridge, where she collaborated with emerging UK biotech companies. Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry.

Richard Godfrey, Chief Executive Officer, BerGenBio AS

Richard Godfrey joined BerGenBio as Chief Executive Officer in 2008. He has more than 25 years’ industry experience leading many international drug development and commercialisation partnerships. Formerly he served as Chief Executive Officer of Aenova Inc., a specialist biopharmaceutical company. Prior to this he was the Managing Director of DCC Healthcare Ltd and previously he held positions of increasing responsibility at Catalant, Eli Lilly and Reckitt Benckiser in R&D and commercial roles. He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University.

Seth Lederman, Chief Executive Officer, Tonix Pharmaceuticals Holding Corp

Seth Lederman is a physician, scientist, and specialty pharmaceuticals entrepreneur. Prior to founding TONIX, from 2007-2008 Dr. Lederman co-founded and was a managing partner of Konanda Pharma Partners, LLC and Konanda Pharma Fund I, LP. He co-founded and served as director and chairman of its wholly-owned operating companies Validus and Fontus Pharmaceuticals Inc., which market Equeetro® (carbamazepine — Extended Release), Marplan® (isosorbide dinitrate) and Rocaltril® (calcitriol). In 2000 Dr. Lederman founded Targent Pharmaceuticals to develop late-stage oncology drugs including pure-isomer levofolinic acid, which was sold to Spectrum Pharmaceuticals and is now FDA-approved and marketed as Fusilev® for colorectal cancer. In 1998 Dr. Lederman co-founded Vela Pharmaceuticals, which developed several drugs for central nervous system disorders, including VLD-cyclobenzaprine.

Dr. Lederman maintains an appointment as Associate Professor at Columbia University. Dr. Lederman joined the faculty of Columbia University’s College of Physicians and Surgeons in 1985, became Assistant Professor of Medicine in 1988, and Associate Professor with tenure in 1996 and Director of the Laboratory of Molecular Immunology in 1997. From 1988 to 2002, Dr. Lederman directed basic science research at Columbia in molecular immunology, infectious diseases and the development of therapeutics for autoimmune diseases. Dr. Lederman is author of numerous scientific articles, and inventor of technologies recognized by a number of issued patents. Dr. Lederman’s fundamental work on the CD40-Ligand (CD154) elucidated the molecular basis of T cell helper function and has led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection in collaboration with Biogen-IDEC and CellTech/UCB. The successful defense of his CD154 patents has led to important precedents in defining the relationship of therapeutics and molecular targets. In collaboration with Prof. David Baltimore (then at Rockefeller University and later MIT), Dr. Lederman identified and functionally characterized the CD40 signaling molecule, TRAF-3. His early work on HIV contributed to the understanding of how the V3 loop of HIV gp120 was involved in fusion with CD4 cell membranes, an early and essential event in viral entry and infection. In addition to his research, Dr. Lederman served as attending physician in the Edward Daniels Arthritis and Autoimmune Clinic on the Medical Service at Columbia Presbyterian Hospital 1988-1996.

Dr. Lederman earned an AB from Princeton University cum laude in 1979 and an MD from Columbia University’s College of Physicians and Surgeons in 1983. Dr. Lederman trained in internal medicine and rheumatology at Columbia’s Presbyterian Hospital. He was an NIH Physician-Scientist 1985-1990 at Columbia.
Speakers

Simon Kerry, Chief Executive Officer, Karus Therapeutics Ltd

Simon is a business professional with two decades’ experience of creating and developing innovative life science companies. Before he joined Karus as the Company’s CEO in 2006, he was Director of Business Development at Ablynx NV (Ghent, Belgium), where he secured a number of research, development and licensing agreements with major pharmaceutical companies including Wyeth (now Pfizer) and Novartis. During this time, he played a key role in Ablynx’s growth from early-stage to one of Europe’s most promising antibody companies.

Siro Perez, Venture Partner, HADEAN VENTURES

Siro has over fifteen years of scientific and international management experience across the whole research, development, commercialization, and investment process in new technologies.

He is a Venture Partner at Hadean Ventures, where he advises the fund on due diligence and identifies investment opportunities. He also actively advises and co-founds start-ups through Roundcape, a boutique consulting firm he founded in 2013.

Prior to founding Roundcape, he served as CEO of ToxoMet, leading the company from a development stage start-up to a fully commercial enterprise with sales in 5 continents, and raising £5m at increasing valuations in the process.

Before joining ToxoMet, he worked investing in pharmaceutical and biotech stocks for one of the world’s leading hedge funds ($14B under management), and as Investment Manager for a global life sciences venture capital fund ($1.5B under management).

Before his investment career, he worked as Project Leader in the Zurich office of The Boston Consulting Group, managing strategy projects for global Pharma, Biotech, and Financial Services companies. Prior to that, he led a group in drug development and conducted research in neurodegenerative diseases at Novartis, and started his scientific career at the Cajal Institute of Neurobiology, with several publications in peer-reviewed journals.

Siro holds a Masters in Finance from the London Business School, and a PhD summa cum laude in Molecular Biology and a MSc in Chemistry with honours from the Autonoma University of Madrid. He also studied Computer Science Engineering at UNED, and speaks English, German, and Spanish fluently.

Sten Verland, Partner, Sunstone Capital A/S

Sten Verland is founding partner at Sunstone Capital. His primary investment focus is within drug development, and he has more than 20 years’ experience as an international executive, entrepreneur and venture investor in biotech companies as well as pre-clinical and clinical CROs. Currently, Sten also serves as non-executive director of Orphazyme A/S, Anergis SA, Vaximm AG and Minervax A/S.

After completing his doctorate, Sten held a number of academic positions in the field of biomedical research including the position of Assistant Professor in Immunology at the University of Copenhagen.

In 1994, Sten headed a Management Buy-Out of a contract research organisation (CRO) specialising in laboratory animal science and non-clinical development. Under his leadership the company successfully introduced a range of new services and technologies within the field of transgenic animal research. After 4 years as a major shareholder, Sten merged the company with another Danish biotech company thus forming M&B A/S with a staff of 100. The company was acquired by Taconic, Inc., New York, in 2000.

In 1998, Sten participated in the foundation of Synarc, Inc., San Francisco (now BioClinica, Inc.), and served for 4½ years as VP, General Manager Europe. During his tenure, Synarc developed from a small start-up clinical service provider into the world’s largest central radiology service company dedicated exclusively to global clinical trials. With 6 offices around the world and a staff of 220, Synarc managed over 150 clinical trials, involving more than 60,000 patients at 1,500 sites worldwide.

From 2003 to 2007, Sten operated his own investment company where he co-founded or invested in 7 life science companies and served as non-executive director on 16 Boards. Sten holds a M.Sc. in Chemistry with honours from the Autonoma University of Madrid and a PhD in Immunology from the University of Copenhagen.
Speakers

Stephen Sands, *Commercial Lead Oncology/Immunology*, F.Hoffmann La Roche AG

Stephen has over 25 years commercial experience in the pharma industry in multiple disease areas, now specializing in oncology. In his current role Stephen is the Oncology Commercial Lead for Roche Partnering, leading the acquisition process for key assets, such as the recently announced partnership between Roche and Oryzon around the epigenetic compound ORY-1001. Prior to this Stephen was the Commercial Director for Roche Oncology and prior to that the Commercial Director for Avastin. In these roles he developed and supported the commercial and marketing strategies for some of the largest brands in the field of oncology.

Stephanie Léouzon, *Principal and Head of Torreya Partners Europe*, Torreya Partners (Europe) LLC

Stephanie Léouzon is Partner and Head of Europe for Torreya Partners, a life sciences boutique advisory firm which she joined in 2012. She also serves on the Board of Directors of Immunovaccine Inc. Previously she worked in Health Care Investment Banking in the US and Europe from 1989-2010, most recently at Credit Suisse as a Managing Director and Senior Advisor. She has advised life sciences clients on more than 20 strategic transactions, valued at over $65 billion, and been involved in over 45 financing transactions to provide over $10 billion to health care clients. Stephanie earned an M.B.A. degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a B.A. degree, cum laude, from Mount Holyoke College in 1985.

Stewart Kay, *Director, Transactions*, GlaxoSmithKline

Stewart started his career at Amersham International (now part of GE) and held various sales, marketing and business development positions in the Life Science and Technology Platforms division. He joined Evotec in 2002 as SVP Business Development for Europe and was part of the operational management team. In 2005 he joined Pharmagene as VP Commercial Development and as a member of the Executive Management team took the company into a merger with Asterand. Stewart joined GSK in 2008 and is currently Director Transactions in Worldwide Business Development, Pharma R&D. Stewart holds a B.Sc in Biochemistry and a MBA from Warwick Business School.

Ted Fjällman, *CEO*, Prokarium Ltd

Spun-out Prokarium from Cobra Biologics in 2012 and raised funds for pre-clinical R&D and phase 1 clinical study for travellers’ diarrhoea. Before joining Prokarium worked in Strategy Consulting and previously in the clinic at one of Europe’s largest hospitals. PhD in Biotechnology (Antibody Engineering) from Canada. Currently a fellow of SynBio LEAP.

Thilo Schroeder, *Partner*, Nextech Venture

Thilo Schroeder is Partner at Nextech Invest Ltd., a global venture fund, focused on investing in oncology companies. Prior to joining Nextech, from 2007 to 2013, Dr. Schroeder was president of SiROP Global, a web based technology company that connects universities in Europe and world-wide. Dr. Schroeder was observer of the board of Tracon Pharmaceuticals and currently serves as a board member of Blueprint Medicines and an observer of the board of Peloton Therapeutics and ImaginAb, all biopharmaceutical companies. He received a B.Sc. in biology from the Technical University of Darmstadt in Germany, an M.Sc. in biotechnology from the Ecole Supérieure de Biotechnologie de Strasbourg in France, and a Ph.D. in biochemistry from the University of Zurich in Switzerland.
8th Annual
European Life Science CEO Forum & Exhibition

Speakers

Thomas Taapken, CEO & CFO, Epigenomics
Dr. Thomas Taapken has served as CEO of Epigenomics AG since September 2012. He joined Epigenomics on April 1, 2011 as Chief Financial Officer from Biotie Therapies (Finland), where he held the position of CFO and was a member of the Executive Management Team. He was appointed to this position in 2008, following a business combination between Biotie Therapies and elbion NV, where Thomas had been CFO since 2005. His extensive international experience in the life sciences industry includes previous positions as investment partner at DVC Deutsche Venture Capital from 2003 to 2005 and San Francisco-based US venture capital firm Burnell & Company from 1998-2002. He also worked several years at Sanofi-Aventis in the U.S.A. and Germany, managing corporate venture capital activities, as well as in the areas of corporate & business development and research. Throughout his career, he has been involved in numerous transactions spanning acquisitions, mergers, divestitures, as well as private and public offerings.

Tim Haines, Partner, Abingworth LLP
Tim has more than 25 years of international management experience in the life sciences industry. Before joining Abingworth in 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for more than five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Current and past board positions include Astex Pharmaceuticals, Fovea, Kspine, Lombard Medical, Pixium Vision, PowderMed, Sientra, Stanmore Implants and XCounter. Tim has a BSc from Exeter University and an MBA from INSEAD. At Abingworth, he identifies and creates new businesses and provides support for portfolio companies.

Tim Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca
Timothy Herpin heads a group of business development professionals involved in all aspects of transactions negotiation and execution at AstraZeneca. Tim joined AstraZeneca in 2011 as Vice-President, Strategic Partnering and Business Development, initially for CNS & Pain and more recently for Oncology. Prior to AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation as well as transaction in multiple disease areas. Before his business development career, Tim worked in R&D at Bristol-Myers Squibb, Aventis and Pharmacaopeia. Tim grew up in Paris and is a graduate of Ecole Polytechnique in France. He also holds a Ph.D. in organic chemistry from University College London and an MBA in Finance from NYU Stern.

Vincent de Groot, Sr. Director, Ventures & Early Stage Collaborations, AbbVie Deutschland GmbH & Co. KG
Vincent de Groot, Ph.D., CLP, Vincent is a business development & licensing professional, entrepreneur, and scientist. He currently serves as Senior Director, Ventures & Early Stage Collaborations at Abbvie. Most recently, he served as Vice-President, Business Development & Licensing at Synthion Biopharmaceuticals. He joined Synthion via its acquisition of Syntarga in 2011. Vincent was founder of Syntarga and led the company as its CEO from inception to M&A. He obtained his Ph.D. degree cum laude from the Radboud University Nijmegen in the Netherlands. He published more than a dozen scientific papers, is inventor on several patents and was awarded several national and international scientific awards. Vincent is a member of the Licensing Executives Society (LES) and has received the Certified Licensing Professional (CLPT) credential from LES.
8th Annual
European Life Science CEO Forum & Exhibition

Speakers

Wilder Fulford, Principal, Torreya Partners (Europe) LLC
Wilder is the founding partner of Torreya Partners Europe, the London branch of Torreya Partners, an international advisory firm assisting Life Science companies with M&A, licensing, alliances, financings and other transactions. Dr. Fulford has had a long career advising healthcare companies of all kinds around the globe. After completing his PhD in molecular biology at the Rockefeller University in 1986, he worked for a few years as a venture capitalist, before embarking on a career as an M&A advisor. He has run healthcare M&A or coverage groups in New York and London at Salomon Brothers, Merrill Lynch, Bank of America and (most recently) Deutsche Bank. He has participated in close to 100 financing and M&A transactions with an aggregate value in excess of $100 billion. Torreya Partners has a full team in London, and about a dozen mandates in execution, and has closed five transactions so far in 2013 in biotechnology, specialty pharma, vaccines, medical devices, and OTC. Globally, Torreya Partners has completed over 100 Life Sciences assignments in the 6 years since inception.

William Hearl, Chief Executive Officer, Immunomic Therapeutics, Inc.
Dr. William Hearl is founder, president and CEO of Immunomic Therapeutics. Prior to founding Immunomics, he also founded Capital Genomix in 2000, a company that identified novel cancer genes using a proprietary platform (GeneSystem320) and converted them to antibodies using ImmunoMouse technology. He has worked at a number of leading companies in the biotech industry including Life Technologies, Pharmacia Diagnostics and KPL. He holds multiple patents (and patents pending) in the field of genetic immunization. He received a Ph.D. in Biochemistry from the University of Tennessee in 1984.

Wouter Latour, Chief Executive Officer, Vaxart, Inc.
Dr. Latour brings more than 20 years of industry experience to Vaxart, including roles as vice president and director, Global Strategy and Business Development at SmithKline Beecham Biologicals (now GSK Vaccines) and as a strategic advisor for Novartis Pharma, Novavax and Berna Biotech (now J&J/Crucell). Most recently, Dr. Latour served as CEO and director at Trinity BioSystems, Inc., a company focusing on oral delivery of biopharmaceuticals. Dr. Latour earned his MD from the University of Amsterdam and his MBA from Stanford University.
CONTACT

Dr. Arne-C. Faisst
Owner and Principal

ADDRESS

4D Lifetec AG
Gebwerbestrasse 10
6330 Cham
Switzerland

TELEPHONE

+41 79 434 10 49

EMAIL

arne.faisst@4dlifetec.com

YEAR FOUNDED

2014

COMPANY PROFILE

4D Lifetec is a company developing and promoting test and screening systems for molecular diagnostics including the production of related consumables.

Based on the single cell gel electrophoreses assay principle the company has recently developed the highly innovative 4D Lifetest™, a molecular diagnostic system improving personalized cancer therapy by quantifying DNA repair mechanisms. Due to its improved technique it generates potential patient benefit by its non-invasive and time saving approach. It also offers cost savings to healthcare providers by its outstanding precision and high degree of standardization both leading to a reduction of false positive results. Due to its high-throughput capacity and its high precision, 4D Lifetest™ also offers a unique solution for DNA defect and repair based screening programs and is therefore the diagnostic method of first choice.

So far 4D Lifetec owns two utility models of the 4D Lifetest™ which are fully functional and IP protected. The analytical part including software application to quantify the outcome is an integral part of the on-going development process.

4D Lifetec profits from different networks within science and healthcare. Direct contacts to several Key Opinion Leaders within the field of Comet Assay, national and international normative bodies as well as within the market leading Contact Research Labs exist.

Contacts to software developing companies exist and they could be used to further foster a potential co-operation on development level.

The company is currently backed by risk capital of the founders to ensure thorough preparation of first phase of capitalization. The company is run by 2 full time equivalents who co-ordinate the specific project management steps for the first 18 months.

MANAGEMENT

Dr. Arne-C. Faisst, Owner and Principal
Dr. Giancarlo Rizzoli, CO-CEO Business
Dr. Oliver Schicht, CO-CEO Development

www.4dlifetec.com
FINANCIAL SUMMARY
The company is currently raising a $12 million series A round (2015) to conduct the phase IIA program with ABTL0812, its first drug candidate, with sales potential over $1.5 Billion in all cancer types.

SHAREHOLDERS: Inveready Capital Company, founders and private Investors. Since 2009 it has raised $4.6 Million in equity and government soft loans.

COMPANY PROFILE
Ability Pharmaceuticals is a clinical stage biopharmaceutical company based in Barcelona focused on the development of a new drug class for cancer treatment.

The company is currently raising a $12 million series A round (2015) to conduct the phase IIA program with ABTL0812, its first drug candidate, with sales potential over $1.5 Billion in all cancer types.

ABTL0812 is currently finishing the first in humans phase I/Ib clinical trial, with good safety and efficacy signals (several disease stabilizations and activity on biomarkers).

ABTL0812 is an Akt/mTOR inhibitor, fully differentiated from other ones marketed or being commercialized. It has efficacy comparable to, or higher than, reference compounds, it is active over resistant tumor cells and synergistic with other anticancer drugs without increasing toxicity. It has an excellent safety profile.

ABTL0812 is developed for the treatment of lung, pancreatic and gynecological cancers. In the phase II program the patients will be selected based on PI3K/PTEN/AKT mutations/deletions and amplifications.

PRODUCT PIPELINE

ABTL0812 - Differentiated mechanism of action
• ABTL0812 is an Akt/mTOR inhibitor through a novel mechanism of action, fully differentiated from other PI3K/Akt/mTOR inhibitors.
• ABTL0812 prevents Akt phosphorylation by mTORC2 and inhibits mTORC1 resulting in the inhibition of the phosphorylation of the ribosomal protein S6.
• ABTL0812 induces cell death by AUTOPHAGY.
• ABTL0812 likely avoids the positive Akt/mTOR feedback loop associated with mTORC1 inhibitors.
• Action on several steps of the PI3K/Akt/mTOR signaling pathway anticipates activity in tumors with different mutation profiles and less probability to develop resistance than with other inhibitors, approved or under development.

ABTL0812 - Antitumor activity
• Active in a broad range of human cancer cell lines: NSCLC lung cancer, pancreatic cancer, hepatoma, melanoma, glioma, breast cancer, colon cancer, neuroblastoma and lymphoma.
• Oral antitumor efficacy in human xenografts as single agent, comparable or higher than reference compounds (docetaxel, erlotinib, gemcitabine, cisplatin),

Continued...
...continued

- Synergy with gold-standard treatments: docetaxel (85x) and gemcitabine (8x) in cell culture. At low doses ABTL0812 potentiates docetaxel antitumor activity in xenografts without increasing toxicity.
- Efficacy in resistant and non-responder cell lines.
- Superiority over other PI3K/Akt/mTOR pathway inhibitors in drug resistant cancer cell lines.

**ABTL0812 – ongoing phase I/II clinical trial**
- Currently ongoing at Hospital Clinic Barcelona and Institut Català Oncologia. Ending in April 2015.
- Phase I/II (First in Humans) in patients with advanced solid tumors, with enrichment in lung, pancreatic and gynecological cancer patients.
- Multi-center, open-label and single-agent study. Oral administration.
- Two parts: i) dose escalation (15 patients - completed) and ii) expansion phase (12 patients - ongoing).
- 28-day cycles of treatment.
- Efficacy: several patients with stable disease, one lasting more than 11 month. Activity in the inhibition of the phosphorylation of Akt in platelets (biomarker). Mild adverse events – High safety and tolerability.

**Phase II program starting in 4Q2015 - 1Q2016.**
- Patient will be stratified according to PI3K mutations, PTEN mutations and deletions and Akt overexpression
- Phase II program with trials in endometrial cancer, squamous cell lung carcinoma and pancreatic cancer.

**OPPORTUNITIES**
- Raising series A financing round of € 10 Million
- Out-licensing ABTL0812

**MANAGEMENT**
Carles Domènech, PhD, Chief Executive Officer - Co-founder.
13 yrs Business Dev & Licensing at Almirall & Lacer, 3 yrs Biotech VC, 8 yrs Cancer Research Memorial Sloan-Kettering Cancer Center, CSIC & Univ. Autònoma of Barcelona.
José Alfón, PhD, VP Research & Development
12 yrs drug discovery, drug development (pre-clinical and clinical) at Palau Pharma & Uriach - 6 yrs Research at Hebrew Univ. of Jerusalem and Univ. of Barcelona.
Mariana Gómez, PhD, Director, Biology Research
12 yrs cancer research at Albert Einstein College of Medicine NY, Mount Sinai Hospital Toronto, CIB CSIC (Madrid) and CRG (Barcelona).
Marc Cortal, MD, Director, Clinical Research
Clinical Practice and Health Management - Clínica Quiró, Hospital Mutua de Terrassa, Middlesex Hospital Saint Mary London / Red Cross Geneva.
Vanessa Ruiz, Director, Finance & Administration.
Formerly Chief Financial Officer of Sevibe Cells.
8th ANNUAL
European Life Science CEO Forum & Exhibition

ADDEX Therapeutics Ltd.
www.addextherapeutics.com

COMPANY PROFILE
Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2A POC in Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter Phase 2B for PD-LID. In parallel, dipraglurant’s therapeutic use in dystonia and treatment resistant depression is being investigated. Addex second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc. Addex also has several preclinical programs including: ADX71441 (GABAB receptor PAM) which has received regulatory approval to start Phase 1 and is being investigated for therapeutic use in Charcot-Marie-Tooth (Type 1A) disease, alcohol use disorder and nicotine dependence; mGlu4PAM for drug abuse and dependence, Parkinson’s disease and other neurodegenerative diseases; mGlu2NAM for treatment resistant depression with cognitive deficits; mGlu7NAM for psychosomatic disorders, TrkBPAM for neurodegenerative disorders; and GLP1PAM for type 2 diabetes. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

PRODUCT PIPELINE

<table>
<thead>
<tr>
<th>MOLECULE/ RESEARCH</th>
<th>ASSET DEVELOPMENT &amp; SUBSTANCING</th>
<th>HIT-TO-LED</th>
<th>LEAD OPTIMIZATION</th>
<th>CANDIDATE ORAL SELECTION</th>
<th>IND EMULGATION</th>
<th>PHASE I</th>
<th>NAACER</th>
<th>COLLABORATORS/ PARTNERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dipraglurant-IR</td>
<td>mGluR5 NAM</td>
<td>Parkinson’s Disease: Dyskinesia (PD-LID) Phases 1-2b/3.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dipraglurant-IR</td>
<td>mGluR2 PAM</td>
<td>Adjunct therapy to dyskinesia in focal dystonia.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADX71441</td>
<td>GABA A/PAM</td>
<td>Generalized Cystinosis patients with Dystonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADX7141</td>
<td>GABA A/PAM</td>
<td>Add-on to levodopa in Parkinson’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADX7140</td>
<td>GABA A/PAM</td>
<td>Charcot-Marie-Tooth Type 1A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADX7139</td>
<td>GABA A/PAM</td>
<td>Charcot-Marie-Tooth Type 1B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADX7138</td>
<td>GABA A/PAM</td>
<td>Dystonia under review</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dipraglurant-IR</td>
<td>mGluR6 NAM</td>
<td>Treatment-resistant depression</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADX7141</td>
<td>GABA A/PAM</td>
<td>Autism, Psychosis, One of the Rarer, Anxiety and Fatigue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mGluR4 PAM</td>
<td>Parkinson’s Disease: Multiple Schizophrenia, Anxiety, Autism and Depression</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mGluR7 NAM</td>
<td>Treatment-resistant Depression and Cognitive Deficits</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADX7177</td>
<td>mGluR7 NAM</td>
<td>Parkinson’s disease (including PD-LID)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GP1117</td>
<td>PAM</td>
<td>Type II Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FSH</td>
<td>PAM</td>
<td>Endothelial, Natural Fibrotic and Metabolic Chronic Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dipraglurant-IR : Preparing Phase IIb trials
Dipraglurant is a negative allosteric modulator of the metabotropic glutamate receptor 5 discovered at Addex in 2003. It is a highly selective, oral small molecule and has potential to be used in combination with levodopa or dopamine agonists for the treatment of Parkinson’s disease.

The Dipraglurant immediate release formula is being developed for the treatment of Parkinson’s disease Levodopa induced dyskinesia. Dipraglurant-IR achieved key objectives in a Phase IIa trial that was co-funded by the Michael J Fox foundation. A phase IIb trial is currently being prepared.
...continued

**ADX71149/mGluR2 PAM : Phase II**
Positive proof-of-concept were reported for ADX71149 as an add-on therapy for treating schizophrenia. Partner Janssen Pharmaceuticals Inc. is reviewing which indication(s) to pursue.

**Dipraglurant-ER : Phase IIa**
Dipraglurant extended release formulation is being developed for the treatment of non-parkinsonian dystonia. Addex has a partnership with the Dystonia Medical Research Foundation to explore its use in dystonia. Two proof of concept trials are planned to start in 2015 with results in 2016.

**ADX71441-CMT1A : Preclinical**
ADX71441 is a novel, first-in-class, oral, small molecule activator of the gamma-aminobutyric acid subtype B (GABAb) receptor functioning through positive allosteric modulation. Activation of the GABAb receptor is preclinically, clinically and commercially validated in a number of indications through the use of baclofen.

ADX71441 is being developed for the treatment of Charcot-Marie-Tooth Subtype 1A (CMT1A) syndrome, a rare neurodegenerative disease. ADX71441 has shown efficacy in CMT1A rat models. A Phase I trial is planned to start in 2015 with results in 2016.

**ADX71441-Addiction : Preclinical**
ADX71441 is also being explore for treating nicotine and/or alcohol addiction. Addex has a partnership with the US NIAAA (National Institute on Alcohol Abuse and Alcoholism), where ADX71441 will be evaluated in a number of preclinical models of alcohol addiction. Another partnership is in place with NIDA (National Institute on Drug Abuse), where ADX71441 will be subjected to a number of tests in preclinical models of nicotine addiction.

**MANAGEMENT**
Tim Dyer, co-founder and Chief Executive Officer
Sonia Poli, Chief Scientific Officer
Robert Lutjens, Head of Discovery
Amphera B.V.
www.amphera.nl/en

COMPANY PROFILE
Amphera B.V. (established December 2012) is a Dutch life sciences company that develops immunotherapies for the treatment of cancer.
Amphera’s lead product focuses on malignant mesothelioma.
Malignant mesothelioma, asbestos induced cancer, is a rare, but fatal disease with a survival after diagnosis of 9 months on average. With the best standard of care (chemotherapy) mean survival is increased to 12 months.
After a first round of EMA Scientific Advice, Amphera is actively looking for investors to finance the pivotal phase II/III study for our dendritic cell therapy.

MANAGEMENT
Ilona Enninga, CEO
Rob Meijer, CCO
AnaptysBio is a privately-held company focused on the generation of antibody therapeutics and is the leader in the use of somatic hypermutation (SHM) for antibody generation. We are developing a pipeline of novel therapeutic antibody candidates, including differentiated programs in cancer immunotherapy, inflammation and fibrosis.

Our internal pipeline antibody pipeline is led by a novel anti-IL-33 therapeutic antibody, ANB020, applicable to a variety of Th2 diseases, including asthma, atop dermatitis and food allergies.

AnaptysBio’s proprietary SHM-XEL™ platform, which couples fully human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate highly functional antibodies, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.

The Company has previously announced partnerships with Merck, Roche, Novartis, Celgene, Gilead, Momenta, Tesaro, DARPA and DTRA.
**Athera Biotechnologies AB**

www.athera.se

**CONTACT**
Carina Schmidt  
CEO

**ADDRESS**
Athera Biotechnologies AB  
Sankt Eriksgatan 117, 4th floor  
113 43 Stockholm,  
Sweden

**TELEPHONE**
+46 76 1938 190

**EMAIL**
c.schmidt@athera.se

**YEAR FOUNDED**
2002

**COMPANY PROFILE**
Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The lead product candidate, the fully human antibody PC-mAb, is in clinical development. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics.

**PRODUCT PIPELINE**
PC-mAb

**MANAGEMENT**
Carina Schmidt, CEO
Atomo Diagnostics
www.atomodiagnostcs.com

FINANCIAL SUMMARY
Please speak with company directly

COMPANY PROFILE
Atomo is an award winning company commercialising disruptive user focused diagnostic solutions for both professional use and consumer health markets.
Atomo’s products replace the need to use complex rapid test kits with a convenient reliable user friendly solution.
Atomo tests are ideal for POC and consumer applications due to their simplicity and ease of use, enabling Atomo to target large market opportunities largely unserviced by existing ‘bits in a box’ test kits.
The AtomoRapid platform is easily re-validated for existing diagnostic assays and typically delivers improved diagnostics performance and overwhelming user preference when compared to existing products.

PRODUCT PIPELINE
AtomoRapid / Rapid test companion diagnostics device / Generation I commercially launched
AtomoRapid is an integrated ehealth compatible disposable rapid test device that can deliver at home diagnostic support of Phase III trials and subsequent drug launch programs.
It enables at home and primary physician monitoring of trial performance, materially reducing trial costs and significantly improving patient compliance and convenience.
AtomoRapid supports a wide range of clinical applications and has already been commercialised for a range of commercial diagnostic markers.

MANAGEMENT
Mr John Kelly, Chief Executive Officer
Mr Ricky Sadler, Director of Operations
Mr Byron Darroch, Director of Business Development
Azanta A/S
www.azanta.com

CONTACT
Claus Møller
President and CEO

ADDRESS
Tranegaardsvej 20
2900 Hellerup

TELEPHONE
+45 70 25 95 45

EMAIL
info@azanta.com

YEAR FOUNDED
2008

FINANCIAL SUMMARY
Sales 2013: 39 mill DKK

COMPANY PROFILE
Azanta A/S is a privately owned specialty pharma company primarily operating within oncology, women’s health and addiction medicine. The vision of Azanta A/S is to become an international market leader within specialty pharma products and innovative pharmaceutical products. Azanta A/S currently markets or makes available a string of specialty pharmaceutical products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy and Angusta for labour induction. In addition, Azanta A/S has a portfolio of low risk development projects for commercialization within the near future.

MANAGEMENT
Claus J. Mølle, CEO
Bo Kruse, CFO
Hanne Damgaard Jensen, CDP/COO
BerGenBio AS
www.bergenbio.com

FINANCIAL SUMMARY
Raised Ca. $30m equity (plus ca. $10m grant) funding through a series of rounds from 2009 to date. From Norwegian VC, private and institutional investors.
Considering an IPO end 2015/ early 2016

COMPANY PROFILE
BerGenBio is a clinical stage biopharmaceutical company focused on developing innovative drugs for aggressive, drug resistant cancers.
The Company is a world leader in understanding epithelial-mesenchymal transition (EMT) biology, which is widely recognised as a key pathway in acquired cancer drug-resistance and metastasis. Building on this original biological insight BerGenBio is developing a promising pipeline of novel EMT inhibitors.
BerGenBio intends to develop its product candidates to proof of concept stage; further clinical development and subsequently commercialisation will be through strategic alliances and partnerships with experienced global bio-pharma oncology businesses.

PRODUCT PIPELINE
BGB324: Phase Ib / IIA
Highly selective, orally bio-available small molecule inhibitor of AXL. Multiple Phase Ib clinical trials are on going and selected Phase II trials planned for unique clinical opportunities.
BGB001: Preclinical
This is three monoclonal antibody programs against AXL, in late stage preclinical development: one program has already been licensed to a specialist biopharma company for forward development and commercialisation.
BGB002: Preclinical
This is a small molecule development program against a novel EMT target, it is in late stage lead optimisation phase. Substantial preclinical data suggests multiple clinical positions, including very aggressive triple negative breast cancer and other drug resistant cancers that are difficult to treat.

MANAGEMENT
Professor James Lorens is the co-founder of BerGenBio. He is also a Professor at the Department of Biomedicine at the University of Bergen. On completing his postdoctoral research studies at Stanford University he joined Rigel Inc., a San Francisco based biotechnology company, as a founding scientist and research director. Prof. Lorens has managed several large scientific collaborations in cancer research and development with major pharmaceutical and biotechnology companies. In addition to BerGenBio, he leads a large internationally active research laboratory comprising 22 researchers. His group is active in EMT, angiogenesis and cancer research. Prof. Lorens is an author of more than 70 peer-reviewed articles and patents.

Dr. Murray Yule joined BerGenBio in 2011 as a consultant and became Chief Medical Officer in 2013. He began his career in the pharmaceutical industry in 1998 after completing his medical training in oncology at Addenbrookes Hospital, Cambridge. Whilst working in the United Kingdom’s National Health Service, Murray supervised multiple early phase clinical studies of novel anticancer products and completed a PhD in experimental pharmacology. In the last ten years, whilst working in several top-ten pharmaceutical companies, he has planned and executed global development strategies for several anticancer drugs, which has led to licensing approvals for novel tubulin binders in solid tumors and epigenetic therapies in acute leukemia.

Petter Nielsen joined BerGenBio in 2015 as CFO. Previously he held the position of CFO at GexCon, an R&D company that developed into an international group of companies focusing on commercial products and services. Nielsen has extensive experience related to mergers and acquisitions, IPOs, valuation and IFRS from Ernst & Young where he has worked in the Transaction Advisory Services group. He obtained an MSc in Auditing and an MSc in Economics and Business Administration, both from the Norwegian School of Economics.
FINANCIAL SUMMARY
BioCrypton is privately funded and raising Series A funding.

COMPANY PROFILE
BioCrypton (San Francisco, US). BioCrypton is a private biotech company specializing in a high-impact ultra-sensitive protein BioChip sensors and comprehensive multiplexed molecular clinical diagnostic tests to improve patient outcomes, provide financial benefits for insurance companies and lower healthcare costs. 

Product: Multiplex protein BioChip and immunochemistry assay/diagnostic test supported by proprietary algorithms. BioChip assay is compatible with a range of patient samples (blood, serum, saliva, urine, biopsy. Product is integrated with Health-IT module (novel algorithms, HIPAA-compliant web, encrypted data, and cloud database).

Platform Technology: Compositions and methods enabling detection and characterization of O-GlcNAc glycosylated sites and O-GlcNAc glycosylated proteins. Our technology is applicable for robust diagnostics and drug development in a number of clinical applications, including cancer, Alzheimer, CNC, cardiovascular diseases, and diabetes. Our are well validated, originated at Caltech and we have publications in Nature, Science, PNAS.

IP: Strong portfolio of issued patents.

Product Applications: 1st focus: BioChip and multiplexed clinical diagnostic test for Pancreatic Cancer and Pancreatitis. 2nd focus BioChip and diagnostic test for Gastrointestinal (GI) cancers and GI chronic diseases (“all-in-one”). 3rd BioChip and diagnostic test for Arthritis. BioCrypton R&D can be easily expanded and applicable to other complex human diseases.

BioCrypton R&D capabilities: BioCrypton has on-going R&D and laboratories in San Francisco. Our workflow directly integrated with global biobank which has operations at 90 clinical sites in 15 countries around. The biobank has significant biorepository (about 100,000 samples from ~7,000 individual cases) and brings to BioCrypton 12 years of expertise in tissue research projects including tissue procurement, study design, regulatory affairs, clinical network management, specimen collection, processing and analysis.

R&D Model: We are leveraging a proven, profitable, advanced and sustainable R&D model; we are integrating our R&D with outsourcing to validated CROs and business partners with whom we have worked before. It will expedite our timelines and reduce the cost of R&D.

Clinical Need and Large Market Opportunity
Pancreatic cancer (PC) is one of the most aggressive and deadliest GI cancers. Population of PC patients is growing and PC is anticipated to be the 2nd leading cause of cancer-related deaths by 2020. PC can be treatable if diagnosed early. PC is asymptomatic in early stages and usually detected at a “too late-to-treat” stage when patients already have significant clinical symptoms (metastasis, organ failure, pain) due to the lack of specific and sensitive diagnostic tests to detect cancer at early stage. Pancreatitis is a disease which can result in serious complications: bleeding, serious tissue damage, infection, cyst formation, and chronic pain. Chronic pancreatitis can get worse over time and can lead to permanent damage. Severe pancreatitis can harm heart, lungs, and kidneys if pancreatitis is not detected, monitored and treated appropriately. Statistics - prevalence: 1.1 million cases per year; ambulatory care visits: 881,000; hospitalizations: 553,000; prescriptions: 766,000. Thus, there is a critical need for a comprehensive, sensitive, non-invasive, robust and cost efficient blood test for diagnostic and monitoring of pancreatic cancer and pancreatitis, especially at early stages. Who will prescribe: Oncologists, general medicine physicians, surgeons and pathologists.

Market is about $1 billion per year. We see the opportunity for our product to be the 1st in class and the best-in-class.

PRODUCT PIPELINE
Pancreatic Cancer and Pancreatitis BioChip and diagnostic test : Discovery clinical R&D
Multiplex protein BioChip and immunochemistry assay/diagnostic test supported by proprietary algorithms. BioChip assay is compatible with a range of patient samples (blood, serum, saliva, urine, biopsy. BioCrypton
...continued

product will be integrated with Health-IT module (novel algorithms, HIPAA-compliant web, encrypted data, and cloud database).

**Arthritis BioChip and diagnostic test: Early stage R&D**

Multiplex protein BioChip and blood based clinical diagnostic test for Arthritis.

**Gastrointestinal BioChip and test: Early stage R&D**


**OPPORTUNITES**

**BioChip Diagnostic product R&D and pipeline**

BioCrypton is looking for Series A funding ($4 million with milestones)

Product: Multiplex protein BioChip and immunochrometry assay/diagnostic test supported by proprietary algorithms. BioChip assay is compatible with a range of patient samples (blood, serum, saliva, urine, biopsy). Product is integrated with Health-IT module (novel algorithms, HIPAA-compliant web, encrypted data, and cloud database).

**IP:** Strong portfolio of issued patents.

**Product Pipeline:**

1. Pancreatic Cancer and Pancreatitis.
2. Gastrointestinal (GI) cancers and GI chronic diseases (“all-in-one” biochip assay).
3. Arthritis.

**Platform Technology (Collaboration or co-licensing opportunity):**

Compositions and methods enabling detection and characterization of O-GlcNAc glycosylated sites and O-GlcNAc glycosylated proteins.

**Platform Technology:**

Compositions and methods enabling detection and characterization of O-GlcNAc glycosylated sites and O-GlcNAc glycosylated proteins. Our technology is validated and applicable for robust diagnostics and drug development in a number of clinical applications, including cancer, Alzheimer, CNC, cardiovascular diseases, and diabetes. Our methods are well validated, originated at Caltech and published in Nature, Science, PNAS.

**BioMarker Discovery program**

Our Biomarker program is comprehensive combination of discovery and characterization of biomarkers of diseases, glycomarkers and histopathology services. In our biomarker program we are also offering a significant collection of human biospecimens (tissue, blood etc) or we can collect biospecimens for your R&D according your specific goals with custom study design and precision medicine clinical implementation program. Our workflow directly integrated with global biobank which has operations at 90 clinical sites in 15 countries around. Our biobank has significant biorespository (about 100,000 samples from ~7,000 individual cases). Biobank has 12 years of track record working with pharma in discovery, translational medicine and diagnostics areas, Government (US) contracts and clinical network management (TCGA, CPTAC). We are providing an expertise in tissue research projects including tissue procurement, study design, regulatory affairs, clinical network management, specimen collection, processing and analysis.

**MANAGEMENT**

Valeria Ossovskaya, Ph.D., is CEO, CSO and co-founder of BioCrypton. Prior, Dr. Ossovskaya was Director of Sanofi Innovation Center and served as Director of R&D at Sanofi Global Oncology. From 2003 to 2009 Dr. Ossovskaya served as a co-founder and Director of R&D at BiPar Sciences (acquired by Sanofi in 2009), where she established preclinical development and translational medicine programs. Prior to joining BiPar, Dr. Ossovskaya served as Assistant Research Professor at UCSF and Scientist at Rigel. Her experience includes a number of collaborations and strategic alliance management with biotech and pharmaceutical companies, including Johnson & Johnson, Janssen, Novartis, and Oxford Gene Technologies. Dr. Ossovskaya holds a B.S. in Virology and Biochemistry, a Ph.D. in Molecular Biology, completed UIC molecular genetics fellowship at the University of Illinois at Chicago and postdoctoral training at departments of Pathology and Surgery at UCSF.

Continued...
Olg Potapova, Ph.D., is the President and co-founding partner of BioCrypton. Since 2003 Dr. Potapova is Chief Executive Officer and Scientific Director of Cureline Inc., a group of biotech companies specializing in human tissue research, histopathology and translational medicine, collaborating with major clinical centers in Europe, Asia, and the USA. Dr. Potapova is a principal investigator at The Cancer Genome Atlas (TCGA) NCI/NIH program since 2010. Prior to Cureline, Dr. Potapova held various scientific positions at NIH, Sugen/Pharmacia/Pfizer. She has been involved in multiple successful research programs including the development of cancer therapy sunitinib (Sutent), human prenatal diagnostic tests, human biospecimen procurement, and multiple preclinical drug development programs. Dr. Potapova is an international expert in strategic alliance management and business collaborations. She holds an M.S. degree in Physics and a Ph.D. in Biochemistry. Dr. Potapova has received multiple awards and fellowships from AACR/AFLAC, NIH and NATO.

Mikhail Gishizky, Ph.D., joined BioCrypton team as Executive Vice President of Product Development and Advisor. Dr. Gishizky is a biotech and pharmaceutical expert and executive with broad experience in biopharmaceutical R&D and technologies that have led to breakthrough drug therapies and diagnostics. Dr. Gishizky was a co-founder of Sugen where he served for 18 years in various positions including VP of Research and Target Discovery through the acquisitions by Pharmacia and Pfizer. After Sugen, Dr. Gishizky served as Chief Scientific Officer at Entelos, leading in silico pathway analysis R&D programs. Dr. Gishizky extensive expertise includes drug development, technology implementation, bioinformatics, translational clinical research at biotech startups and big pharmaceutical companies. Dr. Gishizky business experiences also includes IPO, liaison with government, FDA, non-profit and pharmaceutical organizations. Dr. Gishizky received a B.A. from the University of California, Berkeley, holds a Ph.D. in Endocrinology from the University of California, San Francisco, and completed postdoctoral training at the University of California, Los Angeles.

Macauley Johnson LLC provides comprehensive Chief Financial Officer services to BioCrypton since October 2012. Macauley Johnson LLC has twenty-five years of finance and accounting experience in a biotech industry including start-up operations, accounting and administrative functions, Committed Equity Financing, Private Investment in Public Equity, IPOs, venture debt and VC funding. Previous biotech projects include BiPar Sciences, Pain Therapeutics; Elan, Athena Neurosciences, Chiron and Gilead among others.
8th ANNUAL
European Life Science CEO Forum & Exhibition

Biophytis
www.biophytis.com

CONTACT
Stanislas Veillet
CEO

ADDRESS
1 av. de l’OPERA
PARIS 75001
France

TELEPHONE
+33 14 183 6610

EMAIL
stanislas.veillet@biophytis.com

YEAR FOUNDED
2006

COMPANY PROFILE
BIOPHYTIS develops new therapeutics derived from phytonutrients involved in ageing processes. Its candidates are both drug and nutraceutical products, with a focus on Sarcopenic Obesity and dry AMD.

PRODUCT PIPELINE
BIO103 : sarcopenia : drug candidate : regulatory PC
BIO101 : sarcopenic obesity : nutraceutical candidate : clinical
BIO203 : geographic atrophy : drug candidate : regulatory PC
BIO201 : dry AMD : nutraceutical candidate : clinical

OPPORTUNITIES
15M€ round C investment in 2015

MANAGEMENT
Stanislas Veillet, CEO
René Lafont, CSO
Waly Dioh, COO
J.C. Montigny, CFO
FINANCIAL SUMMARY
Calypso Biotech SA has received initial 2.5 Mi EUR funding from MS-Ventures and is currently raising a 8.4 Mi EUR series A to bring one of its programs, CALY-002, to proof of concept in patients by 2018.

COMPANY PROFILE
Calypso Biotech SA, a spin-off from Merck-Serono incorporated in Switzerland, discovers and develops therapeutic antibodies for severe gastro-intestinal diseases. Our pipeline includes two best-in-class antibodies neutralizing matrix metalloproteinase-9 and Interleukin-15, respectively.

PRODUCT PIPELINE
CALY-001: Preclinical
Fully human selective and neutralizing anti-MMP-9 antibody. Clearly differentiated from competitor GS-5745 (in early clinical trials in IBD, oncology and fibrotic diseases) based on unique mode of action.
Calypso Biotech indications: IBD and immuno-oncology (combination with PD-1/PDL-1 blockade)

CALY-002: Preclinical
Humanized selective and neutralizing anti-IL-15 antibody. Clearly superior to discontinued AMG-714 clinical program.
Calypso Biotech indications: ultra-rare, life threatening refractory celiac disease and other undisclosed niche indications.

OPPORTUNITIES
CALY-001 Fully human selective and neutralizing anti-MMP-9 antibody. Clearly differentiated from competitor GS-5745 (in early clinical trials in IBD, oncology and fibrotic diseases) based on unique mode of action.
Calypso Biotech indications: IBD and immuno-oncology (combination with PD-1/PDL-1 blockade)

CALY-002 Humanized selective and neutralizing anti-IL-15 antibody. Clearly superior to discontinued AMG-714 clinical program.
Calypso Biotech indications: ultra-rare, life threatening refractory celiac disease and other undisclosed niche indications.

MANAGEMENT
Alain Vicari, DVM, PhD, Chief Executive Officer
Yolande Chvatchko, PhD, Chief Scientific Officer
Cell Therapy Ltd.
www.celltherapyltd.com

COMPANY PROFILE

Objective: Founded in 2009 Cell Therapy Ltd (CTL) is a Bio-Pharmaceutical company developing novel Regenerative Medicines. CTL has discovered and developed four in-house products that are undergoing clinical trials with lead product, Heartcel™, having completed PII clinical trial in late stage Heart failure.

Results: In just 5 years, CTL’s in-house innovation has produced 2 platform technologies and four products

Team: World-class scientists (Nobel laureate, President of American Society) and clinicians (Clinical Professors of Cardiac surgery and Cell Therapy from top universities Oxford and Toronto) led by experienced pharmaceutical management (ex-Roche), active Board and Scientific advisory committee of global experts.

Approach: CTL’s extensive IP portfolio was discovered and developed in-house with retention of commercial rights. Close academic collaborations allow completion of trials in a fraction of normal time and cost. IP and clinical data carefully packaged for transaction and tax efficiency. Good results from Heartcel™ trial in 2014, three Skincel™ trials in 2015 and Orphan drug authorisation and marketing approval sought for 2016.

Opportunity: CTL’s product portfolio compares favourably with most listed stem cell companies. To optimise value creation from this portfolio, CTL should complete final trials of Heartcel™ to gain Orphan drug approval. The completed Heartcel™ trial might garner 2013 average PII licensing deal value of ~$643M total including ~$131M upfront but completing PIII and gaining approval may drives average valuation to over $1 Billion.

OPPORTUNITIES

• CTL’s completed and submitted PII results provide evidence of safety and efficacy. Average PII licensing deal value in 2013 was ~$643M total including ~$131M upfront. Publication of PII results will drive M&A and licensing interest.

• However, to optimise value CTL should complete the next clinical trial (Phase III) in-house to capture a PIII licensing deal which averaged ~$355M Upfront and ~1.7B Total leading to a Big Pharma trade sale or IPO in London.

• In 2014, CTL seeks to diversify its shareholder base with sophisticated investors ahead of an IPO or transaction in 2015.

• CTL offers a rare opportunity for investment in a world-class UK Biotechnology company with the innovation and management to capture significant upside while offering near term commercialisation and EIS2 risk mitigation.

MANAGEMENT

Prof. Sir Martin Evans, Chairman & Chief Scientific Officer CTL
Mr. Ajan Reginald, Executive Director CTL
Digby, Lord Jones of Birmingham, Director CTL
Mr. Rhodri Morgan, Director and Head of Audit and Governance Committee CTL
Dr. Mubasher Sheikh, Director CTL
Cellular Biomedicine Group, Inc.
www.cellbiomedgroup.com

COMPANY PROFILE
Addressing unmet medical needs of the world’s largest population, Cellular Biomedicine Group is a biomedicine firm engaged in the development of effective cellular therapies for degenerative joint diseases and airway diseases, immuno-oncology drugs for various cancers, as well as providing biomedical and cellular technical services to healthcare facilities in China. Led by a seasoned management team and board with more than 150 years of relevant experience in China, Europe, and the USA, it is the only pure-play NASDAQ-listed China market-focused biomedicine developmental company.

MANAGEMENT
Dr. William (Wei) Cao, Chief Executive Officer
Dr. Steve (Wentao) Liu, Chairman
Tony (Bizuo) Liu, Chief Financial Officer
DanDrit Biotech
www.dandrit.com

FINANCIAL SUMMARY
Raised $12 million.
Cash reserve for 3 years of operations

COMPANY PROFILE
DanDrit Biotech (OTCQB:DDRT) develops MCV, an immunotherapy to prevent recurrence of colorectal cancer in patients who reached No Evidence of Disease (NED) after resection and chemotherapy. MCV is a dendritic cell vaccine stimulates the immune system to kill remaining or metastatic cancer cells that could grow and lead to relapse. The ‘VIVA’ Phase III clinical trial will start enrollment in March 2015.

PRODUCT PIPELINE
MCV, Phase III CRC

MANAGEMENT
Eric Leire, MD, MBA, CEO
Bob Wolfe, CFO

CONTACT
Eric Leire, MD, MBA
CEO

ADDRESS
PO Box 189
Randolph, VT 05060
United States

TELEPHONE
+1 (646) 460 4077

EMAIL
epl@dandrit.com

YEAR FOUNDED
2001
Epigenomics AG
www.epigenomics.com

FINANCIAL SUMMARY
Epigenomics is publicly listed at the Frankfurt Stock Exchange, Prime Standard: (ECX, ISIN DE000A1K0516) and has established a Level 1 ADR program in the U.S.A. (OTCQX: EPGNY).
For financial information please refer to the Investor Relations section of the Company’s website.

COMPANY PROFILE
Epigenomics is a molecular diagnostics company developing and commercializing innovative products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe, has received approval by the Chinese Food and Drug Administration for China and is under regulatory review by the U.S. Food and Drug Administration (FDA). Additionally, the Company markets its tissue assay for use in lung cancer diagnosis, Epi proLung®, in Europe. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A.

PIPELINE PRODUCT
Epi proColon® test
Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe, has received approval by the Chinese Food and Drug Administration for China and is under regulatory review by the U.S. Food and Drug Administration (FDA).

Epi proLung®
Epi proLung® is a tissue assay for use in lung cancer diagnosis in Europe.

MANAGEMENT
Epigenomics is lead by a highly skilled and motivated management team with track records in the industry in the U.S. and Europe.
The team is headed by Dr. Thomas Taapken (formerly Biotie Therapies, Deutsche Venture, Burrill & Company) and Dr. Uwe Staub (formerly Abbott Diagnostics, Digene and Qiagen).

Dr. Thomas Taapken, CEO/CFO
Dr. Uwe Staub, COO
Noel Doheny, Epigenomics Inc.
Albert Weber, Senior Vice President Finance, Accounting & Controlling
8th Annual European Life Science CEO Forum & Exhibition

**Exploris Health AG**
www.exploris.info

**COMPANY PROFILE**

**Exploris Health – A pioneer in eDiagnostic solutions**

Cardioexplorer is a non-invasive eDiagnostic test that timely detects patients with coronary artery disease. Cardioexplorer has already been validated in a prospective clinical study at the University Hospital Basel. An additional study is underway. So far no other eDiagnostic approach has been able to produce such reliable results.

The convergence of biology and computer engineering is turning healthcare into an information based industry that will be disruptive, bringing huge benefits to patients, physicians and payers.

Exploris Health provides physicians with an innovative platform of non-invasive eDiagnostic tests for detection of life-threatening diseases, using easily available patient data and a routine blood test.

The aim is to establish the Cardioexplorer test as the gold standard CAD triage tool in primary care. Exploris Health has several partnerships with leading Swiss institutions, including, health insurance company Helsana, telecom provider Swisscom and others. Additionally we are in advanced discussions with diagnostic companies.

Growing demand for better clinical outcomes, treating diseases at the earliest stage, increasing the efficiency of the healthcare process and reducing healthcare costs are some of the major drivers that are stated to propel this market.

The healthcare analytics market showcases a lucrative growth potential due to its several advantages, such as regulatory compliance, reduction of hospital readmissions and hospital stays, prediction and prevention of chronic diseases, quality care, claims processing and prevention.

**PRODUCT PIPELINE**

**Cardioexplorer Test : Successfully completed prospective clinical study**

Accurate diagnosis of CAD status – costly, invasive and in hospital setting

Coronary artery disease (CAD) is the leading cause of death in the developed world. Reliable and early detection of CAD is crucial to improve outcomes and reduce costs. Until now, there is no non-invasive diagnosis available, which directly assesses a life threatening narrowing of the heart arteries (stenosis).

Cardioexplorer – A new gold standard eDiagnostic test for coronary heart disease

Exploris has developed Cardioexplorer, the new gold standard stratification test for primary care physicians to timely detect patients with a high risk of developing coronary artery disease (CAD). The Cardioexplorer test assesses the actual hemodynamic situation in the artery (stenosis Y/N).

Reduction in unnecessary referrals and angiographies yields substantial cost savings

Cardioexplorer avoids unnecessary referrals to a cardiologist for a costly and invasive angiography, where pursuant to a recently published study in the New England Journal of Medicine in >30% of the patients no stenosis is detected. Exploris successfully completed a prospective clinical study with Cardioexplorer, which was published in the International Journal of Cardiology in 2014. Importantly, next to robust and reliable CAD diagnosis, Cardioexplorer shows low false positive and false negative rates.

**MANAGEMENT**

Peter Ruff, Founder / CEO
Prof. Michael Zellweger, Clinician / Cardiologist
Dr. Michael Failer, Head Business Development
Andrew Tsirkin, Head Modeling and Software Development
Galecto Biotech AG
www.galecto.com

COMPANY PROFILE
Galecto Biotech is focused on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases. The company’s products target galectins or galactoside binding lectins, which are a group of proteins shown to be involved in many disease processes. Galecto Biotech’s high potency Galectin Modulators may open new treatment possibilities for many patients. The company is led by top-level scientists and biotech executives. Galecto Biotech is funded by Novo Seeds, MS Ventures*, Sunstone Capital and SEED Capital. Galecto Biotech is located in Copenhagen, Denmark, with close proximity to the founders’ research groups.

In November, 2014, Galecto Biotech announced that it has entered into an option agreement with Bristol-Myers Squibb for a total potential payment of $444 million.

PRODUCT PIPELINE
TD139
Inhalable small molecule Galectin-3 inhibitor in development for the treatment of idiopathic pulmonary fibrosis

MANAGEMENT
Dr. Hans T. Schambye, CEO
Anders Pedersen, COO
Dr. Paul Ford, CMO
8th ANNUAL
European Life Science CEO Forum & Exhibition

GamaMabs Pharma SA
www.gamamabs.com

CONTACT
Stéphane Degove,
CEO (co-founder)

ADDRESS
Centre Pierre Potier
1 place Pierre Potier
ONCOPOLE entrée B
BP 50624 - 31106 Toulouse
Cedex 1
FRANCE

TELEPHONE
+33 (0)5 31 61 60 69

YEAR FOUNDED
2013

FINANCIAL SUMMARY
GamaMabs raised a €3.6m series A led by Innobio (Bpifrance, France).

COMPANY PROFILE
GamaMabs is a private French biopharmaceutical company dedicated to the development of original optimized monoclonal antibodies (mAbs) in cancer.

GamaMabs' innovation originates from 3 sources:
- 3C23K, a humanized mAb in pre-IND stage which binds to AMHRII, an unaddressed target specifically expressed in gynecological cancers. 3C23K increases dramatically complete responses in pertinent in vivo ovarian cancer models.
- Access to glyco-engineering Emabling® technology which enhances antibodies' efficacy
- Follow-on program with “best-in-class” potential: HER3 fully-human optimized mAbs.

GamaMabs addresses high therapeutic needs indications:
- Ovary and other gynecologic cancers (endometrium) for AMHRII program, including granulosa cells tumors and mucinous ovarian cancer with potential fast-track registration
- Triple-Negative Breast cancer and pancreatic cancer for HER3 program

GamaMabs' experienced management has a successful track record in Biotech / Pharma.

PRODUCT PIPELINE
3C23K: Pre-IND
3C23K is a first-in-class monoclonal antibody directed against the receptor of the anti-Müllerian hormone (AMHRII / MISIIR). AMHRII is a pertinent unaddressed target widely expressed in gynecologic cancers, including ovarian cancer, cervix adenocarcinoma and endometrial cancer patients' samples.

3C23K is a glyco-engineered mAb which leverages tumor-associated immune cells, increasing their ability to destroy tumor cells. Ovarian cancer is a clinical setting well-suited for 3C23K, as these effector cells are dominant in patients' samples.

3C23K displays a high efficacy in multiple relevant patho-mimetic in vivo models. This efficacy is also shown to be synergistic with carboplatin (CT) and paclitaxel (PT), the first lines chemotherapeutic agents, translating into outstanding improvement in Complete Response (CR) and survival.

3C23K is in the pre-IND stage, its Clinical Trial Application being scheduled in Q3 2015. 3C23K has demonstrated a particularly safe profile in regulatory preclinical studies.

H4B-121: Preclinical
H4B-121 is a glyco-engineered fully human monoclonal antibody targeting HER3. H4B-121 leverages immune cells and displays outstanding in vitro and in vivo efficacy.

OPPORTUNITIES
Investment in series-B financing
GamaMabs is looking to raise €9m+ to finance 3C23K early clinical trials up to initial proof of concept.

At targeted closing (Q2 2015), all preclinical activities will be completed for 3C23K (financed by previous financing round).

This series-B proceeds will finance the company up to year-end 2017, including:
- A dose escalation phase Ia with 3C23K in gynecological cancers
- An expansion cohort with 3C23K in combination with chemotherapy in resistant gynecological tumors (n=25-30)
- An expansion cohort with 3C23K as a single agent in granulosa tumors (n=15)

The financing needs for a “3C23K-only” scenario amounts to €9m.

Continued...
GamaMabs Pharma SA
www.gamamabs.com

ADC/T cell engager partnering on AMHRII

GamaMabs is looking to leverage its know-how and antibodies targeting AMHR2 through collaborations on ADC or T cell engager programs targeting AMHR2.

The targeted partners are biotech or pharma with validated ADC or T cell engager technologies and interested in a target specific of gynecological cancers.

MANAGEMENT

Stéphane Degove, CEO (co-founder)

Has 18 years’ experience in Pharma (Sanofi), Strategy Consulting (OC&C) and in biotech. He was a co-founder & CFO of Endotis Pharma where he raised €37m.

Jean-François PROST, MD, VP R&D and Strategy (co-founder)

Leads the R&D of several European Pharmas (Servier, Pierre Fabre, UCB pharma and LFB). He discovered, developed and/or registered in Europe/US Protelos, Procoralan, Artex, Valdoxan, bexl, Keppra and Wilfact. At LFB he contributed to develop the Enabling® technology and two Enabling® mAbs up to phase II: roledumab (anti-D) and ublituximab (CD20).

Anne Bousseau, MD, Senior Advisor Oncology

Has more than 25 years’ experience in the pharmaceutical industry R&D. She developed expertise all along the value chain, having served successively as Discovery program head (AIDS, Oncology early and late development in global R&D at Sanofi. In her last position, Anne was heading the Oncology early development teams.
FINANCIAL SUMMARY
£11m invested pre 2013 in 5 rounds £14m Invesco Perpetual Feb 2013.

COMPANY PROFILE
Glide Technologies is a clinical stage device and diagnostic development business. Glide’s octreotide solid dose injection generates clinical data Q4 2015 and its prostate cancer diagnostic generates initial clinical read out Q1 2015. The preclinical pipeline includes peptides and vaccines. Glide intends to complete a £15m funding 2015 enabling three clinical POC trials and partnering.

PRODUCT PIPELINE

<table>
<thead>
<tr>
<th>Pipeline</th>
<th>Development Status</th>
<th>Results expected</th>
<th>Market Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>SDI® octreotide</td>
<td>Clinical bioequivalence trial 2015</td>
<td>H2 2015</td>
<td>£200m</td>
</tr>
<tr>
<td>Prostate cancer diagnostic</td>
<td>Awaiting clinical readout</td>
<td>H1 2015</td>
<td>£2bn</td>
</tr>
<tr>
<td>SDI® parathyroid hormone</td>
<td>Preclinical equivalence</td>
<td>H1 2015</td>
<td>£2bn</td>
</tr>
<tr>
<td>SDI® Pfenex* anthrax vaccine</td>
<td>Preclinical studies</td>
<td>H2 2015</td>
<td>£525m</td>
</tr>
<tr>
<td>SDI® GLP1 agonist</td>
<td>Feasibility studies</td>
<td>H2 2015</td>
<td>£2bn</td>
</tr>
<tr>
<td>Seasonal flu vaccine*</td>
<td>Feasibility studies</td>
<td>H1 2015</td>
<td>£4bn</td>
</tr>
</tbody>
</table>

Glide octreotide : Clinical bioequivalence trial 2015
In mid-2014 Glide’s octreotide solid dose formulation achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Sandostatin®). Glide recently announced the appointment of Albany Molecular Research Inc for manufacture for a clinical study targeted to take place in the second half of 2015.

Glide ‘PROSPECT’ prostate cancer diagnostic : Awaiting clinical readout
In July 2014 Glide announced it had taken an exclusive worldwide licence to an innovative non-invasive prostate cancer diagnostic technology from FScan Ltd. Renamed ‘Prospect’ the technology is being developed initially as an analyte-specific reagent in the USA. In the longer term the company intends to develop ‘Prospect’ as a diagnostic test and to pursue regulatory approvals in the US and in Europe.

Glide parathyroid hormone (PTH) : Preclinical equivalence
In November 2012 Glide was awarded £2.3m by the UK’s Biomedical Catalyst for the development of a novel solid dose formulation of teriparatide (PTH) for the treatment of osteoporosis. A preclinical PK study is targeted for completion in Q2 2015.

Glide Anthrax Vaccine : Preclinical studies
In April 2013 Glide was awarded a development contract by Pfenex Inc to develop a solid dose formulation containing the Anthrax bacillus recombinant protective antigen (‘rPA’). The Pfenex project is funded in whole with Federal Funds from the US National Institute of Allergy and Infectious Diseases (‘NIAID’). Precinical studies will continue during 2015.

Glide GLP1 agonist : Feasibility studies
Glide is continuing its exploration of the solid dose formulation platform for the delivery of therapeutics currently self-administered by patients. The field of GLP-1 agonists is attracting a great deal of commercial attention and proof-of-principle formulation data with exenatide are being generated throughout 2015.

Continued...
Glide Technologies
www.glide-technologies.com

...continued

OPPORTUNITIES
• £15m Fundraising 2015
• Licensing – Partner to advance octreotide SDI® beyond clinical PoC
• Licensing – Partner to co-develop parathyroid hormone SDI® after preclinical results

MANAGEMENT
Mr Bryan Morton, Chairman
Dr Mark Carnegie-Brown, Chief Executive Officer
Mr Richard Bungay, Chief Financial Officer
Dr Genevieve Motte, Development & Operations Director
Dr Tony Mills, Business Development Director

CONTACT
Dr Mark Carnegie-Brown
Chief Executive Officer

EMAIL
mark.carnegie-brown@glide-technologies.com

YEAR FOUNDED
2001

© Glide Pharma 2015

Developing patient centric devices & diagnostics
mark.carnegie-brown@glide-technologies.com

Portfolio
Pipeline
Development
Status
Results

expected
Market
Size

SDI® octreotide
Clinical bioequivalence trial 2015
H2 2015
$200m

Prostate cancer diagnostic
Awaiting clinical readout
H1 2015
$2bn

SDI® parathyroid hormone
Preclinical equivalence
H1 2015
$2bn

SDI® Pfenex
* anthrax vaccine
Preclinical studies
H2 2015
$525m

SDI® GLP1 agonist
Feasibility studies
H2 2015
$2bn

Seasonal flu vaccine*
Feasibility studies
H1 2015
$4bn

*Partner programmes

...continued
Hansa Medical AB
www.hansamedical.com

FINANCIAL SUMMARY
Operating profit 2014 TSEK -24,709, TSEK -17,629 2013

COMPANY PROFILE
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. The company is based in Lund, Sweden. Hansa Medical’s share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.

PRODUCT PIPELINE
IdeS : Clinical phase II
IdeS, a unique molecule with a novel mechanism, is a bacterial enzyme that cleaves human IgG antibodies. IdeS degrades all IgG specifically, swiftly and efficiently. IdeS has been tested for safety and efficacy in numerous in vitro and in vivo models. During 2013, a Phase I clinical trial on 29 healthy subjects was conducted, demonstrating IdeS as efficacious and well tolerated with a favorable safety profile. During 2014 and 2015, a Phase II clinical trial in sensitized patients awaiting kidney transplantation has been conducted. Preliminary data shows that IdeS has very good efficacy in highly sensitized patients on the kidney transplant waitlist. The study shows that IdeS has the capacity to make sensitized patients eligible for transplantation by decreasing HLA antibodies to levels acceptable for transplantation. In addition to transplantation, IdeS has potential indications within a variety of rare autoimmune diseases including anti-GBM disease. IdeS is protected by several patents and has been published in numerous peer review journals.

MANAGEMENT
Fredrik Lindgren, President and CEO
Emanuel Björne, Corporate Development Director DR.
Christian Kjellman, Chief Scientific Officer
Dr Lena Windstedt, Clinical Research Director
Helsinn Healthcare SA
www.helsinn.com

CONTACT
Roberto De Ponti
Head of Corporate Business Development

ADDRESS
Helsinn Healthcare SA
Via Pian Scairolo 9
6912 Lugano/Pazzallo
Switzerland

TELEPHONE
+41 (0) 91 985.21.21

EMAIL
info-HHC@helsinn.com

YEAR FOUNDED
1976

COMPANY PROFILE
Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the USA and a representative office in China. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care.

Helsinn Group in-licenses early-to-late stage new chemical entities, completing their development by performing pre-clinical/clinical studies as well as associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn’s products are out-licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. Helsinn has built a large product portfolio of cancer care products with the alliance of over 65 global partners. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn’s products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers. Further information on Helsinn Group is available at www.helsinn.com

OPPORTUNITIES
Partnering strategy/collaborations
Purpose of our participation to the meeting is the identification of in licensing opportunities in the fields of Cancer Supportive Care, Oncology, G.I., Pain & Inflammation.

In addition we are also looking for late stage products to be commercialized directly in the US.

MANAGEMENT
Riccardo Braglia, Group CEO
Giorgio Calderari, Group General Manager and COO
Roberto De Ponti, Head of Corporate Business Development
CONTACT
Malcolm Weir
CEO

ADDRESS
BioPark
Broadwater Road
Welwyn Garden City
AL7 3AX
UK

TELEPHONE
+44 (0)1707 358 628

EMAIL
malcolm.weir@heptares.com

YEAR FOUNDED
2007

FINANCIAL SUMMARY
USD60m raised in seed, Series A and Series B venture financing rounds.

COMPANY PROFILE
Heptares creates transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of drug receptors linked to a wide range of human diseases. Our proprietary structure-based drug design technology enables us to engineer drugs for highly validated, yet historically undruggable or challenging, GPCRs. Using this approach, we have built an exciting pipeline of new medicines with the potential to transform the treatment of Alzheimer’s disease, ADHD, diabetes, schizophrenia, migraine, and other diseases. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures.

PRODUCT PIPELINE
Selective muscarinic M1 receptor agonist (Phase 1)
Alzheimer’s disease, Schizophrenia
First selective muscarinic M1 receptor agonist for treatment of Alzheimer’s disease and other disorders of cognitive impairment.
M4 and Dual M1/M4 receptor agonists (preclinical)
Psychosis in Schizophrenia, Alzheimer’s and other diseases
First-in-class selective M4 agonists for the treatment of psychosis and related behavioural & psychiatric symptoms. Dual M1/M4 agonists for patients with co-morbid psychosis and cognitive impairment.
Adenosine A2A receptor antagonists (late preclinical)
ADHD, ADD, Attention disorders
Novel small molecule antagonists that selectively enhance dopaminergic transmission in key regions of the brain linked to ADHD. Target profile is once daily, fast-acting, effective non-stimulant with superior safety and tolerability vs. current agents.
GCRP antagonists (preclinical)
Migraine Treatment & Prophylaxis
Novel oral/intra-nasal small molecule antagonists of the calcitonin gene-related peptide (CGRP) receptor, a clinically validated mechanism for treating & preventing migraine attacks.
GPR39 agonists (preclinical)
Type 2 Diabetes
First oral small molecule GPR39 agonist, a novel and biologically validated mechanism for improving glycaemic control and preventing disease progression via preservation of islet cell function.
GLP-1 agonists (preclinical)
Type 2 Diabetes
First oral once-daily GLP-1 agonist. GLP-1 is a breakthrough mechanism for controlling glycaemia and reducing weight in patients with type 2 diabetes.
Orexin 1 antagonists (preclinical/discovery)
Binge Eating, Nicotine Addiction
First selective Orexin 1 subtype receptor antagonist for treatment of addiction and compulsive disorders.
mGlu5 receptor modulator (preclinical/discovery)
Autism, Depression, Dyskinesia
Novel mGlu5 receptor negative allosteric modulator with potential best-in-class selectivity, pharmacokinetics and safety.

Continued...
Heptares Therapeutics
www.heptares.com

...continued

OPPORTUNITIES
Selective muscarinic M1 receptor agonist
M4 and Dual M1/M4 receptor agonists
Adenosine A2A receptor antagonists
CGRP antagonists
GPR39 agonists

MANAGEMENT
Malcolm Weir, CEO and co-founder
Fiona Marshall, CSO and co-founder
Daniel Grau, President
Tim Tasker, CMO & VP Development
Barry Kenny, CBO
Miles Congreve, VP Chemistry
Histide AG
www.histide.com

COMPANY PROFILE
Histide™ is pioneering Recoding Therapeutics™, a novel therapy using non-mutagenic extracellular technologies to direct cell fate.

Based on the universal understanding of the mechanisms underlying mammalian cell behavior, HistideTM has created an innovative platform of complex microenvironments with the capacity to dictate the precise commitment of various cell types. These include cells from different tissue origins and at contrasted differentiation stages, ranging from stem cells to specialized mature cells.

Histide™ has developed a broad and disruptive intellectual property portfolio including Recoding Molecules™, Micro-environmental Design and Therapeutical Development being a technological break-through with vast indication spectra of pharmaceuticals, medical devices and medical cosmetics.

Based in Europe, Histide™ has developed strong international collaborations with leading Universities and Institutes around the globe in order to make its expertise and technology known and promote the Recoding Therapeutics™.

PRODUCT PIPELINE
Cell Recoding Molecule - Oncology: Discovery
Non-mutagenic, extracellular recoding of neoplastic cells into healthy cells.

Cell Recoding Molecule - Tissue Regeneration: Discovery
Non-mutagenic, extracellular regeneration of any type of human tissue.

OPPORTUNITIES
Oncology Out-Licensing
Specific targeted CRP molecules to heal different types of cancer.

Tissue Regeneration Out-Licensing
Specific targeted CRP molecules to regenerate tissue (drug-device combinations)

MANAGEMENT
Romain Julia, Exec. Chairman;
Florian Kemmerich, CEO
Dr. Omar F. Zouani, CSO
8th ANNUAL
European Life Science CEO Forum & Exhibition

ImmunID
www.immunid.com

CONTACTS
Bernhard Sixt, PhD
Chairman and CEO

ADDRESS
ImmunID
7, parvis Louis Néel
BP50
38040 Grenoble
France

TELEPHONE
+33 0 438 785 770

EMAIL
bsixt@immunid.com

YEAR FOUNDED
2005

FINANCIAL SUMMARY
$5m investments, several $ millions in grants.

COMPANY PROFILE
ImmunID is a pioneer of immune molecular diagnostics aiming to set the global immune diagnostics standard. Its clinical product ImmunTraCkeR evaluates the T cell repertoire diversity at the genomic level. The company is ISO9001/ISO13485 accredited and provides testing worldwide to leading clinical centers and blue-chip pharmaceutical companies.

ImmunTraCkeR and ImmunIg are proprietary immune molecular diagnostics test analysing and quantifying immune competence. ImmunTraCkeR measures T-Cell repertoire diversity and ImmunIg measures B-Cell repertoire diversity using multi-N-plex qPCR on genomic DNA.

Current industrial customers are Roche, Sanofi-Pasteur, and confidential cooperations. Current clinical research customers in Europe, US and Asia.

MANAGEMENT
Bernhard Sixt, PhD, Chairman and CEO
Kurt Schmidt, Chief Financial Officer
Immunomic Therapeutics, Inc.
www.immunomix.com

FINANCIAL SUMMARY
Immunomic Therapeutics has raised over $17 million in private equities most recently with a Series A Preferred round of $7 million (2014). The Company recently closed on a licensing transaction with Astellas Pharma with $15 million as an upfront payment and an additional $55 million in milestones plus clinical and CMC support. The Company is expecting to open a Series B round in 2015.

COMPANY PROFILE
Immunomic Therapeutics is developing next generation vaccines with a particular focus on allergy using our patented and proprietary LAMP Technology Platform. Our LAMP-vax Technology has been shown in the clinic to induce potent helper T-cell responses to targets in allergy and oncology. Our current lead products are for Japanese red cedar pollen (ASP4070, JRC-LAMP-vax) which is being advanced through the clinic in Japan with our partner, Astellas Pharma and for Peanut Allergy. Our Allergy Vaccine Therapy is a unique approach to treating allergy and represents the first true advance in allergy therapy in over 100 years. In addition to our recent licensing and collaborative deal with Astellas, Immunomics also has a relationship in animal health for canine atopic dermatitis and for a cancer vaccine with Asterias (formerly with Geron). Immunomic Therapeutics is currently a privately held company but is exploring funding options for 2015 and beyond.

PRODUCT PIPELINE
JRC-LAMP-vax / Allergy Vaccine : Phase I/II
JRC-LAMP-vax (ASP4070 in Japan) is a DNA vaccine formulated to treat allergy caused by red cedar pollen. The Company plans to apply the vaccine to also treat mountain cedar and juniper & cypress tree species. The first clinical studies showed that 4 bi-weekly skin treatments resulted in 100% of the subjects converting from skin test positive to skin test negative by month 8. The product will be entering the clinic in Japan in 2015 under the guidance of Astellas Pharma and in the U.S. for mountain cedar.

ARA-LAMP-vax : Phase I
ARA-LAMP-vax is a DNA vaccine formulated to treat food allergy caused by peanuts. The Company plans to begin Phase I clinical studies in 2015 first in healthy subjects then in moderately allergic adults. The product is formulated as an allergy vaccine therapeutics and will be given as four doses biweekly. The Company has a pre-IND meeting on the proposed study in March and will be filing the complete IND by the end of Q3.

OPPORTUNITIES
LAMP-Vax Platform
LAMP-vax can be widely applied to stimulate the immune system via MHC-II presentation and helper T-cells. The CD4+ mediated response has been documented in multiple clinical studies and has had success in allergy and oncological applications. In addition, it has been shown to be effective in animal health applications for allergy and for infectious diseases. The technology is supported by a substantial literature portfolio.

MANAGEMENT
Dr. William Hearl, CEO
Dr. Tim Coleman, VP Operations
Dr. Teri Heiland, VP R&D
Ms. Sia Anagnostou, Dir Marketing & Strategy
Mr. Colin Magowan, Dir Business Development
Mr. Bernie Rudnick, Acting CFO
ISA Pharmaceuticals
www.isa-pharma.com

COMPANY PROFILE

ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology, which enable the generation of safe and effective drugs with a known mechanism of action. Synthetic long peptides are broadly applicable to multiple targets and ideally suited for monotherapy, as essential components in combination with conventional cancer treatments, and as novel immunomodulators. SLP® immunotherapies are capable of fully harnessing and directing the body’s own defenses towards fighting the disease.

PRODUCT PIPELINE

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Pre clinical</th>
<th>Phase 1</th>
<th>Phase 1/2</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISA101 (HPV16)</td>
<td>Cervical Cancer (Chemo combi)</td>
<td>CerviSA - ongoing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>H&amp;N/Cervical/Anel Cancer (POI combi)</td>
<td>Start 2015Q1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neoplasia (Vuln - VIN3)</td>
<td>Proof of Concept *</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neoplasia (Anal - AIN)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISA201 (HPV16)</td>
<td>Head &amp; Neck Cancer</td>
<td>VaccAIH - ongoing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISA203 (PRAME)</td>
<td>Multiple cancer indications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISA204 (HBV)</td>
<td>Chronic Hepatitis B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additional SLP® AMPLIVANT®</td>
<td>Cancer and infectious diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ISA101 : Phase II
ISA101 consists of 13 synthetic long peptides (25-35 amino acids long) derived from the E6 and E7 oncogenic proteins of the HPV 16 virus. This strain is responsible for 50% of human cervical cancers and cervical intraepithelial neoplasias and more than 85% of HPV-positive head and neck cancers, anal cancers and premalignant HPV-induced anal lesions (termed anal intra-epithelial neoplasia, or AIN). It is administered either subcutaneously or intradermally.

ISA101 has completed a Phase II trial in vulvar intra-epithelial neoplasia, establishing clinical proof-of-concept. In cervical cancer, ISA101 has completed a Phase I/II trial and has entered into further clinical development in 2013. In addition, a Phase I/II trial in patients with anal intra-epithelial neoplasia (AIN) has started in 2013.

ISA203 : Preclinical
ISA203 is derived from the human antigen PRAME (PReferentially expressed Antigen in MElanoma) and is useful for the treatment of different types of cancers. ISA203 consists of synthetic long peptides (SLP®) conjugated to ISA’s proprietary adjuvant AMPLIVANT®.

The tumor-specific expression and association with proliferation makes PRAME attractive to develop an immunotherapy for multiple indications. PRAME-expressing cancer cells would not be able to escape from PRAME-directed cell-mediated immunity, unless the cells would down-regulate PRAME expression, which in turn would decrease their aggressiveness.

ISA204 : Preclinical
ISA204 is a combination of selected Synthetic Long Peptides (SLP®s) derived from conserved regions of hepatitis B antigens with ISA’s AMPLIVANT® adjuvant technology. It is designed as an effective immunotherapy for the entire patient population, and avoids virus escape mutants by inducing a T cell response against multiple conserved viral antigens.

ISA204 is capable of inducing an effective immune response against hepatitis B virus (HBV)-infected cells by avoiding immune tolerance and viral resistance. It can be easily combined with the current standard of care, and aims to induce sterilizing immunity against HBV.

Continued...
SLP®-AMPLIVANT® Conjugates: Phase I

Toll-like receptor ligands (TLRL) are among the most powerful stimulants of the immune system. They are involved in all diseases caused by a deregulation of the immune system, including infections, inflammation, autoimmune diseases, atherosclerosis and cancer. TLRs act in a much more chemically defined way than conventionally used adjuvants like Alum and (incomplete) Freund’s adjuvants.

ISA has substantially improved a known TLR ligand (TLR1/2 ligand) by changes guided by crystallographic structure modeling of the ligand receptor interaction.

Moreover, ISA Pharmaceuticals has conjugated this newly developed proprietary class of TLR ligands to its SLP® immunotherapeutics. These SLP®-AMPLIVANT® conjugates have been shown to be 100- to 1000-fold more potent in inducing an immune response compared to unconjugated SLP®s in preclinical and mouse tumor models.

OPPORTUNITIES

ISA101 partnering
- Actively seeking partners to expand current clinical pipeline.
  - New indications
  - Combine with Check point control blockers, preclinical work demonstrates synergy in established HPV-tumor models
  - Combine with Chemotherapies, preclinical and clinical data demonstrate the synergy in established HPV-tumor models

SLP® Technology licensing
ISA’s SLP® immunotherapeutics are rationally designed, off-the-shelf, synthetic peptides. Between 20 to 50 amino acids in length, they are longer than conventional peptide immunotherapeutics, and hence are optimal for an efficient and prolonged presentation by antigen-presenting cells. Furthermore, the greater length of SLP®s allows the full array of HLA alleles (no HLA-restriction) to be used, thereby enabling an SLP® immunotherapeutic to activate the immune system of all human beings, irrespective of individual HLA types. A typical SLP® product contains between 4 and 13 different carefully selected long peptides. It thereby covers the most immunogenic regions of a therapeutic target and contains epitopes for the efficient induction of both CD4 and CD8 T cell responses.

SLP® immunotherapeutics are fully synthetic, off-the-shelf compounds. No ex vivo manipulation of dendritic cells (DC) is required, because efficient DC-targeting is achieved directly in vivo.

AMPLIVANT® Technology licensing
ISA’s AMPLIVANT® technology comprises a proprietary and synthetic small molecule TLR1/2 ligand with enhanced immunostimulatory activity that has been chemically coupled to the peptide in the standard SLP® manufacturing process. SLP®-AMPLIVANT® conjugates allow lower dosing at higher efficacy through better dendritic cell antigen processing and presentation as well as enhanced T cell priming.

This technology is not only applicable to all SLP® immunotherapeutics, but also to any other type of targeted immunotherapy, significantly enhancing its efficacy. ISA Pharmaceuticals’ AMPLIVANT® technology improves the immuno-stimulatory potency of SLP® based immunotherapeutics 100- to 1000-fold.

AMPLIVANT® conjugates mediate direct dendritic cell targeting with the TLR ligand-coupled antigen and activation of these dendritic cells, leading to long-term, effective antigen presentation and T cell response induction.

Strategic partnering/investment opportunity

MANAGEMENT
Ronald Loggers, CEO
Cornelis (Kees) Melief, CSO
Richard (Rick) Stead, acting CMO
Karus Therapeutics
www.karustherapeutics.com

CONTACT
Dr Simon Kerry
Chief Executive Officer

ADDRESS
93 Innovation Drive
Milton Park
Abingdon
Oxfordshire OX14 4RZ

TELEPHONE
+(44)1235 829140

EMAIL
info@karustherapeutics.com

YEAR FOUNDED
2006

FINANCIAL SUMMARY
2005 Seed Round (£0.75m): IP Group, Wyvern
2007 - 2011 Various investments (£4m): IP Group, Esperante, Angels, others
2012 Series B VC investment (£ND): SV Life Sciences, New Leaf Venture Partners, Novo A/S

COMPANY PROFILE
Karus Therapeutics is a leader in the development of innovative medicines that have breakthrough potential in treating inflammatory disease and cancer.

The Company’s scientific excellence is reflected in its proprietary PI3K and HDAC6 inhibitor programmes, from which innovative small molecule drugs with significant clinical and commercial potential have been developed.

The UK-based Company is privately-held with a strong financial track record and experienced investors including SV Life Sciences, New Leaf Ventures, Novo A/S and IP Group.

Karus Therapeutics is led by a strong management team with considerable experience of building, developing and partnering therapeutic assets in Europe and North America.

PRODUCT PIPELINE
KA2237 : Preclinical complete
Dual-selective PI3K-p110bd inhibitor for the treatment of solid tumors (immuno-oncology) and hematological tumors, including DLBCL.

KA1463 : Preclinical
Dual-selective PI3K-p110bd inhibitor for the treatment of immune complex disorders, including RA, EBA, PV, NMO, MG, etc.

KAR3000 inflammation : Candidate Nomination
Potent and selective HDAC6 inhibitor for the treatment of a broad range of inflammatory disorders and transplantation rejection.

KAR3000 cancer
Potent and selective HDAC6 inhibitor for the treatment of a broad range of hematological malignancies with a focus on Multiple Myeloma ad GvHD

MANAGEMENT
Dr Simon Kerry, Chief Executive Officer
Prof Stephen J Shuttleworth, Chief Scientific Officer
Dr Penny Ward, Chief Medical Officer
Mr Simon Jones, Finance Director
Dr Simon Roitt, Head of Development
Dr Peter Finan, Head of Biology
Dr Tom Coulter, Head of Chemistry
Dr Elisabeth Bone, Head of Preclinical
Dr Kemal Haque, Head of Toxicology and Safety Pharmacology
KineMed
www.kinemed.com

FINANCIAL SUMMARY

- $5.1 million cash and cash equivalents at December 31, 2014
  - $5.4 million revenue for 2014
  - $9.6 million net loss for 2014 (unaudited)
  - 11.8M shares undiluted / 13.7M fully diluted & outstanding December 31, 2014
  - Series D Offering
- $12.5M
- $58.5M pre
  - Estimated close Q2 2015

COMPANY PROFILE

KineMed is a revenue-generating health technology company that has developed a proprietary kinetic proteomics biomarker platform that can improve the quality, efficiency and cost-effectiveness of drug development. Our biomarkers capture the underlying causes of disease and are predictive of longer-term clinical outcomes, making them particularly valuable in FDA Phase 2 proof-of-concept trials in humans. Our predictive biomarker tests are designed to rapidly establish whether a drug lead is working as intended on a targeted pathway, what are the most responsive disease indications and patient populations for the lead, what the best dose and regimen is, how the candidate compares to competitive therapies, and whether a companion diagnostic test would help the drug to gain approval. For approved drugs, our biomarker platform also are designed to enable more personalized medical care.

PRODUCT PIPELINE

Noscapine ALS: IND
- New therapeutic use for the microtubule-modulating agent noscapine
- US Patent allowed for Rx ALS, PD, DM neuropathy
- Based on pre-clinical biomarkers of neuronal transport
- Phase 1B/2A ALS small and rapid biomarker studies
  - 30 patients, 7-week trial
  - H2 2015

FX-5A Cardiovascular: Preclinical
FX-5A is a 37 amino acid peptide designed to mimic the anti-atherosclerotic activities of ApoA1 by maximizing the mobilization of cholesterol from macrophages via ABCA1, the major transporter of cholesterol. FX-5A peptide is bi-helical peptide based on the sequence of ApoA1. By substituting five non-polaramino acids on the hydrophobic face of one helix with alanine, (hence its name, 5A) the lipid affinity of the second helix is diminished, reducing cytotoxicity and increasing specificity for removing cholesterol from cells via ABCA1.

Efficacy: Extensive pre-clinical and clinical trial data exists demonstrating reductions in atheroma volume after 5 treatments of ApoA1 and HDL mimetics. The ApoA1 mimetic activity of FX-5A has been extensively characterized in preclinical studies performed by leading academic researchers. FX-5A reduces atherosclerosis and vascular inflammation in animal models.

Clinical trials of Acute HDL Therapy have utilized normal and modified full length ApoA1, the major protein component of HDL, showing that a short course can significantly reduce atherosclerotic plaque size and volume. There are currently two HDL mimetics in clinical development, Cer-001 and CSL-112, based on recombinant and human plasma derived full length ApoA1, respectively.

Preclinical studies confirm that FX-5A peptide, in vivo, activates multiple pathways which have cardiovascular benefits normally associated with HDL. FX-5A has been shown to increase reverse cholesterol transport (RCT) and macrophage specific cholesterol efflux, two indicators of cholesterol mobilization from plaques and reversal of atherosclerosis. In rat studies, 5A increases RCT in a dose-dependent manner indistinguishable from the result obtained using human ApoA1 (reconstituted HDL).

Intravenous administration of the 5A peptide complexed with phospholipid was found in ApoE-KO mice to promote RCT, and reduce atherosclerosis, indicating that 5A shares many of the same beneficial antitherogenic features of ApoA-I and may be a suitable substitute for ApoA-I in HDL therapy.

Continued...
OPPORTUNITIES

FX-5A Out
FX-5A is a 37 amino acid peptide designed to mimic the anti-atherosclerotic activities of ApoA1 by maximizing the mobilization of cholesterol from macrophages via ABCA1, the major transporter of cholesterol. FX-5A peptide is bi-helical peptide based on the sequence of ApoA1. By substituting five non-polaramino acids on the hydrophobic face of one helix with alanine, (hence its name, 5A) the lipid affinity of the second helix is diminished, reducing cytotoxicity and increasing specificity for removing cholesterol from cells via ABCA1.

Efficacy
Extensive pre-clinical and clinical trial data exists demonstrating reductions in atheroma volume after 5 treatments of ApoA1 and HDL mimetics. The ApoA1 mimetic activity of FX-5A has been extensively characterized in preclinical studies performed by leading academic researchers. FX-5A reduces atherosclerosis and vascular inflammation in animal models.

Clinical trials of Acute HDL Therapy have utilized normal and modified full length ApoA1, the major protein component of HDL, showing that a short course can significantly reduce atherosclerotic plaque size and volume. There are currently two HDL mimetics in clinical development, Cer-001 and CSL-112, based on recombinant and human plasma derived full length ApoA1, respectively.

Preclinical studies confirm that FX-5A peptide, in vivo, activates multiple pathways which have cardiovascular benefits normally associated with HDL. FX-5A has been shown to increase reverse cholesterol transport (RCT) and macrophage specific cholesterol efflux, two indicators of cholesterol mobilization from plaques and reversal of atherosclerosis. In rat studies, 5A increases RCT in a dose-dependent manner indistinguishable from the result obtained using human ApoA1 (reconstituted HDL).

Intravenous administration of the 5A peptide complexed with phospholipid was found in ApoE-KO mice to promote RCT, and reduce atherosclerosis, indicating that 5A shares many of the same beneficial antiatherogenic features of ApoA-I and may be a suitable substitute for ApoA-I in HDL therapy.

Noscapine ALS Out
New therapeutic use for the microtubule-modulating agent: noscapine
– US Patent allowed for Rx ALS, PD, DM neuropathy
– Based on pre-clinical biomarkers of neuronal transport
– Phase 1B/2A ALS small and rapid biomarker studies
• 30 patients, 7-week trial
• H2 2015

Liver Fibrosis NASH Biomarkers
Treatment of fatty liver disease and NASH has become one of the highest priorities in contemporary drug development. KineMed's blood test has the potential to capture the rate of disease activity in liver fibrosis non-invasively and can potentially answer the two central questions holding back testing of drug candidates in fatty liver disease and NASH: 1) which patients are at risk for progression (who to treat) and 2) whether a treatment is working (identifying early whether a drug is working).

We are presently conducting several clinical studies in fibrotic liver disease with key opinion leaders from academic medicine. The aim of these studies is to clinically validate our blood test of liver fibrosis in different sets of patients.

We have initiated clinical studies with three academic leaders in fatty liver disease and fibrosis that serve several purposes with regard to validation. The goal of these studies is: 1) to demonstrate early response of our biomarker to therapeutic interventions that reduce fibrosis; 2) to show that our tests identify who are the rapid progressors with fatty liver disease (i.e., who needs anti-fibrotic treatment); and 3) to show the technical reproducibility and analytic robustness of our non-invasive biomarker tests. Additionally, we have several submitted publications from our work in liver disease and other fibrotic conditions, including scleroderma.
**COMPANY PROFILE**

Kuros Biosurgery AG is dedicated to the development of innovative biologic and biomaterial-based product candidates for localized therapy in the fields of orthobiologics, sealants and surgical wounds. The company was founded in 2002 and is a spin-off from the Swiss Federal Institute of Technology (ETH) and University of Zurich.

Kuros Biosurgery has a broad pipeline of clinical stage products based on its biomaterial and biologic technology platforms. Kuros’ priority programs are:

- **KUR-023** – A synthetic sealant which has successfully completed a European clinical study and is being prepared for CE Mark.
- **KUR-111** – an orthobiologic that has demonstrated non-inferiority to autograft in a large Phase IIb study.
- **KUR-115** – an orthobiologic that has completed preclinical testing and is designed to have equivalent efficacy, but be safer, than gold standard and other leading products.

The company’s investors include: Venture Incubator, NeoMed Management and CDC Innovation.

**Areas of activity:** Biomaterials and Tissue Regeneration.

**PRODUCT PIPELINE**

<table>
<thead>
<tr>
<th>Initial indication</th>
<th>Biomaterial</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td>KUR-111: Tibial Plateau Fractures – long bone</td>
<td>Fibrin</td>
<td>Phase 2b Trial Completed</td>
<td>FDA</td>
<td>FDA</td>
<td>FDA</td>
</tr>
<tr>
<td>KUR-113: Tibial Shaft Fractures – long bone</td>
<td>Fibrin</td>
<td>FDA</td>
<td>FDA</td>
<td>FDA</td>
<td>FDA</td>
</tr>
<tr>
<td>KUR-115: Spinal Fusion - vertebral bone</td>
<td>Fibrin</td>
<td>FDA</td>
<td>FDA</td>
<td>FDA</td>
<td>FDA</td>
</tr>
<tr>
<td>KUR-111: Dural sealant</td>
<td>Synthetic</td>
<td>FDA</td>
<td>FDA</td>
<td>FDA</td>
<td>FDA</td>
</tr>
<tr>
<td>KUR-113: Other sealant</td>
<td>Synthetic</td>
<td>FDA</td>
<td>FDA</td>
<td>FDA</td>
<td>FDA</td>
</tr>
<tr>
<td>KUR-212: Mesh burns</td>
<td>Fibrin</td>
<td>FDA</td>
<td>FDA</td>
<td>FDA</td>
<td>FDA</td>
</tr>
<tr>
<td>KUR-213: Flap surgery</td>
<td>Fibrin</td>
<td>FDA</td>
<td>FDA</td>
<td>FDA</td>
<td>FDA</td>
</tr>
</tbody>
</table>

**KUR-023: Registration**

KUR-023 is a synthetic sealant for application to the dura during cranial and spinal surgeries.

KUR-023 has successfully completed a 41 patient clinical study in Europe and is being prepared for CE-marking. For US registration Kuros intends to complete a US pivotal study.

Kuros has extensive granted patents and patent applications covering KUR-023 and its synthetic sealant technologies.

**KUR-111: Phase III**

KUR-111 is an orthobiologic being developed for bone regeneration in trauma.

KUR-111 will compete in the $3bn per annum bone graft substitute market of which >$1.5bn is US.

KUR-111 has completed a Phase IIb study in which it met its primary endpoints. It is currently being prepared for entry into a Phase III study.

Kuros has extensive patents and patent applications covering KUR-115 and its related fibrin technologies.

**KUR-113: Phase III**

KUR-113 is a bone growth promoter design to improve fracture healing and addresses a currently under-developed market that Kuros estimates has the potential to be greater than $2bn worldwide.

A Phase IIb study involving approximately 200 patients has demonstrated superiority to standard of care in open tibial shaft fracture healing. The product would need to complete Phase III prior to market authorization.

Kuros has extensive patents and patent applications covering KUR-113 and its related fibrin technologies.

Continued...
Kuros Biosurgery AG
www.kuros.ch

...continued

KUR-115: Phase II
KUR-115 is an orthobiologic designed to compete with, and improve on, InFuse™ (peak sales ~$800M) in spinal fusion.
KUR-115 is being prepared for entry into a Phase II clinical study. A pre-IND meeting has been held with the FDA.
Kuros has extensive patents and patent applications covering KUR-115 and its related fibrin technologies

KUR-212: Phase II
KUR-212 is designed to be the first product for surgical wounds that both adheres skin grafts (avoiding the use of sutures or staples) and improves wound healing (reducing the time to wound closure which in turn reduces infection and potentially reduces hospital stay).
KUR-212 has completed a Phase Ila study in burns patients with a Phase IIb dosing study being the next development stage.

MANAGEMENT
Mr. Didier Cowling, Chief Executive Officer
Dr. Alistair Irvine, Chief Business Officer
Dr. Jason Schense, Chief Technology Officer
Lanthio Pharma www.lanthiopharma.com

CONTACTS
Heinz Schwer, PhD, MBA
CEO
Jessica Mann, MD, PhD
CMO

ADDRESS
PO Box 719, 9700 AS Groningen
Rozenburglaan 13 B, 9727 DL
Groningen
The Netherlands

TELEPHONE
+31 50 30 50 240

EMAIL
info@lanthiopharma.com

YEAR FOUNDED
2012

FINANCIAL SUMMARY
Series A November 2012 4.8M Eur

COMPANY PROFILE
Lanthio Pharma is a biopharmaceutical company focusing on the discovery and development of therapeutic peptides. Based on its proprietary LanthioPep technology the company is building a pipeline of constrained lanthionine containing peptides with improved drug-like properties. Introduction of lanthionines not only improves the proteolytic stability of peptides but also leads to enhanced receptor specificity and activity. Lanthio’s lead product, LP2, is a selective angiotensin II type 2 receptor agonist, in preclinical development for lung and kidney fibrosis.

OPPORTUNITIES
LP2 – Selective AT2 receptor agonist
LP-2 is a lanthionine-stabilized highly specific agonist of the AT-2 receptor of the renin-angiotensin system. Activation of the AT2 receptor is associated with tissue protection, anti-inflammatory and anti-fibrotic activity. In-vivo studies have shown promising results in lung and kidney fibrosis models and LP2 is currently in preclinical development for organ fibrosis. First-in-man studies are scheduled to commence in 2015.

PanCyte – Selective MAS receptor agonist
Lanthionine-stabilized Angiotensin-(1-7) is an agonistic peptide that was discovered by Lanthio Pharma, using its proprietary LanthioPep technology. The compound is stable and resistant to angiotensin-converting enzyme. PanCyte has high specificity for the MAS receptor and shows increased intrinsic activity compared to wild-type Angiotensin-(1-7).
PanCyte has therapeutic potential in cardiovascular diseases, diabetic ischemia and stroke.

Lanthipeptide apelin – Selective APJ receptor agonist
Based on the natural apelin ligand Lanthio Pharma is developing proteolytically stabilized lanthipeptide apelin analogs. Several analogs have been selected for in-vivo testing in myocardial infarction and heart failure models.

MANAGEMENT
Heinz Schwer, PhD, MBA, CEO
Gert Moll, PhD, CSO
Jessica Mann, MD, PhD, CMO
Sjoerd Wadman, PhD, VP Research and Development
Michiel Lodder, PhD, VP Business Development
MedLumics S.L.
www.medlumics.com

CONTACT
Eduardo Margallo

ADDRESS
MedLumics S.L.
Ronda de Poniente 16 – 1E
28760 Tres Cantos
SPAIN

TELEPHONE
+34 91 803 39 25

EMAIL
investors@medlumics.com
emargallo@medlumics.com

YEAR FOUNDED
2011

COMPANY PROFILE
MedLumics solves the problem of execution in RF ablation for atrial fibrillation and other arrhythmias, providing accurate local navigation and real-time assessment of lesion formation. The company is developing a therapeutic catheter guided by Optical Coherence Tomography. The design has reached pre-clinical validation, showing clear contact quantification, detection of lesion borders, direct visualization of necrosis and size prediction in thick ventricle walls.
MedLumics is now developing a clinical version of its catheter for first-in-human work in 2016.

MANAGEMENT
Eduardo Margallo, PhD, President & CEO
Pioneer in the photonic integration of optical coherence tomography (8+ yr. experience) and with a strong background in business administration and management.
Mendor
www.mendor.com

FINANCIAL SUMMARY
Trailing 12 mo. revenue: 2M€
Monthly Net Burn: <300k €
Breakeven Date: 2017
Capital Raised to Date: € 17 M
Debt: 6,5M€ (3M€ government soft-debt / 3,5M€ venture debt)
Current Investors: Risto Siilasmaa, Industry Investment, Ilmarinen pension fund, Biothom, Finnvera, Life Science Partners (LSP), Angels

<table>
<thead>
<tr>
<th>Financials</th>
<th>Revenue (k€)</th>
<th>EBITDA (k€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>3200</td>
<td>-1567</td>
</tr>
<tr>
<td>2016</td>
<td>7156</td>
<td>-1953</td>
</tr>
<tr>
<td>2017</td>
<td>14272</td>
<td>967</td>
</tr>
<tr>
<td>2018</td>
<td>26512</td>
<td>7210</td>
</tr>
</tbody>
</table>

COMPANY PROFILE

Business Description:
Mendor is a next generation diabetes technology & solution company, working to bringing top-endocrinologist decision making into patient’s & provider’s hands, in real time.
Mendor’s revenue comes from the sales of Mendor Discreet® blood glucose meter & strips, and from Mendor ONE service solution (Software & Devices As A Service).
Mendor’s 1st product (BGM) is currently being sold in 16 EU countries & China through partners: Menarini Diagnostics, Mediq and Tagene.
Mendor’s vision is a world where diabetes care is integrated, individual and outcome driven.

Products/Solutions:
1. Mendor ONE™ - new game changing digital & wireless glucose monitoring & diabetes management solution, consisting of a cellular glucose meter, cloud software, patient smartphone app and strips/lancets with home delivery, all with a fixed monthly fee, paid by the payers and used by diabetes clinics & patients.
2. Mendor Discreet blood glucose meter – the first true all-in-one blood glucose meter on the market, enabling discreet and user-friendly daily measurements of blood glucose.

Target Markets:
Target segment is Type 1 & 2 diabetics on injectable drugs needing frequent monitoring & management, and being a major cost & risk segment in diabetes. Target markets are: glucose monitoring (9b) and an emerging diabetes management for outcome driven care (6b)

Barriers to Entry:
Barriers to entry include slow adoption of new technologies & solution offerings by payers & providers, as well as major players such as J&J, Roche, Sanofi etc.

Customer Pipeline:
Current customers: Sanofi, Menarini Diagnostics, City of Tampere (major payer in Finland), Mediq (Baltics) and Tagene Medical (China),

Competition/Substitution:
There are currently only two competing companies offering a holistic glucose monitoring & diabetes management solution with wireless connectivity and individual data driven care, in the market: Telcare (US) & Livongo (US).
Mendor
www.mendor.com

...continued

Business Model:
Software and Devices As A Service (SDAAS). Mendor sells glucose monitors and strips as a service with a fixed monthly fee directly to payers. Each patient gets a personal meter for 2-3 years with a subscription of unlimited test strips & licenses to use cloud software & smartphone app.

Future Products (Pipeline for R&D):
2nd generation integrated wireless glucose meter. Software development, adding eg. insulin pump & CGM compatibility & support for clinics & patients.

Distribution/Sales Model: Sales through distributors and sales directly to payers (insurance companies, cities and pharma).

Technologies/IP: Key patents granted in EU, USA & China. More patents filed and pending. Global FTO validated by several research reports.

PRODUCT PIPELINE
Mendor ONE™ : On the market
New game changing digital & wireless glucose monitoring & diabetes management solution, consisting of a cellular glucose meter, cloud software, patient smartphone app and strips/lancets with home delivery, all with a fixed monthly fee, paid by the payers and used by diabetes clinics & patients.

Mendor Discreet blood glucose meter : On the market
The first true all-in-one blood glucose meter on the market, enabling discreet and user-friendly daily measurements of blood glucose.

MANAGEMENT
Kristian Ranta, CEO – ex. CRF Health
Oliver Davies, CTO – ex LifeScan head of R&D
Minna Isotalus, CFO – ex PwC & E&Y
Jukka Lehtinen, VP Production – ex Flextronics
Niina Vilkas, VP Q&R – ex GE
Metys Pharmaceuticals
www.metys-pharma.ch

FINANCIAL SUMMARY
Seed investment rounds totalling CHF 1.2 million as convertible loan, repayable in shares valued at 20% discount to pre-money valuation agreed at Series A closing.

Series A round intends to raise CHF 18 million.
Series A investor exit as tradesale or IPO foreseen 2.5 to 3 years after signing of Series A investment.

COMPANY PROFILE
Metys Pharmaceuticals is developing dimiracetam for the prevention and treatment of chemotherapy-induced neuropathic pain.

PRODUCT PIPELINE
Dimiracetam
Dimiracetam is an orally active small molecule with more than 180 subjects’ safety and tolerability data, a complete preclinical safety package, more than 75 kg of GMP drug substance, and an open IND. Dimiracetam is active in multiple animal models of neuropathic pain, including drug-induced neuropathy models. Dimiracetam is effective after a single oral dose; with repeated twice-daily dosing, the effect becomes more persistent. Dimiracetam is more effective than pregabalin, and unlike pregabalin, dimriacetam’s effect does not wane with prolonged use: there is no evidence of tachyphylaxis.

Dimiracetam acts by blocking glutamate-induced glutamate release. This is believed to prevent and to reverse glutamate-dependent long term potentiation at the first and only anatomical site where a peripheral axon connects to spinal neurons in the spinal dorsal horn.

Metys Pharmaceuticals is preparing the DISTALL trial of dimiracetam for the prevention of oxaliplatin-induced peripheral neuropathy. DISTALL is a randomized, placebo-controlled, multi-center, dose-ranging study of three different dose levels of dimiracetam in 184 patients treated twice-daily for three months at the outset of their oxaliplatin-treatment regimen. The primary endpoint is the change from baseline in the weekly average score of a patient-reported numeric rating scale of oxaliplatin-induced neuropathy symptoms.

OPPORTUNITIES
Dimiracetam, prevention of oxaliplatin-induced peripheral neuropathy

MANAGEMENT
Michael Scherz, CEO & Founder
Midatech Pharma PLC
www.midatechpharma.com

**COMPANY PROFILE**

Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need.

Midatech is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer, and neuroscience/ophthalmology. Midatech’s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

**MANAGEMENT**

Dr. Jim Phillips, Chief Executive Officer
Dr. Craig Cook, Chief Medical Officer and Chief Operating Officer
Mr. Nick Robbins-Cherry, Finance Director
Dr. Tim Sparey, Chief Business Officer
Dr. Daniel Palmer, Chief Scientific Officer
Mr. Justin Barry, Head of Manufacturing

**CONTACT**

Dr. Jim Phillips  
Chief Executive Officer

**ADDRESS**

Milton Park Innovation Centre  
99 Park Drive  
Milton Park  
Abingdon  
Oxfordshire OX14 4RY  
United Kingdom

**TELEPHONE**

44 (0)1235 841 575

**EMAIL**

info@midatechpharma.com
Mirna Therapeutics
www.mirnarx.com

CONTACT
Casi DeYoung
Chief Business Officer

ADDRESS
2150 Woodward St., Suite 100
Austin, TX 78744
USA

TELEPHONE
+1 512 901 0900

EMAIL
busdev@mirnarx.com

YEAR FOUNDED
2007

COMPANY PROFILE

Mirna Therapeutics, Inc. (Mirna) is a clinical-stage biopharmaceutical company developing a broad pipeline of leading microRNA-based oncology therapeutics.

Mirna’s lead product candidate, MRX34, is the first microRNA Replacement Therapy that has advanced into clinical testing in cancer patients. MRX34 was designed to deliver a mimic of the naturally occurring microRNA tumor suppressor miR-34, which is under expressed in a wide variety of cancers. MRX34 entered clinical testing in 2013 and is currently being studied in a multicenter, open-label Phase 1 trial in patients with unresectable primary liver cancer or solid cancers with liver involvement. The Phase 1 clinical trial is expected to enroll approximately 120 patients and also includes a separate cohort of patients with hematological malignancies. Results of the Phase 1 clinical trial are expected in late 2015.

microRNA Replacement Therapy restores the body’s natural ability to fight cancer on multiple levels, including repression of tumor immune evasion, tumor growth, cancer stem cells and metastasis, by replacing naturally occurring tumor suppressor microRNAs that are under expressed in cancer cells with microRNA mimics. Controlling these multiple cancer pathways may also reduce the risk of the development of drug resistance, one of the more prevalent problems of modern cancer therapies.

Tumor suppressor microRNA mimics have great potential as cancer therapeutics due to their capacity to regulate many different oncogenes across multiple pathways as well as to repress PD-L1, as compared to other targeted cancer therapies that affect only one or two oncogenes or oncogenic pathways.

Mirna’s patent portfolio relating to its proprietary microRNA mimics technology consists of ten issued U.S. patents that include cancer and non-cancer therapeutic use claims related to 15 tumor suppressor microRNAs and more than 100 U.S. and foreign pending patent applications that it either owns or in-licenses from third parties. The company, founded in 2007 and located in Austin, TX, has received significant funding from New Enterprise Associates, Pfizer Venture Investments, Sofinnova Ventures and other private investors. Mirna is also funded by the State of Texas, both through the State’s Emerging Technology Fund, and from CPRIT.

MANAGEMENT

Casi DeYoung, Chief Business Officer
MISSION Therapeutics is a specialist biopharmaceutical company (SME) whose aim is to translate new molecular understandings of human cell biology into drugs that will markedly improve the management of life-threatening diseases, particularly cancer.

MISSION Therapeutics is developing a broad platform of technologies for the discovery and further development of first-in-class modulators of enzymes involved in cancer and other diseases. The company will predominantly exploit the new and exciting research emerging on ubiquitin pathways, in particular the deubiquitylating enzymes (DUBs), that control many cellular responses including DNA damage. MISSION Therapeutics’ scientists are developing drugs to inhibit the proliferation of tumour cells, building on their experience in exploiting the concepts of synthetic lethality, now an established and powerful mechanism to selectively kill genetically defined cancers. Moreover MISSION is exploiting its DUB drug discovery platform (Ubi-Sphere™) and expertise in order to identify chemistry’s for DUBs across several therapeutic areas, out with cancer, including neurodegeneration and muscle wasting.

**COMPANY PROFILE**

The company was founded in 2011 with an initial focus on cancer therapeutics. MISSION Therapeutics has since expanded its therapeutic areas to include neurodegeneration and muscle wasting. The company has a unique platform for the discovery and development of first-in-class inhibitors of DUBs, which are enzymes that control various cellular processes, including those involved in DNA damage. MISSION Therapeutics is led by a team of experienced scientists and business professionals with expertise in biotechnology, pharmacology, and business development.

**MANAGEMENT**

Anker Lundemose, CEO
Chief Executive Officer of MISSION Therapeutics. He has extensive experience from business and corporate development as well as R&D in several key therapeutic areas including oncology, diabetes and anti-infectives. He has a comprehensive international experience and network, and has been responsible for successful mergers and acquisitions within biotech, venture investments and licensing. His background includes biotech startups, large biotech and big pharma, as well as an initial career in academia.

He was Chief Executive Officer and President of Bionor Pharma ASA from 2013 to 2015, Chief Executive Officer of Prolisio Limited in the UK from 2003 to 2005, Executive Vice President OSI Pharmaceuticals Inc. in the US and President of Prolisio Ltd from 2005 to 2009. He was Executive Vice President Corporate & Business Development, OSI Pharmaceuticals Inc., from 2009 until Astellas Pharmaceutical Inc’s acquisition of OSI in 2010. He has previously held positions as Managing Director at OSI Pharmaceuticals venture arm in Zug, Switzerland, and as Business Development Director at Novo Nordisk, Denmark. Anker has MD, PhD and DMSc qualifications in medical microbiology.

**CONTACT**
Anker Lundemose
CEO

**ADDRESS**
Babraham Research Campus
Moneta (Building 280)
Cambridge
CB22 3AT
United Kingdom

**TELEPHONE**
+44 (0)1223 497 454

**EMAIL**
info@missiontherapeutics.com

**YEAR FOUNDED**
2011
CONTACT
Adrian Mills  
Chief Business Officer

ADDRESS
14 Chemin des Aulx  
1228 Plan-Les-Ouates  
Geneva  
Switzerland

TELEPHONE
+41 22 839 71 41

EMAIL
contact@novimmune.com

FINANCIAL SUMMARY
As Novimmune is a privately owned, development stage company, financial information is confidential.

COMPANY PROFILE
Novimmune is a drug discovery and development company focused on the creation of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer.

To date, Novimmune has generated several therapeutic antibodies designed to treat immune-related disorders and is now poised to enter the immune-oncology space with new products that aim to fight cancer.

The pipeline is a balance of preclinical and clinical compounds, specific for clinically validated and novel targets. Each of these portfolio products has the potential of becoming a medicine for multiple medical conditions due to the intrinsic mechanism of action.

Five of these compounds are currently in early clinical development with the three most advanced in clinical Phase II. In addition, Novimmune has initiated two internal, bispecific antibody programs against Acute Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma, as well as other oncology targets to yet be announced.

The company has also been purposefully targeting a number of orphan drug indications, with the express hope of eventually providing safe and effective treatment options to some of the often neglected populations suffering from rare diseases.

Where the mechanism of action of a discovered antibody indicates broader applications or multiple indications, Novimmune has partnered the development of the compound with larger pharmaceutical companies. In 2010, for example, the company signed an exclusive partnering agreement to co-develop its NI-1401 compound with Genentech/Roche. That compound completed Phase I clinical trials in 2013.

In addition to these compounds, Novimmune has developed two unique and proprietary antibody generation platforms — a monoclonal antibody platform and a bispecific antibody platform — designed to streamline the identification, production, and characterization of fully-human antibodies. Novimmune makes these technology platforms available to create unique antibodies for outside pharmaceutical companies.

In 2009, Novimmune received the European Biotechnica Award in recognition of being the European biotechnology company with “the greatest future potential.”

The company is based in the Plan-les-Ouates suburb of Geneva, Switzerland, and maintains strong ties to a number of academic research institutions, including the University of Geneva.

PRODUCT PIPELINE
NI-0501 : Phase II Pilot
NI-0501 is a fully human monoclonal antibody discovered and developed by Novimmune as a potent inhibitor of IFNγ. Novimmune advanced NI-0501 through Phase I clinical trials, in which the drug candidate was well tolerated at therapeutically relevant doses.

A Phase II clinical trial of NI-0501 in patients with hemophagocytic lymphohistiocytosis is currently recruiting study participants.

NI-0101 : Phase I
Novimmune’s NI-0101 monoclonal antibody potently suppresses inflammatory reactions by blocking TLR4 signaling driven by the previously mentioned ligands.

Activation of TLR4 leads to release of many types of inflammatory modulators including Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6). These responses help to isolate and clear bacteria and, through the adaptive immune system heighten resistance of the host in the event of re-infection.

However, abnormal TLR4 signaling can provoke various acute inflammatory conditions, including sepsis, and has been implicated in various chronic inflammatory diseases including, among others, arthritis, atherosclerosis, asthma, lupus, osteoporosis, transplant rejection, and contact dermatitis. Even obesity and Type II diabetes have been linked to excessive TLR4 signaling.

NI-0101 has completed as successful phase I trial in healthy volunteers and an IND for phase II will be submitted in Q1 2015.

Continued...
NI-1701 : Pre-clinical
A bispecific antibody that may enhance tumor killing without collateral damage
NI-1701 is intended to fight cancer by luring our immune system to seek and destroy tumor cells using antibody-mediated immunotherapy.

For decades, therapeutic antibodies have been injected into patients in order to attach to the cancer cells, acting as “flags” so that immune cells, such as macrophages or neutrophils, kill and “eat” the targets in a process called phagocytosis. This process involves attaching the antibody through its two Fab arms to the tumor cells and bridging to the immune cell via the antibody’s tail (the Fc portion).

However, cancer cells often adapt and trick the immune system to back off. One method is by overexpressing the protein, CD47, hijacking the means by which healthy cells “tell” macrophages to leave them alone. Indeed, the more CD47 expressed by a tumor, the worse the prognosis for the patient across a variety of cancers.

Thus, blocking the CD47 “don’t eat me” signal is an excellent therapeutic strategy except for the fact that healthy cells also express this protein.

The bispecific nature of the kappa-lambda body offers a three-armed solution to overcoming tumor resistance to antibody therapies.

NI-0401, foralumab : Phase II
Novimmune’s NI-0401 monoclonal antibody (mAb) is intended to alter auto-aggressive T-cell responses by targeting the T-cell receptor complex through binding with the CD3 epsilon receptor.

A Phase I and Phase IIa clinical trial in Crohn’s disease, and a Phase I / II open-label study in renal allograft transplantation have been completed.

NI-1401 : Phase I
NI-1401 is an anti-IL17 monoclonal antibody.
Interleukin-17 affects a broad range of immune and non-immune target cells, in which they induce the release of neutrophil-attracting chemokines and other mediators, such as CXCL1 / Gro-a, CXCL2 / MIP-2a, CXCL5 / ENA-78, CXCL8 / IL-8, TNF, IL-1, IL-6, G-CSF, GM-CSF, antimicrobial peptides, and matrix metalloproteinases.
IL-17 has been linked to a wide variety of autoimmune and inflammatory diseases, including rheumatoid arthritis, asthma, inflammatory bowel diseases, psoriasis, lupus, and allograft rejection. They may also play a role in anti-tumor immunity.

OPPORTUNITIES
NI-0101
Novimmune’s NI-0101 monoclonal antibody potently suppresses inflammatory reactions by blocking TLR4 signaling driven by the previously mentioned ligands.

Activation of TLR4 leads to release of many types of inflammatory modulators including Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6). These responses help to isolate and clear bacteria and, through the adaptive immune system heighten resistance of the host in the event of re-infection.

However, abnormal TLR4 signaling can provoke various acute inflammatory conditions, including sepsis, and has been implicated in various chronic inflammatory diseases including, among others, arthritis, atherosclerosis, asthma, lupus, osteoporosis, transplant rejection, and contact dermatitis. Even obesity and Type II diabetes have been linked to excessive TLR4 signaling.

NI-0101 has completed as successful phase I trial in healthy volunteers and an IND for phase II will be submitted in Q1 2015
NI-1701
A bispecific antibody that may enhance tumor killing without collateral damage

NI-1701 is intended to fight cancer by luring our immune system to seek and destroy tumor cells using antibody-mediated immunotherapy.

For decades, therapeutic antibodies have been injected into patients in order to attach to the cancer cells, acting as “flags” so that immune cells, such as macrophages or neutrophils, kill and “eat” the targets in a process called phagocytosis. This process involves attaching the antibody through its two Fab arms to the tumor cells and bridging to the immune cell via the antibody’s tail (the Fc portion).

However, cancer cells often adapt and trick the immune system to back off. One method is by overexpressing the protein, CD47, hijacking the means by which healthy cells “tell” macrophages to leave them alone. Indeed, the more CD47 expressed by a tumor, the worse the prognosis for the patient across a variety of cancers.

Thus, blocking the CD47 “don’t eat me” signal is an excellent therapeutic strategy except for the fact that healthy cells also express this protein.

The bispecific nature of the kappa-lambda body offers a three-armed solution to overcoming tumor resistance to antibody therapies.

MANAGEMENT
Jack Barbut, Chief Executive Officer
Jack Barbut has been Chief Executive Officer at Novimmune since 2000. With more than 30 years of professional experience in clinical trials management and drug development, Jack is the former President and Chief Executive Officer of Synarc, and was the founder, Vice-Chairman and President of Clinical Services of Chrysalis International.

Cristina de Min, Chief Medical Officer
Cristina de Min has over 15 years of drug development experience and has been the Chief Medical Officer at Novimmune since May 2010. Previously, Cristina held various leadership positions at Roche, where she was also responsible for the global development of a series of compounds primarily targeting autoimmune and endocrine diseases.

Marie Kosco-Vilbois, Chief Scientific Officer
Marie Kosco-Vilbois is Novimmune’s Chief Scientific Officer, joining the company in 2002. With over 25 years of experience, she was previously Head of Immunology and preclinical pharmacology at the Serono Pharmaceutical Research Institute, Head of Immunology at the Glaxo Wellcome Research Institute in Geneva, and a Scientific Member of the Basel Institute for Immunology.

Adrian Mills, Chief Business Officer
Adrian Mills joined Novimmune in July 2014 after an extensive career with GSK. Most recently he was the EU Commercial Director in the Rare & Critical Diseases Business Unit. Adrian has over 20 years of experience in life sciences leading commercial functions in both R&D, strategy development and commercial operations. Prior to GSK, Adrian worked in consulting (Booz & Co) and investment banking (Schroders) advising life sciences companies.

Nathalie Muller, Director of Legal Affairs, Administration, & Intellectual Property
Nathalie Muller is Novimmune’s Director Administration, including legal affairs and intellectual property. Prior to joining Novimmune in 2000, Nathalie was Head of Administration and Legal Affairs at Medabiotec. She previously worked for the Legal and Intellectual Property Department of Debiopharm, and handled legal, administrative and HR issues for the United Nations and the International Labour Organization.
OCT
www.oct-clinicaltrials.com

COMPANY PROFILE
OCT is a leading CRO operating in Central and Eastern Europe, Russia and the US. With the team of more than 120 professionals, OCT provides a full range of high-quality services within Phase I to IV including the organization and conduct of BE studies.

OCT believes in a partnering approach to clinical development and is interested in exploring risk-share and co-development opportunities with products in early stage clinical development.

With local expertise in our countries of operations and a focus on quality, OCT ensures that your product advances through clinical development and approval efficiently and effectively. Our experienced team delivers quality results to fulfill your development needs from standalone CRO services such as medical writing, consultancy, project management/monitoring, data management / statistics to the management and conduct of full clinical programs.

Since 2005 OCT has been involved in more than 150 full-service and functional service projects in a wide range of therapeutic areas, but with a focus on oncology.

MANAGEMENT
Dmitry Sharov, President
Irina Petrova, Clinical Operations Director
Graham Birrell, Regional Head, Business Development
FINANCIAL SUMMARY
Fully financed to complete Phase II studies with the lead compound melflufen in multiple myeloma in US and Western Europe.

COMPANY PROFILE
Oncopeptides is working to enhance oncology therapies, by creating cytosuperiors of existing basic cytotoxic compounds. Oncopeptides lead compound, named melflufen, is a cytosuperior of the chemotherapeutic alkylator melphalan. Melflufen is currently undergoing Phase II efficacy studies in US and Western European patients with relapsed and/or refractory multiple myeloma. A family of enzymes that is expressed at very high levels in cancer cells, such as multiple myeloma cells, causes melflufen and its metabolites to accumulate in the diseased cells. This results in partially targeted delivery of the chemotherapeutic compound to the cancer cells, and thereby better treatment of the disease.

PRODUCT PIPELINE
Melflufen
Oncopeptides is currently running a Phase II study of melflufen combined with dexamethasone in relapsed-refractory multiple myeloma (median of 4-5 previous lines of therapy) at six centers, 2 in US and 4 in Western Europe. Based on preliminary data we have achieved efficacy data with Overall Response Rates and Clinical Benefit Rates that are roughly double compared to recent approvals in this late stage patient population. This difference seems to translate well into Progression Free Survival rates as well. The clinical trial will be completed in first half of 2015.

Recently at the ASH meeting in December 2014 we presented results from the first six (6) patients evaluated at MTD (40 mg/m2) with an ORR of 60% and CBR at 100%. You are able to review the full poster here: (http://www.oncopeptides.se/wp-content/uploads/2015/02/Oncopeptides-poster-presented-at-ASH-20141.pdf)

An investment in Oncopeptides AB will be made with Phase II data available as well as meeting notes from western regulatory agencies in the second half of 2015.

Melphalan flufenamide (abbreviated melflufen and previously called J1) is a potent and highly lipophilic alkylator designed for efficient targeting of tumor cells. In contrast to other alkylating agents that are hydrophilic, the lipophilicity of melflufen leads to rapid and extensive distribution into tissues and cells. Inside cells, melflufen can directly bind DNA or is readily metabolized by intracellular peptidases into the well-known antitumor compound melphalan or by esterases into des-ethylmelflufen, which also has alkylating properties. Due to the high activity of peptidases and esterases in human tumor cells, the formation of melflufen’s metabolites is rapid in these cells with subsequent inflow of more melflufen. Since melphalan is hydrophilic and des-ethylmelflufen is hydrophobic, there is a possibility for intracellular trapping of these alkylators. In multiple myeloma cells melflufen gives at least a 20-fold higher intracellular exposure (as AUC) of alkylating agents compared to that seen after an equimolar dose of melphalan. This can be explained by a more efficient transport of melflufen into these cells, an efficient conversion into other alkylating molecules inside the cells and a less rapid disappearance from the cells.

OPPORTUNITIES
Melflufen
Oncopeptides is currently running a Phase II study of melflufen combined with dexamethasone in relapsed-refractory multiple myeloma (median of 4-5 previous lines of therapy) at six centers, 2 in US and 4 in Western Europe. Based on preliminary data we have achieved efficacy data with Overall Response Rates and Clinical Benefit Rates that are roughly double compared to recent approvals in this late stage patient population. This difference seems to translate well into Progression Free Survival rates as well. The clinical trial will be completed in first half of 2015.

An investment in Oncopeptides AB will be made with Phase II data available as well as meeting notes from western regulatory agencies in the second half of 2015.

Melphalan flufenamide (abbreviated melflufen and previously called J1) is a potent and highly lipophilic alkylator...
designed for efficient targeting of tumor cells. In contrast to other alkylating agents that are hydrophilic, the lipophilicity of melflufen leads to rapid and extensive distribution into tissues and cells. Inside cells, melflufen can directly bind DNA or is readily metabolized by intracellular peptidases into the well-known antitumor compound melphalan or by esterases into des-ethylmelflufen, which also has alkylating properties. Due to the high activity of peptidases and esterases in human tumor cells, the formation of melflufen’s metabolites is rapid in these cells with subsequent inflow of more melflufen. Since melphalan is hydrophilic and des-ethylmelflufen is hydrophobic, there is a possibility for intracellular trapping of these alkylators. In multiple myeloma cells melflufen gives at least a 20-fold higher intracellular exposure (as AUC) of alkylating agents compared to that seen after an equimolar dose of melphalan. This can be explained by a more efficient transport of melflufen into these cells, an efficient conversion into other alkylating molecules inside the cells and a less rapid disappearance from the cells.

MANAGEMENT
Dr. Bjorn Hammarberg, Business Development
Ms. Eva Nordstrom, Head of Clinical
Dr. Fredrik Lehmann, Director CMC
Mr. Jakob Lindberg, CEO
Dr. Johan Harmenberg, CMO
Mr. Alan Hulme, Chairman of the Board
Oncos Therapeutics
www.oncos.com

COMPANY PROFILE
Oncos Therapeutics is a clinical stage company developing off-the-shelf cancer immunotherapeutics. The mechanism of action of its lead product has been elucidated in Ph I and is thought to be highly complementary to that of checkpoint modulators. It will soon enter into combination studies with other cancer (immuno)therapies. We look forward to clinical collaborations with other companies developing complementary therapies.

PRODUCT PIPELINE
ONCOS-102 : Ph Ib
Off-the-shelf immunotherapy based on an immunogenic adenovirus with a GM-CSF transgene (Ad5/3D24-GMCSF) inducing a strong systemic cellular (CD8+ T-cell) immune response that has been clinically demonstrated to target tumor antigens upon local administration.

ONCOS-402 : Ready for Ph I
Off-the-shelf immunotherapy based on an immunogenic adenovirus with a CD40L transgene (Ad5/3D24-CD40L).

OPPORTUNITIES
ONCOS-102
Collaboration opportunities for proof-of-concept studies combining ONCOS-102 with mechanistically complementary cancer therapy in man.

ONCOS-402
Collaboration opportunities for (non-)clinical studies combining ONCOS-402 with mechanistically complementary cancer therapy.

Pipeline
Preclinical collaboration opportunities to build novel agents (including immunomodulators) as transgenes into Oncos platform constructs. The advantage of this is that a systemic, tumor targeted immune response can be generated simultaneously avoiding systemic adverse events by delivering the agents locally via transgene expression in cancer cells rather than administering them systemically. Simultaneously Oncos products have been clinically demonstrated to cause a powerful and tumor targeted activation of the cellular immune system.

MANAGEMENT
Frans Wuite, President & CEO
Antti Vuolanto, COO
Magnus Jaderberg, CMO
FINANCIAL SUMMARY

Oryx is backed by private investors / UHNWs, 25 Mio. € raised since 2007.

COMPANY PROFILE

ORYX picks up promising cancer projects from research institutions like the German Cancer Research Center (DKFZ) or German Universities and develops them through preclinical and clinical phases until clinical proof of concept/efficacy. ORYX oversees a product portfolio of 3 projects currently in phase I/IIa clinical trials. ORYX holds exclusive, world-wide licenses for all its development projects.

PRODUCT PIPELINE

ParvOryx : Phase I/IIa
ParvOryx: Parvovirus H1 (H-1PV) against a variety of human tumors

Oncolytic parvovirus H1 is a wild type rat virus that readily infects and lyses cancer cells from a wide variety of human tumors. These tumor types include glioblastoma multiforme, pancreatic, breast and lung cancer, as well as melanoma, lymphoma, pediatric tumors (neuroblastoma and medulloblastoma), prostate cancer and renal cancer. Unlike other natural or modified oncolytic viruses currently under investigation wild-type H-1PV is completely apathogenic for humans. This adds a unique safety property to the clinical investigation.

Mode of action
H-1PV acts at relatively low multiplicities of infection. The virus exerts a cytotoxic/oncolytic effect, predominantly mediated by the non-structural protein (NS1) resulting in dysregulation of transcription, cell cycle arrest, shut off of replication, activation of cellular stress response and induction of cell death. In addition, viral oncolysis appears to trigger a marked immunostimulatory effect. Through the selective lysis of tumor cells and the subsequent stimulation of the adaptive immune system minimal residual disease (MRD) will be recognized and tumor cells eliminated by the selective action of primed immune cells (bystander effect). Since the virus is able to cross the blood brain barrier glioblastoma multiforme (GBM) was chosen as the tumor entity for the present clinical Phase I/IIa study.

Highly convincing preclinical data show that treatment with H-1PV results in complete tumor remissions in animal models bearing human GBM.

MicOryx : Phase I/IIa
Therapeutic FSP vaccine against microsatellite instable (MSI-H) cancers

High level MSI-H is characterized by a lack of DNA mismatch repair (MMR) and observed in about 15% of colorectal cancers. Virtually all tumors occurring in the frame of hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome, the most common hereditary cancer predisposition syndrome, are characterized by MSI-H. MSI tumorigenesis is mainly driven by mutations occurring at coding microsatellites, which lead to the inactivation of the corresponding protein products and to the translation of tumor-specific frame shift-derived neopeptides (FSPs). These FSPs are both foreign and tumor specific antigens.

Mode of action
In MSI-H tumors, FSPs are strongly expressed. These tumors include colorectal, endometrial, gastric and small bowel cancer as well as tumors of the urinary tract and other solid tumors. In patients with MSI-H colorectal cancer, humoral and cellular immune responses against FSPs are observed, which demonstrates that FSPs are recognized by the immune system and can trigger an immune response. This observation is taken up by the first in class vaccination approach to prime the adaptive immune system against FSPs using a cocktail of three FSPs [AIM2(-1), HT001(-1) and TAF1B(-1)] to prevent outgrowth or destroy MSI-H tumors.

The FSP vaccination concept represents also a prime candidate for a preventive cancer vaccine for Lynch syndrome mutation carriers.
...continued

**VicOryx : Phase I/IIa**
Therapeutic p16INKa vaccine against high-risk human papilloma virus (HR-HPV) induced cancer

About 5% of all cancers are associated with high-risk human papilloma virus including virtually all cervical cancers, 85-95% anal and vulvar cancers, 20-40% of vaginal and penile cancers and 30-60% of head and neck cancers. Currently, two prophylactic vaccines are approved for prevention of HPV infection causing high grade cervical intraepithelial neoplasia (CIN), which induce HPV-type specific protective immunity but do not have a therapeutic effect on HPV infections.

**Mode of action**
The human cyclin dependent kinase inhibitor p16INKa is a non-viral, strongly expressed tumor antigen in HR-HPV associated cancers and precursor lesions independently of the viral subtype once cells achieve a transformed and possibly malignant phenotype. When expressed, p16INK4a prevents the progression of "normal" cells through the G1 phase, which leads to an irreversible cell cycle arrest. In HR-HPV transformed cells however, the p16INK4a pathway is blocked thus promoting unlimited cell division. Under physiological conditions p16INKa is only expressed in senescent/dying cells. In patients with HPV associated cancers humoral and cellular immune responses against p16INK4a occur spontaneously, which demonstrates that p16INKa is recognized by the immune system and can trigger an immune response. This observation is taken up by the vaccination approach to prime the adaptive immune system against p16INKa using a synthetic p16INK4a peptide to prevent outgrowth or cure of HR-HPV associated cancers.

No signs of autoimmunity have been detected in any patients. In healthy individuals, immune responses against p16INK4a have not been observed. Since p16INKa antigen overexpression in the cell is an early consequence of transformation in all HR-HPV associated cancers this vaccination approach represents also a prime candidate for a preventive cancer vaccine.

**OPPORTUNITIES**
- ParvOryx : Available for out-licensing
- MicOryx : Available for out-licensing
- VicOryx : Available for out-licensing

**MANAGEMENT**
- Dr Bernard Huber, CEO and Founder
- Dr Dr Michael Dahm, CMO
- Mr Klaus Kirschenhofer, CFO
- Dr Ottheinz Krebs, COO
- Dr Sven Rohmann, CBDO

---

**CONTACT**
Dr Bernard Huber
CEO and Founder

**ADDRESS**
Marktplatz 1
85598 Baldham
Germany

**TELEPHONE**
+49 8106 21 311 0

**EMAIL**
info@oryx-medicine.com

**YEAR FOUNDED**
2007
FINANCIAL SUMMARY
USD 6 M were raised since inception. Company is raising now USD 10 M.

COMPANY PROFILE
OticPharma develops differentiated therapeutic products for the treatment of Ear, Nose, Throat (ENT) disorders. The company’s leading product, FoamOtic Externa, which is currently being prepared for a Phase III clinical trial, is a novel dosage form based on the industry’s most commonly-used, non-ototoxic antibiotic, Ciprofloxacin. Based on the company’s proprietary FoamOtic platform, FoamOtic Externa enables sustained drug exposure, fewer administrations and lower doses for treatment of Acute Otitis Externa (AOE, “swimmer’s ear”). This steroid-free product offers a more convenient administration of self-applied medication to the ear, with no need to tilt the head or lie on the side to ensure that the medication remains in the ear. This makes administration much easier and more convenient, especially for children, and thus can improve compliance and safety.

Other products targeted for unique indications and based on the FoamOtic platform in development include FoamOtic Sinus for Chronic Sinusitis, Foam-O-Vet for Otitis Externa in dogs and FoamOtic Media for the treatment of Otitis Media.

The company has a strong IP portfolio for a wide range of applications. OticPharma was established in 2008, the company is privately held with headquarters in Israel.

PRODUCT PIPELINE
FoamOtic Externa : ready for Phase 3
FoamOtic Externa is a steroid-free, single agent (Ciprofloxacin) investigational foam product for the potential treatment of Acute Otitis Externa. The product successfully completed a proof-of-concept clinical study in 220 minor and adults patients. Currently it is being prepared for a U.S.-based Phase 3 clinical study. The foam is given once a day for 7 successive days.

Foam-O-Vet : ready for Phase 2
Foam-O-Vet is a combination drug (antibiotic, steroid and anti fungal) designated for the treatment of Canine Otitis Externa. The product will be administered once by the veterinarian (one and done) instead of the current standard of care which is twice daily administration of ear drops by the pet owner. The product was tested in dogs for acceptability, practicability and residence time. The product is ready for POC study in sick dogs.

FoamOtic Sinus : research
FoamOtic Sinus is designated for the treatment of Chronic Sinusitis in patients undergoing Sinus surgery. The product is based on FoamOtic technology and will minimize the risks related to multiple administrations of antibiotics and steroids.

FoamOtic Media : research
FoamOtic Media is designated for the treatment of patients undergoing tympanostomy tube insertion surgery. The product is based on FoamOtic technology.

OPPORTUNITIES
FoamOtic Externa
Investment is required to complete the pivotal study. Study will strat in the summer of 2015.

FoamOtic Sinus
Investment is required to conduct a clinical trial.

Foam-O-Vet
Investment is required to conduct the field study in dogs.

Ear disorders
Otic Pharma is willing to license-in products for ENT disorders.

Continued...
...continued

MANAGEMENT

Orna Palgi, PhD, Executive VP R&D
Dr. Palgi is a seasoned pharmaceutical and biotechnology drug development executive, and held senior positions at Teva (NYSE:TEVA), Proneuron and Pharmos Corporation (NASDAQ:PARS).

Rodrigo Yelin, PhD, Chief Operating Officer
Dr. Yelin was Project Manager and Director of Computational Genomics at Evogene (NYSE:EVGN), and served as a project leader at Compugen (NYSE:CGEN). He has extensive experience leading biotechnology projects from inception to licensing.

Anat Nursella, CPA, Chief Financial Officer
Ms. Nursella is the former CFO of NasVax Ltd and Elutex and brings over a decade of experience in financial management and operations in a wide range of industries.

Galit Itzhaki, B. Pharm, Clinical Director
Ms. Itzhaki is an experienced manager of Phase II and pivotal clinical trials both in international CRO companies and with industry-sponsored companies.
Pre Diagnostics AS
www.pre-diagnostics.com

CONTACT
Håkon Sæterøy
CEO

ADDRESS
P.O.Box 1413 Vika
N-0115 Oslo
Norway

TELEPHONE
+47 926 95 175

EMAIL
Haakon@pre-diagnostics.com

COMPANY PROFILE
A new blood-based test with high accuracy in the early disease stages is warranted for effective drug development within the Alzheimer’s space.

MANAGEMENT
Håkon Sæterøy, CEO
COMPANY PROFILE
Probiodrug AG is a publicly traded (Euronext, PBD) biopharmaceutical company dedicated to the research and development of new therapeutic products for the treatment of Alzheimer’s disease (“AD”). Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes — the DP4 inhibitors — which provided the basis for a novel class of antidiabetics — the gliptins.

Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s Disease treatments and to thereby provide a better life for Alzheimer’s Disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s Disease. The Company has medical use and composition of matter patents related to the inhibition of QC and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research.

PRODUCT PIPELINE
PQ912 : Phase II, Ila, Iib
PQ912 is the lead product candidate of the Company, currently entering into a Phase 2a study. PQ912 is a small molecule that was discovered and profiled by Probiodrug and was nominated by the Company for regulatory development in 2010. PQ912 is a specific inhibitor of QC which has shown therapeutic benefit in Alzheimer animal models. PQ912 has shown to be safe and well tolerated and revealed a high level of QC-inhibition in a Phase 1 study with 200 healthy young and elderly volunteers. The preparation of the Phase 2a study started in March 2014. The Clinical Trial Application (“CTA”) filing started in August 2014. The first patient is expected to be treated with PQ912 in the first quarter of 2015 with the first data expected to be available in mid 2016.

PBD-C06 : Preclinical
PBD-C06 is a monoclonal antibody, currently in preclinical research. PBD-C06 targets pGlu-Abeta, aiming to selectively clear the brain from pGlu-Abeta while leaving non-toxic forms of Abeta untouched. The Company believes that, due to the high specificity of PBD-C06 for pGlu-Abeta, the amount of antibody reaching the brain will be sufficient to neutralize the toxic peptides.

PQ1565 : Preclinical
PQ1565 is a QC-inhibitor, currently in late preclinical research. The product candidate has shown attractive drug-like properties in preclinical studies.

MANAGEMENT
Dr Konrad Glund, CEO
Hendrik Liebers, CFO
Dr Inge Lues, CDO
8th ANNUAL
European Life Science CEO Forum & Exhibition

Prokarium Ltd.
www.prokarium.com

CONTACTS
Dr. Ted Fjallman
CEO
Dr. Steven Chatfield
Chairman Board of Directors

TELEPHONE
+44 (0)781 1367729

EMAIL
ted.fjallman@prokarium.com

YEAR FOUNDED
2012

FINANCIAL SUMMARY
Seed funding in 2012 of $5.5 million which enabled acquisition of vector IP from Emergent BioSolutions as well as working capital for preclinical R&D on two vaccines.
Currently raising a Series B of $20 million to cover ETEC-diarrhoea challenge and Chlamydia phase 1 study 2016 and onwards.

COMPANY PROFILE
UK Clinical-stage vaccine development company with three products under development (travellers’ diarrhoea, typhoid, C.difficile, and Chlamydia vaccines)
The oral vaccine delivery platform, Vaxonella, which forms the basis of all our vaccines, is based on a Salmonella Typhi strain that has been in 8 clinical trials as a typhoid vaccine (up to and incl. phase 2 challenge). It was safe and very well tolerated in almost 500 volunteers including 101 children.
Prokarium is a limited company with full FTO (10 patents owned or under exclusive license), backed by one angel investor. We have partnerships with Cambridge, Oxford and Birmingham universities on various R&D projects as well as with a big pharma company on Clostridium difficile.
Our strategy is to partner and eventually out-license/sell rights to some indications to pursue the development of a small number of our own vaccines.
Our anticipated highlight for end of 2015: First company to show immunogenicity against all ETEC strains in human clinical trial, resulting in 45% of all causes of travellers diarrhea covered by vaccine (current Dukoral vaccine covers <10% of all causes and is primarily a cholera vaccine)

MANAGEMENT
Dr. Ted Fjallman, CEO
Mr. Peter Coleman, CFO
Dr. Rocky Cranenburgh, CSO
Dr. Mike Darsley, Head of Clinical Development
Dr. Alireza Shamaei-Tousi, Clinical Project Manager
Dr. Steven Chatfield, Chairman Board of Directors
Dr. Carl-Johan Spak, Director, Board of Directors
Dr. Allan Jarvis, Director, Board of Directors
Prof. David Sherratt, Scientific Advisory Board Member
Dr. Elisabeth Lindner, Scientific Advisory Board Member
Prof. Ian Henderson, Scientific Advisory Board Member
Prof. Nigel Slater, Scientific Advisory Board Member
FINANCIAL SUMMARY
Series B: US $ 18 M (2013-14)

Main Investors
1) Lilly ventures
2) JJDC (Johnson & Johnson Development Corporation)
3) Starfish Ventures
4) PharmStandard

COMPANY PROFILE
Protagonist is a peptide therapeutics company with a validated technology platform that is discovering &
developing ‘oral peptide drugs’ as a targeted therapy for GI (gastro-intestinal) diseases. It envisions a game
changing treatment paradigm shift in the treatment of IBD through its targeted therapy approach on those
autoimmune targets that offer multibillion dollar opportunities and which are currently addressed only by
injectable antibodies (eg. Humira, Remicade, Entyvio).

Our current financing plans call for a $ 35 M Series C/Mezzanine raise in 1H 2015 that should enable us to
progress three different assets in the clinic in 2015-16, and achieve phase 2A clinical POC with alfa4beta7
integrin oral peptide antagonist PTG-100 by end of 2016.

PRODUCT PIPELINE
PTG-100 : Preclinical Development
The company recently nominated PTG-100, an alpha-4-beta-7 integrin-specific oral peptide antagonist, as its
first development candidate for oral targeted therapy of IBD, specifically for Ulcerative Colitis. PTG-100 will enter
human clinical trails in October 2015 with the anticipation of Ph 2A clinical POC completion by end of 2016.

Oral IL-23r Antagonist : Preclinical Research
Preclinical proof-of-concept has been established with an oral peptide in its second program aimed at
intervention of the IL-23 pathway. A development candidate nomination is anticipated in 2015.

OPPORTUNITIES
PTG-100, oral integrin antagonist
The company recently nominated PTG-100, an alpha-4-beta-7 integrin-specific oral peptide antagonist, as its
first development candidate for oral targeted therapy of IBD, specifically for Ulcerative Colitis. PTG-100 will enter
human clinical trials in October 2015 with the anticipation of Ph 2A clinical POC completion by end of 2016.
The company is interested in creative partnerships and/or co-development scenarios .

Oral Il23r Antagonist
The company is interested in creative partnerships and/or co-development scenarios around this preclinical
stage asset.

MANAGEMENT
Dinesh Patel, President and CEO
**COMPANY PROFILE**

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, cancers of the liver, and breast cancer. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.

**PRODUCT PIPELINE**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Pre-Clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase 1/2 combination study of PV-10 + immune checkpoint blockade is being designed 2014 into 2015.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Request for Breakthrough Therapy Designation submitted to FDA Mar 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Type C FDA meeting Dec 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Enrolled Phase 2 Jun 2012 and Sep 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Third End-of-Phase 2 FDA meeting Oct 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Second end-of-Phase 2 FDA meeting Mar 2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase 2 study completed May 2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>End of Phase 2 FDA meeting Apr 2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase 2 treatments completed Sep 2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase 2 enrollment completed May 2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase 2 study initiated Sep 2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Orphan drug status Feb 2007</td>
</tr>
<tr>
<td>Melanoma (Method of Action)</td>
<td>PV-10</td>
<td></td>
<td></td>
<td></td>
<td>Protocol for Phase 3 study for treatment of locally advanced cutaneous melanomas submitted to FDA in 2014 for study in 2015.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase 1 study at R. Lee Moffitt Cancer Center and Research Institute to detect immune cell infiltration into melanomas treated with PV-10 initiated Jan 2015 into 2014 and 2015</td>
</tr>
<tr>
<td>Liver Metastasis</td>
<td>PV-10</td>
<td></td>
<td></td>
<td></td>
<td>Protocol for Phase 3 study for treatment of locally advanced cutaneous melanomas submitted to FDA in 2014 for study in 2015.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase 1/2 combination study of PV-10 + immune checkpoint blockade is being designed 2014 into 2015.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Protocol for Breakthrough Therapy Designation submitted to FDA Mar 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Type C FDA meeting Dec 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Protocol for Breakthrough Therapy Designation submitted to FDA Mar 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase 1/2 combination study of PV-10 + immune checkpoint blockade is being designed 2014 into 2015.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Protocol for Breakthrough Therapy Designation submitted to FDA Mar 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase 1/2 combination study of PV-10 + immune checkpoint blockade is being designed 2014 into 2015.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Protocol for Breakthrough Therapy Designation submitted to FDA Mar 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase 1/2 combination study of PV-10 + immune checkpoint blockade is being designed 2014 into 2015.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Protocol for Breakthrough Therapy Designation submitted to FDA Mar 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td>Atopic Dermatitis</td>
<td>PH-10</td>
<td></td>
<td></td>
<td></td>
<td>Protocol for Phase 3 study for treatment of locally advanced cutaneous melanomas submitted to FDA in 2014 for study in 2015.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase 1/2 combination study of PV-10 + immune checkpoint blockade is being designed 2014 into 2015.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Protocol for Breakthrough Therapy Designation submitted to FDA Mar 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full Phase 2 study report submitted to FDA Aug 2013 reported in 2015</td>
</tr>
</tbody>
</table>

* In addition to clinical trials, patients enrolled in the Compassionate Use Program for PV-10 are also receiving PV-10 treatments.

Continued...
Provectus Biopharmaceuticals, Inc.
www.pvct.com

...continued

PV-10
Rose Bengal based drugs to treat cancer, including but not limited to melanoma, cancers of the liver, and breast cancer.

PH-10
Rose Bengal based drugs to treat inflammatory dermatoses, including psoriasis and atopic dermatitis

OPPORTUNITIES
- Utilize great global potential of PV-10
- PV-10 is a platform technology for solid cancers and has shown preclinical or clinical activity in many types of solid tumors
- Build partnerships in selected geographies
- Control supply chain
- Actively participate in the development to commercialization

MANAGEMENT
Craig Dees, PhD, Chief Executive Office and Chairman
Timothy Scott, PhD, President and Board Member
Eric Wahter, PhD, Chief Technology Officer
Peter Culpepper, CPA, MBA, Chief Financial Officer/Chief Operating Officer
Saphetor provides big-data analysis for next generation DNA sequencing in clinical diagnostics. To empower the medical professional to make the best choice for the patient, we have seamlessly integrated the world’s leading genetic databases into our proprietary systems in order to accurately identify causal genomic alterations for a large range of diseases. We thus enable diagnostic labs, using our web platform to provide timely reports based on the most up-to-date information from academic and clinical research, and connect patients to treatments and clinical trials. We are now testing our platform in partnership with leading diagnostic labs, and are looking to expand our reach to the pharmaceutical and biotech industries to help find and validate new therapeutic targets.

MANAGEMENT
Andreas Massouras PhD, CEO
Chris Maggos, Business Development
**COMPANY PROFILE**

Serendex at Glance At Serendex we believe that patients with severe lung diseases need better treatment. With our GM-CSF we focus on respiratory conditions such as PAP (Pulmonary Alveolar Proteinosis), BE (Bronchiectasis), CF (Cystic Fibrosis infections) and ARDS (Acute Respiratory Distress Syndrome). For our Factor Vila (FVila) we focus on inhalation treatment of DAH (Diffuse Alveolar Haemorrhage). With a high commercial focus, we have a vision to develop inhalation products for the treatment of these lung diseases by developing specific existing systemic drugs (GM-CSF, FVila) into inhalation drugs. We will succeed through a worldwide distribution of our drugs for inhalation based on an extensive outsourcing strategy and international strategic alliances. **OUR DEVELOPMENT STRATEGY** Serendex’ development strategy is focusing on development of GM-CSF and FVila to be used for inhalation for several different pulmonary indications. These indications have been chosen based on published documentation and patient cases showing the potential for our products used for inhalation. Serendex has worldwide exclusive rights to the API (Active Product Ingredient) for both GM-CSF and FVila. Serendex has submitted or obtained IPR (Intellectual Property Rights) for all its indications. By using the API of well know systemic drugs as the active ingredient for our inhalation products, we are able to lower development risks and costs, as well as reducing time to market. This allows Serendex to efficiently develop drugs to meet high medical needs. The main part of our focus indications have an Orphan Drug Designation (ODD) due to their relative rareness. The potential of the Serendex pipeline is treatment of more than 700,000 persons annually in the EU and US alone. Our Pipeline We have planned for a pivotal study phase II/III with GM-CSF (Molgradex) in PAP starting in Q4 2015 in Europe and Japan. In Q3 2015 phase II trials will be initiated for CF, BE and ARDS in Europe. Pre-clinical trials will commence in Q3 2015 for FVila. If you wish to know more about our products and focus indications, please refer to our website: www.serendex.com.

**MANAGEMENT**

Dr Kim Arvid Nielsen, **CEO**
FINANCIAL SUMMARY
£22m cash as at November 30, 2014.

<table>
<thead>
<tr>
<th>Financial Summary</th>
<th>Sales (£m)</th>
<th>EBITDA (£m)</th>
<th>Adj. EPS (p)</th>
<th>Cash (£m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012A</td>
<td>0.2</td>
<td>(4.9)</td>
<td>(2.1)</td>
<td>8.9</td>
</tr>
<tr>
<td>2013A</td>
<td>0.1</td>
<td>(7.1)</td>
<td>(20.3)</td>
<td>15.9</td>
</tr>
<tr>
<td>2014E</td>
<td>0.0</td>
<td>(10.6)</td>
<td>(23.7)</td>
<td>21.5</td>
</tr>
</tbody>
</table>

COMPANY PROFILE
Silence Therapeutics is a leading RNA therapeutics company. It has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need. Silence’s technology is currently in the clinic in a Phase 2a pancreatic cancer trial.

PRODUCT PIPELINE

<table>
<thead>
<tr>
<th>Research</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atu027 Pancreatic cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atu027 Head and neck cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atu111 Lung indications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Licenses of our cRNA trigger (AtuRNAi)
Silence may receive potential milestones but has no future obligations in regard to these programmes.

- PF-655 (Quark and Pfizer) Diabetic Macular Edema: Phase 2, Phase 3 triggers £4m milestone
- PF-655 (Quark and Pfizer) Wet Age-related Macular Degeneration: Phase 2, Phase 2b pending OME results
- QPI 1092 (Quark and Novartis) Kidney Transplant (DG): Phase 2, Phase 2 completed, favourable results, Quark reviewing

Atu027
Atu027, metastatic pancreatic cancer, phase 2a

MANAGEMENT
Ali Mortazavi, CEO
Tim Freeborn, Finance Director
Dr Lars Karlsson, Head of R&D
Dr Mike Khan, Head of Translational Medicine
Synthena AG
www.synthena.com

COMPANY PROFILE
Synthena AG is a privately held, Swiss biopharmaceutical company focused on the development of new tricycleDNA based oligonucleotide drugs for the treatment of severe neuromuscular diseases. Its lead product SYN01 is in preclinical development for Duchenne muscular dystrophy, where it has shown unprecedented efficacy in restoring skeletal muscle, respiratory, cardiac and cognitive functions in different animal models. Further research programs are ongoing in Spinal Muscular Atrophy, Steinert’s disease, and Pompe disease.

MANAGEMENT
Wolfgang Renner PhD, Chief Executive Officer
Tonix Pharmaceuticals develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden.

Tonix's lead product candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201 (R)-isometheptene mucate is in development for episodic tension-type headache, the most common form of headache.

Tonix has announced top-line results from the Phase 2b BESTFIT trial (BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy), and plans to initiate a Phase 3 program in fibromyalgia in the second quarter of 2015 to support registration. A Phase 2 trial of TNX-102 SL in PTSD was initiated in January 2015. A Phase 1 study of TNX-201 has been successfully completed, and Tonix plans to begin a Phase 2 clinical study in episodic tension-type headache in the second quarter of 2015.
8th ANNUAL
European Life Science CEO Forum & Exhibition

Vaxart, Inc.
www.vaxart.com

CONTACT
Wouter Latour
CEO

ADDRESS
385 Oyster Point Blvd., Suite 9A
South San Francisco,
CA 94080

TELEPHONE
+1 650 550 3500

EMAIL
info@vaxart.com

YEAR FOUNDED
2004

COMPANY PROFILE
Recombinant Tablet Vaccine Platform – Room Temperature Stable Tablet
Vaxart is a privately held company developing recombinant antigen vaccines that are administered by tablet rather than by injection. The tablets are temperature stable and can be held at room temperature for up to one year.

Suitable for Wide Range of Indications
The Vaxart tablet vaccines are based on a modular vector based platform that is suitable for any recombinant antigen, including those that are contained in licensed vaccines for seasonal influenza, human papilloma virus (HPV) and hepatitis B, as well as any recombinant antigens currently in the industry pipeline. New vaccine constructs are routinely assembled in a matter of days, a significant advantage in addressing indications such as seasonal influenza or newly emerging pathogens.

Product Profile of Tablet Vaccine Comparable to Injectable Vaccines
In recent randomized, double blind, placebo controlled phase I studies, Vaxart’s H1N1 seasonal influenza tablet vaccine generated safety and immunogenicity results comparable to marketed vaccines. After a single dose, 90% of subjects generated robust systemic antibody responses as measured by haemagglutinin inhibition (HAI) and microneutralization (MN) assay. 75% of subjects seroconverted by HAI, the industry correlate for protection. In addition, robust T-cell and mucosal responses were generated in 90% of subjects, a unique and differentiating feature when compared to injectable vaccines. Only mild adverse events (AEs) occurred in the study, and were evenly distributed between placebo and vaccine recipients.

Tablet Vaccines have the Potential to Significantly Increase Vaccination Rates
Vaxart tablet vaccine can be shipped and stored without refrigeration and can be self-administered or administered under administrative supervision, opening up opportunities to administer vaccine in the work place, at school or even at home.

Vaxart Pipeline
Three high value vaccine candidates are currently in the clinic, or advancing into the clinic in 2015:
• Seasonal Influenza   • Norovirus   • RSV

Impact
Seasonal influenza is currently a $3 Billion Market worldwide. In the US, the largest market, only 45% of all those for who vaccine is recommended are actually vaccinated in any given year. In adults age 18 – 64 vaccination rates are much lower, just over 30%. A tablet vaccine could dramatically impact vaccination rates, particularly in the 18 – 64 age group, the largest segment of the population.

RSV causes significant morbidity and mortality in children as well as in elderly. Annually some 150,000 – 200,000 adults and elderly are hospitalized due to RSV infection.

Norovirus is a highly prevalent viral intestinal infection, affecting some 20 million people annually in the US alone. It is best known as the “cruise-ship” bug, but is causing significant morbidity among the population. Travelers, health care workers, food industry workers, military and first responders would all greatly benefit from vaccination, particularly by convenient tablet that can be self-administered.

All three indications will likely require annual vaccination campaigns offering significant synergies. A portfolio consisting of tablet vaccines for flu, RSV and norovirus will be ideal to address these high volume – high value markets, and offer a formidable competitive advantage vis a vis other products currently in development

MANAGEMENT
Wouter Latour, MD, MBA, Chief Executive Officer and Director
Sean Tucker, PhD., Founder, Chief Scientific Officer and Director
John Cornwell, MBA, Chief Operating Officer and Vice President Development
David Liebowitz, MD, PhD, Chief Medical Officer
John Harland, MBA, Chief Financial Officer
VTU Technology
www.vtu-technology.com

COMPANY PROFILE
VTU Technology is a leading contract research and development company, providing time-saving development of cost-efficient recombinant protein production processes for manufacturing of biologics and other proteins. Cutting-edge, exclusive, proprietary technologies and know-how together with a strong IP portfolio are the basis for the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities ever reported with production processes being
– economically viable
– robust and readily scalable
– safe with negligible risk of contamination
– environmentally friendly
– accompanied by simplified protein purification procedures

VTU Pichia pastoris Protein Expression Excellence:
– High speed expression strain development
– Upstream process development and optimization
– Downstream and analytical process development
– Small-scale production of purified non-GMP material
– Sound technology & data transfer to our customers
– Outlicensing / co-development opportunities for several recombinant proteins.

Business model:
– Development & commercialization of industrial protein production processes by application of exclusive and proprietary technologies and know-how
– Granting commercial technology licenses furnishing milestone and royalty payment incomes
– Production and distribution of high-margin proteins
– VTU has already entered into commercial technology license and partnership agreements with key industry players

MANAGEMENT
Dr. Michael Koncar, CEO
Experienced business manager and highly skilled entrepreneur, 5 companies founded since 1990, PhD in Process Engineering

Dr. Thomas Purkarthofer, CBDO
Business Development Manager, responsible for new business development, PhD in Chemistry

Dr. Roland Weis, CTO
Head of expression strain development and engineering, PhD in Molecular Biotechnology

Dr. Iskandar Dib
Principal R&D manager fermentation and downstream processing, PhD in Biotechnology and Biochemical Engineering
Zytoprotec GmbH
www.zytoprotec.com

CONTACT
Bernd Seibel
Board member (investor relations)

ADDRESS
Mariannengasse 28/2
1090 Wien

TELEPHONE
+43 1 406 20 02

EMAIL
office@zytoprotec.com

YEAR FOUNDED
2007

FINANCIAL SUMMARY
Biotech company, i.e. no revenues, grant income only
Additional EUR 2.0-3.0 million equity financing needed to complete Phase II clinical trial of lead product PD-protec

COMPANY PROFILE
Zytoprotec is developing drugs using a novel therapeutic approach – cytoprotection.
Zytoprotec’s lead product, PD-protec®, is being developed to improve the survival of patients on peritoneal dialysis, a treatment for kidney failure.
PD-protec® has shown safety and promising efficacy effects in a Phase I/II trial. A randomized, blinded, multicenter Phase II trial has commenced at the end of Q2 2014.
Worldwide, 2.3 million patients annually receive dialysis treatment. About 10 percent of these patients are treated with peritoneal dialysis (PD).
Cytoprotective PD solutions have the potential to significantly improve the outcomes of PD treatment and consequently to increase the share of PD within the overall dialysis market.

PRODUCT PIPELINE
PD-protec : clinical phase II
PD-protec is targeted to improve side effects of peritoneal dialysis significantly such as peritonitis and membrane failure.
OMNI-protec : pre-clinical
OMNI-protec is targeted to all peritoneal dialysis patients who do not receive glucose solutions.

MANAGEMENT
Michael Hoffmann, CEO
Prof. Christoph Aufricht, CSO and Founder
Prof. Uwe Schlokat, Chairman
Bernd Seibel, Board member (investor relations)
COMPANY PROFILE
Genecode Ltd is an R&D company focussing on the discovery and development of innovative preclinical drug candidates and the commercialization of novel technologies mostly in the field of biomedicine and gene technology.

Genecode has two main business fields linked together by the competence in computational chemistry:
• development of an antisense technology platform for suppressing unwanted gene expression, and applying the platform for finding cures against several medical indications;
• development of neurotrophic factor mimetics as drug candidates against neurological diseases.

MANAGEMENT
Katrin Idla, Managing Director
Paavo Pilv, Executive Director
Kaupo Karelson, Executive Director
Andres Merits, Scientific Team Leader
Tõnis Timmusk, Scientific Team Leader
Mart Saarma, Scientific Team Leader
Mati Karelson, Non-Executive Chairman
Mehis Pilv, Non-Executive Director
Thomas Björn Waldin, Non-Executive Director
**COMPANY PROFILE**

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, cancers of the liver, and breast cancer. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.

**PRODUCT PIPELINE**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Pre-Clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Protocol for Phase 3 study for treatment of locally advanced melanoma submitted to FDA in 2014 for study in 2015.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 1/2b combination study of PV-10 + immune checkpoint blockade is being designed 2014 into 2015.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Request for Breakthrough Therapy Designation submitted to FDA Mar 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Type II FDA meeting Dec 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Full Phase 2 study report submitted to FDA Aug 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Enrolled Phase 2 Oct 2012 and Sep 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Third End-of-Phase 2 FDA meeting Oct 2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Second End of Phase 2 FDA meeting Mar 2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 2 study completed May 2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• End of Phase 2 FDA meeting Apr 2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 2 treatments completed Sep 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 2 recruitment completed May 2019</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 2 study initiated Sep 2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Orphan drug status Feb 2017</td>
</tr>
<tr>
<td>Liver Metastasis</td>
<td>PV-10</td>
<td></td>
<td></td>
<td></td>
<td>• Phase 1 study initiated planned 2014 into 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 1 protocol expansion Sep 2012 into 2014 and 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Orphan drug status Apr 2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 1 patient accrual and treatment completed Jan 2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 1 study initiated Oct 2009</td>
</tr>
<tr>
<td>Breast Cancer</td>
<td>PV-10</td>
<td></td>
<td></td>
<td></td>
<td>• Phase 1 study completed Jul 2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 1 initial cohort treatment completed April 2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 1 study initiated October 2005</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>PH-10</td>
<td></td>
<td></td>
<td></td>
<td>• Full Phase 2c study report submitted to FDA Feb 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Toxicity study R&amp;D for advanced studies 2012 to 2014 and 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 2c final data collected Feb 2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 2c randomized study initiated Dec 2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 2c study completed Apr 2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 2b recruitment completed Oct 2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Replacement Phase 2b initiated Jul 2009 due to dose regimen change</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 2a study initiated Nov 2007</td>
</tr>
<tr>
<td>Psoriasis (Mechanism of Action)</td>
<td>PH-10</td>
<td></td>
<td></td>
<td></td>
<td>• Phase 2 study initiated Jan 2015</td>
</tr>
<tr>
<td>Atopic Dermatitis</td>
<td>PH-10</td>
<td></td>
<td></td>
<td></td>
<td>• Toxicity study R&amp;D for advanced studies 2012 to 2014 and 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Full Phase 2 study report submitted to FDA May 2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 2 recruitment completed Jan 2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase 2 study initiated Feb 2009</td>
</tr>
</tbody>
</table>

* In addition to clinical trials, patients enrolled in the Compassionate Use Program for PV-10 are also receiving PV-10 treatments.

**CONTACT**

Peter Culpepper, CPA, MBA
Chief Financial Officer/Chief Operating Officer

**ADDRESS**

7327 Oak Ridge Highway
Knoxville, TN 37931
USA

**TELEPHONE**

+1 866 594-5999

**EMAIL**

marlon@plrinvest.com

**YEAR FOUNDED**

2002
8th ANNUAL
European Life Science CEO Forum & Exhibition

Provectus Biopharmaceuticals, Inc.
www.pvct.com

...continued

PV-10
Rose Bengal based drugs to treat cancer, including but not limited to melanoma, cancers of the liver, and breast cancer.

PH-10
Rose Bengal based drugs to treat inflammatory dermatoses, including psoriasis and atopic dermatitis

OPPORTUNITIES
• Utilize great global potential of PV-10
• PV-10 is a platform technology for solid cancers and has shown preclinical or clinical activity in many types of solid tumors
• Build partnerships in selected geographies
• Control supply chain
• Actively participate in the development to commercialization

MANAGEMENT
Craig Dees, PhD, Chief Executive Officer and Chairman
Timothy Scott, PhD, President and Board Member
Eric Wahter, PhD, Chief Technology Officer
Peter Culpepper, CPA, MBA, Chief Financial Officer/Chief Operating Officer

CONTACT
Peter Culpepper, CPA, MBA
Chief Financial Officer/Chief Operating Officer

ADDRESS
7327 Oak Ridge Highway
Knoxville, TN 37931
USA

TELEPHONE
+1 866 594-5999

EMAIL
marlon@plrinvest.com

YEAR FOUNDED
2002
**Provectus Biopharmaceuticals, Inc.**

*Advancing a New Front in the War against Cancer*

Provectus Biopharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers - melanoma, liver and breast - while minimizing side effects.

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, cancers of the liver, and breast cancer. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
SILVER SPONSORS

Torreya Partners LLC

Torreya Partners LLC is a leading boutique advisory firm that provides strategic advice and assistance with Mergers & Acquisitions, Partnering and Financings to life science companies worldwide.

Torreya Partners provides the long-term thinking and objective advice required for life science companies to create lasting value. We take great pride in handling complex financial and strategic matters for some of the most sophisticated private and public life science companies in the world. Our reputation has been built on quality advice, excellence in deal execution and good outcomes for our clients. We bring the caliber of people and quality of relationships found in some of the largest investment banks along with the attentive, detailed service you expect from a boutique advisory firm. Torreya Partners has offices located in New York, Philadelphia and San Francisco.
Supporting Organisations

**Berlin Partner**

First choice: Berlin Partner for Business and Technology

Business and technology support for companies, investors and scientific institutions in Berlin – this is the Berlin Partner für Wirtschaft und Technologie GmbH mission. With customized services and an excellent science and research network, our many experts provide an outstanding range of programs to help companies launch, innovate, expand and secure their economic future in Berlin.

A unique public-private partnership, Berlin Partner for Business and Technology collaborates with the Berlin State Senate and over 200 companies dedicated to promoting their city. Berlin Partner is also responsible for marketing the German capital to the world, for example with the successful “be Berlin” campaign.

www.berlinpartner.de
As the sector association of the biotechnology industry, BIO Deutschland has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences.

The Berlin-based association currently has over 300 members. It is run by a board of ten members consisting of CEOs and managing directors of biotechnology companies, as well as directors of BioRegions. This committee comprehensively represents the various fields in the sector.

The member companies and their experts are organised in working groups that deal with the following topics: finance and taxation; licences and technical contracts; regulatory matters; innovation and entrepreneurship; HR; German-US cooperation; health policy; competition and regulatory policy; technology transfer; and PR. Using a wide range of political initiatives, BIO Deutschland lobbies for improvements to the legal parameters for innovative small and medium-sized enterprises.

BIO Deutschland is Germany’s biotechnology sector representative at the European association, EuropaBio, in Brussels. BIO Deutschland also works closely with other biotech organisations in Europe and the USA in order to lobby for the interests of the sector in an internationally coordinated way. The association is also very active in a broad range of events with the aim of providing biotechnology with a platform for discussion and interaction.
Supporting Organisations

Biotech Gate

Your source for life science companies and licensing information.

If you are about to negotiate a licensing deal between a Biotech and a Pharma company. Or you are looking for a big Pharma company to out-license your Biotech product. Or you are active in the medical technology (Medtech) sector and just want to identify potential cooperation partners or customers. Or you are an investor looking for investment opportunities - or you just want to know about historical financing rounds and valuations in the life sciences, Biotech, Pharam and medical device field. This portal can solve all of these problems -- and even more.
Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and corporate communications across the UK, Europe, North America and Asia.

Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from the company’s overall strength and from the cross-fertilisation of ideas across sectors.

The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia.

Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including: METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera Pharmaceuticals (SWX – CHF88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - £35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million).

Citigate Dewe Rogerson
3 London Wall Buildings
London Wall
London EC2M 5SY

Tel: +44 (0)-207-638-9571
Edison is a UK-based investment intelligence firm.

It employs more than 70 equity analysts operating from offices in London, New York, Sydney, Wellington and Frankfurt that provides research coverage on more than 700 publicly traded companies, making it one of the largest dedicated small and mid-cap research providers worldwide. Healthcare is the largest industry group within Edison with 12 analysts covering some 150 biotech/medical device companies located in UK, Continental Europe, North America and Australia.
FreeMind
www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen.

FreeMind’s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist our clients in making non-dilutive funding a key tool in their long-term financial strategy.

Tel: (617) 648-0340
Fax: (617) 904-1767
Email: info@freemindconsultants.com

Boston
FreeMind Group
423 Brookline Ave. #124
Boston, MA 02215

Washington DC
FreeMind Consultants
4094 Majestic lane # 269
Fairfax, VA 22033

Jerusalem
FreeMind Group
Hi - Tech Center
Hebrew University
Jerusalem 95702
Israel
Supporting Organisations

*Instinctif Partners*  
www.lifesiences.instinctif.com

*Instinctif Partners is an international business communications consultancy.*

With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities.

Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our bases in London, Manchester, Munich, Boston, Melbourne and Sydney.
LaBiotech.eu is the free and extensive European biotechnology news website.

Launched in September 2014, this young and dynamic media is the best way for you to keep a watch on the business and innovations of biotechnologies. Thanks to our partnerships with major european biotech events we are also your dedicated website for event summaries and agenda. You can also subscribe to our weekly newsletter to receive the latest news.
Supporting Organisations

Life Science Nation

Life Science Nation (LSN) accelerates the business of early stage life science via a Match.com-like sourcing platform.

This platform enables executives to find firms that are a fit for their business profile. Professionals leverage LSN to generate a global target list (GTL) of qualified prospects, greatly enhancing marketing efficiency. LSN researches and curates market intelligence on two industry sectors: The first is emerging biotech and medtech companies, which by their ephemeral nature are challenging to find and track. Second, LSN tracks ten categories of early stage life science investors and identifies who is filling the void left by venture capital. LSN has developed unique methodologies for tracking and keeping up-to-date with both of these dynamic market segments.

LSN created and manages the successful Redefining Early Stage Investments (RESI) conference series, which brings together global early stage biotech and medtech companies with early stage investors. LSN has also written and published a book, The Life Science Executive’s Fundraising Manifesto as well as a weekly newsletter, Next Phase, with a readership of 15,000. Finally, LSN presents a Fundraising Boot Camp at conferences and partnering events around the globe and provides seminars on branding, messaging, outbound marketing and sales to incubators and venture development centers within the life sciences.
**Supporting Organisations**

**Life Science Austria**

Life Science Austria - LISA - is a program acting as a hub for people from all over the world who are interested in the life science sector in Austria. Together with its associates in the Austrian regions, LISA is the first point of contact for anyone with questions about scientific collaboration, setting up an operation, or funding and sponsoring projects and businesses in Austria.

Working with all existing life science clusters in the Austrian regions – ecoplus, human. technology.styria, Life Science Austria Vienna Region, Health Technology Cluster, and Life Science Cluster Tirol - LISA is able to build on their expertise and services. The aims of LISA and its partners are: contribute to the success of life science enterprises in Austria by helping to introduce scientific discoveries to the market, assist in the search for funding, and provide general business consultancy and support to ensure healthy commercial development.

Austria Wirtschaftsservice GesmbH (aws), is responsible for running this program on behalf of the Austrian Federal Ministry of Economics, Family and Youth (BMWFJ).

Tel.: +43 (1) 501 75 - 0  
Fax: +43 (1) 501 75 - 900  
Email: office@awsg.at

*Austria Wirtschaftsservice Gesellschaft mbH,*  
*Ungargasse 37,*  
*1030 Wien,*  
*Austria*
Supporting Organisations

One Nucleus

One Nucleus is a membership organisation for international life science and healthcare companies. We are based in Cambridge and London UK, the heart of Europe's largest life science and healthcare cluster.

Vision: For One Nucleus and our members to be the top European life science and healthcare network.

Mission: We will achieve this by maximising the global competitiveness of our members.

Organisation History: Established in 1997, and formerly known as ERBI, One Nucleus is a not-for-profit, membership organisation and located in Cambridge and London – the centre of Europe’s leading life science and healthcare cluster.

The company has over 470 organisations as members including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

One Nucleus’s mission is to maximise the global competitiveness of our members. For our science and technology-based members, that means being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people's lives around the world. For our business and professional services members, it means delivering exceptional services that significantly enhance the business performance of their clients.
Supporting Organisations

Swiss Biotech Association

Swiss Biotech Association

Swiss Biotech Association
www.swissbiotech.org

Swiss Biotech – One Nation – One Biotech Cluster

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, Basel Area, Biopolis Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies.

Swiss Biotech’s mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

Further inquiries:
SwissBiotech, Executive Office
Tel. +41 (0)44 455 56 78
info@swissbiotech.org
Tiberend Strategic Advisors, Inc.
www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies.

1. To enhance valuation
2. To build visibility for partnerships and strategic alliances

Tiberend Strategic Advisors, Inc.
35 W. 35th Street, 5th Floor,
New York, NY 10001-2205

Tel: 212.827.0020
Fax: 212.827.0028 Fax
Sachs Associates is a London based international conference organiser which produces high profile events for the bio-pharmaceutical and financial community. These events are held in Europe and the USA; currently in Boston and Zurich.

The company was established in 1992 and ran emerging growth and emerging market investor forums in association with Dow Jones and then Bloomberg LP over a ten year period.

The benefits of conference participation with Sachs Associates may be summarised as follows:

Multimedia Exposure
Sachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well focused electronic and print media. Regular extensive coverage of all the Company’s conferences is carried out through video streaming and extensive events coverage through major international financial news agencies, including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long established relationships with other financial press organisations globally, which allow further effective distribution on behalf of its clients.

Eminent Speakers
Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the Company has attracted the very senior political and economic personalities as speakers at its events.

Sponsorship and Marketing Opportunities for forthcoming events
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.

Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

The following sponsorship and marketing opportunities are available at future conferences:

- Conference Sponsor – including workshops and social events
- Exhibition stands
- Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities please call Silvia Kar on +44 203 463 4890.
We look forward to seeing you at:

**Sachs Immuno-Oncology: BD&L and Investment Forum**
29th May 2015 • Hyatt Chicago Magnificent Mile • USA

---

**15th Annual Biotech in Europe Forum**
For Global Partnering & Investment
29th – 30th September 2015 • Congress Centre Basel
[www.sachsforum.com/basel15](http://www.sachsforum.com/basel15)

---

**3rd Annual Medtech & Diagnostics Innovations Summit**
16th November 2015 • Düsseldorf • Germany
Review the 2014 Forum: [www.sachsforum.com/mdis14](http://www.sachsforum.com/mdis14)

---

SACHS ASSOCIATES
27 Belsize Lane
London NW3 5AS
Tel: +44 (0)203 463 4890
Fax: +44 (0)207 691 7919
Follow us on Twitter – @SachsAssociates

[www.sachsforum.com](http://www.sachsforum.com)